Author: "Ramon Y Cajal T" / Publication Year Range: Last 50 years - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Ramon Y Cajal T"' showing total 94 results

Start Over Author "Ramon Y Cajal T" Publication Year Range Last 50 years

94 results on '"Ramon Y Cajal T"'

1. Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis

Author: Metcalfe, K, Huzarski, T, Gronwald, J, Kotsopoulos, J, Kim, R, Moller, P, Pal, T, Aeilts, A, Eisen, A, Karlan, B, Bordeleau, L, Tung, N, Olopade, O, Zakalik, D, Singer, C, Foulkes, W, Couch, F, Neuhausen, S, Eng, C, Sun, P, Lubinski, J, Narod, S, Velsher, L, Poll, A, Warner, E, Mccuaig, J, Armel, S, Saal, H, Steele, L, Lemire, E, Serfas, K, Senter, L, Sweet, K, Panchal, S, Cullinane, C, Blum, J, Rayson, D, Ramon y Cajal, T, Dungan, J, Fruscio, R, Zovato, S, Cohen, S, Metcalfe K., Huzarski T., Gronwald J., Kotsopoulos J., Kim R., Moller P., Pal T., Aeilts A., Eisen A., Karlan B., Bordeleau L., Tung N., Olopade O., Zakalik D., Singer C. F., Foulkes W., Couch F., Neuhausen S. L., Eng C., Sun P., Lubinski J., Narod S. A., Velsher L., Poll A., Warner E., McCuaig J., Armel S., Saal H., Steele L., Lemire E., Serfas K., Senter L., Sweet K., Panchal S., Cullinane C. A., Blum J. L., Rayson D., Ramon y Cajal T., Dungan J., Fruscio R., Zovato S., Cohen S., Metcalfe, K, Huzarski, T, Gronwald, J, Kotsopoulos, J, Kim, R, Moller, P, Pal, T, Aeilts, A, Eisen, A, Karlan, B, Bordeleau, L, Tung, N, Olopade, O, Zakalik, D, Singer, C, Foulkes, W, Couch, F, Neuhausen, S, Eng, C, Sun, P, Lubinski, J, Narod, S, Velsher, L, Poll, A, Warner, E, Mccuaig, J, Armel, S, Saal, H, Steele, L, Lemire, E, Serfas, K, Senter, L, Sweet, K, Panchal, S, Cullinane, C, Blum, J, Rayson, D, Ramon y Cajal, T, Dungan, J, Fruscio, R, Zovato, S, Cohen, S, Metcalfe K., Huzarski T., Gronwald J., Kotsopoulos J., Kim R., Moller P., Pal T., Aeilts A., Eisen A., Karlan B., Bordeleau L., Tung N., Olopade O., Zakalik D., Singer C. F., Foulkes W., Couch F., Neuhausen S. L., Eng C., Sun P., Lubinski J., Narod S. A., Velsher L., Poll A., Warner E., McCuaig J., Armel S., Saal H., Steele L., Lemire E., Serfas K., Senter L., Sweet K., Panchal S., Cullinane C. A., Blum J. L., Rayson D., Ramon y Cajal T., Dungan J., Fruscio R., Zovato S., and Cohen S.
Abstract: Background: Risk-reducing mastectomy (RRM) is offered to women with a BRCA1 or BRCA2 pathogenic variant, however, there are limited data on the impact on breast cancer mortality. Methods: Participants were identified from a registry of women with BRCA1/2 pathogenic variants. We used a pseudo-randomised trial design and matched one woman with a RRM to one woman without a RRM on year of birth, gene, and country. We estimated the hazard ratio (HR) and 95% confidence intervals (CI) for dying of breast cancer in the follow-up period. Results: There were 1654 women included; 827 assigned to the RRM arm and 827 assigned to the control arm. After a mean follow-up of 6.3 years, there were 20 incident breast cancers (including 15 occult cancers) and two breast cancer deaths in the RRM arm, and 100 incident breast cancers and 7 breast cancer deaths in the control arm (HR = 0.26; 95% CI 0.05–1.35; p = 0.11). The probability of dying of breast cancer within 15 years after RRM was 0.95%. Conclusions: In women with a BRCA1 or BRCA2 pathogenic variant, RRM reduces the risk of breast cancer, and the probability of dying of breast cancer is low.
Published: 2024

2. MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations

Author: Lubinski, J, Kotsopoulos, J, Moller, P, Pal, T, Eisen, A, Peck, L, Karlan, B, Aeilts, A, Eng, C, Bordeleau, L, Foulkes, W, Tung, N, Couch, F, Fruscio, R, Ramon Y Cajal, T, Singer, C, Neuhausen, S, Zakalik, D, Cybulski, C, Gronwald, J, Huzarski, T, Stempa, K, Dungan, J, Cullinane, C, Olopade, O, Metcalfe, K, Sun, P, Narod, S, Lubinski, Jan, Kotsopoulos, Joanne, Moller, Pal, Pal, Tuya, Eisen, Andrea, Peck, Larissa, Karlan, Beth Y, Aeilts, Amber, Eng, Charis, Bordeleau, Louise, Foulkes, William D, Tung, Nadine, Couch, Fergus J, Fruscio, Robert, Ramon Y Cajal, Teresa, Singer, Christian F, Neuhausen, Susan L, Zakalik, Dana, Cybulski, Cezary, Gronwald, Jacek, Huzarski, Tomasz, Stempa, Klaudia, Dungan, Jeffrey, Cullinane, Carey, Olopade, Olufunmilayo I, Metcalfe, Kelly, Sun, Ping, Narod, Steven A, Lubinski, J, Kotsopoulos, J, Moller, P, Pal, T, Eisen, A, Peck, L, Karlan, B, Aeilts, A, Eng, C, Bordeleau, L, Foulkes, W, Tung, N, Couch, F, Fruscio, R, Ramon Y Cajal, T, Singer, C, Neuhausen, S, Zakalik, D, Cybulski, C, Gronwald, J, Huzarski, T, Stempa, K, Dungan, J, Cullinane, C, Olopade, O, Metcalfe, K, Sun, P, Narod, S, Lubinski, Jan, Kotsopoulos, Joanne, Moller, Pal, Pal, Tuya, Eisen, Andrea, Peck, Larissa, Karlan, Beth Y, Aeilts, Amber, Eng, Charis, Bordeleau, Louise, Foulkes, William D, Tung, Nadine, Couch, Fergus J, Fruscio, Robert, Ramon Y Cajal, Teresa, Singer, Christian F, Neuhausen, Susan L, Zakalik, Dana, Cybulski, Cezary, Gronwald, Jacek, Huzarski, Tomasz, Stempa, Klaudia, Dungan, Jeffrey, Cullinane, Carey, Olopade, Olufunmilayo I, Metcalfe, Kelly, Sun, Ping, and Narod, Steven A
Abstract: IMPORTANCE Magnetic resonance imaging (MRI) surveillance is offered to women with a pathogenic variant in the BRCA1 or BRCA2 gene who face a high lifetime risk of breast cancer. Surveillance with MRI is effective in downstaging breast cancers, but the association of MRI surveillance with mortality risk has not been well defined. OBJECTIVE To compare breast cancer mortality rates in women with a BRCA1 or BRCA2 sequence variation who entered an MRI surveillance program with those who did not. DESIGN, SETTING, AND PARTICIPANTS Women with a BRCA1 or BRCA2 sequence variation were identified from 59 participating centers in 11 countries. Participants completed a baseline questionnaire between 1995 and 2015 and a follow-up questionnaire every 2 years to document screening histories, incident cancers, and vital status. Women who had breast cancer, a screening MRI examination, or bilateral mastectomy prior to enrollment were excluded. Participants were followed up from age 30 years (or the date of the baseline questionnaire, whichever was later) until age 75 years, the last follow-up, or death from breast cancer. Data were analyzed from January 1 to July 31, 2023. EXPOSURES Entrance into an MRI surveillance program. MAIN OUTCOMES AND MEASURES Cox proportional hazards modelingwas used to estimate the hazard ratios (HRs) and 95% CIs for breast cancer mortality associated with MRI surveillance compared with no MRI surveillance using a time-dependent analysis. RESULTS A total of 2488 women (mean [range] age at study entry 41.2 [30-69] years), with a sequence variation in the BRCA1 (n = 2004) or BRCA2 (n = 484) genes were included in the analysis. Of these participants, 1756 (70.6%) had at least 1 screening MRI examination and 732 women (29.4%) did not. After a mean follow-up of 9.2 years, 344 women (13.8%) developed breast cancer and 35 women (1.4%) died of breast cancer. The age-adjusted HRs for breast cancer mortality associated with entering an MRI surveillance program were 0
Published: 2024

3. Prognostic gene expression signature for high-grade serous ovarian cancer

Author: Bowtell, D., Chenevix-Trench, G., Green, A., Webb, P., DeFazio, A., Gertig, D., Traficante, N., Fereday, S., Moore, S., Hung, J., Harrap, K., Sadkowsky, T., Pandeya, N., Malt, M., Mellon, A., Robertson, R., Vanden Bergh, T., Jones, M., Mackenzie, P., Maidens, J., Nattress, K., Chiew, Y.E., Stenlake, A., Sullivan, H., Alexander, B., Ashover, P., Brown, S., Corrish, T., Green, L., Jackman, L., Ferguson, K., Martin, K., Martyn, A., Ranieri, B., White, J., Jayde, V., Mamers, P., Bowes, L., Galletta, L., Giles, D., Hendley, J., Alsop, K., Schmidt, T., Shirley, H., Ball, C., Young, C., Viduka, S., Tran, Hoa, Bilic, Sanela, Glavinas, Lydia, Brooks, Julia, Stuart-Harris, R., Kirsten, F., Rutovitz, J., Clingan, P., Glasgow, A., Proietto, A., Braye, S., Otton, G., Shannon, J., Bonaventura, T., Stewart, J., Begbie, S., Friedlander, M., Bell, D., Baron-Hay, S., Ferrier,a, A., Gard, G., Nevell, D., Pavlakis, N., Valmadre, S., Young, B., Camaris, C., Crouch, R., Edwards, L., Hacker, N., Marsden, D., Robertson, G., Beale, P., Beith, J., Carter, J., Dalrymple, C., Houghton, R., Russell, P., Links, M., Grygiel, J., Hill, J., Brand, A., Byth, K., Jaworski, R., Harnett, P., Sharma, R., Wain, G., Ward, B., Papadimos, D., Crandon, A., Cummings, M., Horwood, K., Obermair, A., Perrin, L., Wyld, D., Nicklin, J., Davy, M., Oehler, M.K., Hall, C., Dodd, T., Healy, T., Pittman, K., Henderson, D., Miller, J., Pierdes, J., Blomfield, P., Challis, D., McIntosh, R., Parker, A., Brown, B., Rome, R., Allen, D., Grant, P., Hyde, S., Laurie, R., Robbie, M., Healy, D., Jobling, T., Manolitsas, T., McNealage, J., Rogers, P., Susil, B., Sumithran, E., Simpson, I., Phillips, K., Rischin, D., Fox, S., Johnson, D., Lade, S., Loughrey, M., O’Callaghan, N., Murray, W., Waring, P., Billson, V., Pyman, J., Neesham, D., Quinn, M., Underhill, C., Bell, R., Ng, L.F., Blum, R., Ganju, V., Hammond, I., Leung, Y., McCartney, A., Buck, M., Haviv, I., Purdie, D., Whiteman, D., Zeps, N., Millstein, J., Budden, T., Goode, E.L., Anglesio, M.S., Talhouk, A., Intermaggio, M.P., Leong, H.S., Chen, S., Elatre, W., Gilks, B., Nazeran, T., Volchek, M., Bentley, R.C., Wang, C., Chiu, D.S., Kommoss, S., Leung, S.C.Y., Senz, J., Lum, A., Chow, V., Sudderuddin, H., Mackenzie, R., George, J., Steed, H., Koziak, J.M., Köbel, M., McNeish, I.A., Goranova, T., Ennis, D., Macintyre, G., Silva De Silva, D., Ramón y Cajal, T., García-Donas, J., Hernando Polo, S., Rodriguez, G.C., Cushing-Haugen, K.L., Harris, H.R., Greene, C.S., Zelaya, R.A., Behrens, S., Fortner, R.T., Sinn, P., Herpel, E., Lester, J., Lubiński, J., Oszurek, O., Tołoczko, A., Cybulski, C., Menkiszak, J., Pearce, C.L., Pike, M.C., Tseng, C., Alsop, J., Rhenius, V., Song, H., Jimenez-Linan, M., Piskorz, A.M., Gentry-Maharaj, A., Karpinskyj, C., Widschwendter, M., Singh, N., Kennedy, C.J., Harnett, P.R., Gao, B., Johnatty, S.E., Sayer, R., Boros, J., Winham, S.J., Keeney, G.L., Kaufmann, S.H., Larson, M.C., Luk, H., Hernandez, B.Y., Thompson, P.J., Wilkens, L.R., Carney, M.E., Trabert, B., Lissowska, J., Brinton, L., Sherman, M.E., Bodelon, C., Hinsley, S., Lewsley, L.A., Glasspool, R., Banerjee, S.N., Stronach, E.A., Haluska, P., Ray-Coquard, I., Mahner, S., Winterhoff, B., Slamon, D., Levine, D.A., Kelemen, L.E., Benitez, J., Chang-Claude, J., Gronwald, J., Wu, A.H., Menon, U., Goodman, M.T., Schildkraut, J.M., Wentzensen, N., Brown, R., Berchuck, A., deFazio, A., Gayther, S.A., García, M.J., Henderson, M.J., Rossing, M.A., Beeghly-Fadiel, A., Fasching, P.A., Orsulic, S., Karlan, B.Y., Konecny, G.E., Huntsman, D.G., Bowtell, D.D., Brenton, J.D., Doherty, J.A., Pharoah, P.D.P., and Ramus, S.J.
Published: 2020
Full Text: View/download PDF

4. RETRACTED: Metastatic Prostate cancer (mPCa) and Homologous Recombination Deficiency (HRD) in daily practice: experience of 6 years in a tertiary hospital.

Author: Gavira, J., primary, Tapia, J.C., additional, Romano, A., additional, Anguera, G., additional, Aguado, M., additional, Piedra, A., additional, Bosma, F., additional, Sanchez, S., additional, Sanz, J., additional, Molina, M.A., additional, Martin, C., additional, Algaba, F., additional, Arce, Y., additional, Ramon y Cajal, T., additional, and Maroto, P., additional
Published: 2023
Full Text: View/download PDF

5. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

Author: Kobel, M, Kang, E-Y, Weir, A, Rambau, PF, Lee, C-H, Nelson, GS, Ghatage, P, Meagher, NS, Riggan, MJ, Alsop, J, Anglesio, MS, Beckmann, MW, Bisinotto, C, Boisen, M, Boros, J, Brand, AH, Brooks-Wilson, A, Carney, ME, Coulson, P, Courtney-Brooks, M, Cushing-Haugen, KL, Cybulski, C, Deen, S, El-Bahrawy, MA, Elishaev, E, Erber, R, Fereday, S, Fischer, A, Gayther, SA, Barquin-Garcia, A, Gentry-Maharaj, A, Gilks, CB, Gronwald, H, Grube, M, Harnett, PR, Harris, HR, Hartkopf, AD, Hartmann, A, Hein, A, Hendley, J, Hernandez, BY, Huang, Y, Jakubowska, A, Jimenez-Linan, M, Jones, ME, Kennedy, CJ, Kluz, T, Koziak, JM, Lesnock, J, Lester, J, Lubinski, J, Longacre, TA, Lycke, M, Mateoiu, C, McCauley, BM, McGuire, V, Ney, B, Olawaiye, A, Orsulic, S, Osorio, A, Paz-Ares, L, Ramon Y Cajal, T, Rothstein, JH, Ruebner, M, Schoemaker, MJ, Shah, M, Sharma, R, Sherman, ME, Shvetsov, YB, Singh, N, Steed, H, Storr, SJ, Talhouk, A, Traficante, N, Wang, C, Whittemore, AS, Widschwendter, M, Wilkens, LR, Winham, SJ, Benitez, J, Berchuck, A, Bowtell, DD, Candido dos Reis, FJ, Campbell, I, Cook, LS, DeFazio, A, Doherty, JA, Fasching, PA, Fortner, RT, Garcia, MJ, Goodman, MT, Goode, EL, Gronwald, J, Huntsman, DG, Karlan, BY, Kelemen, LE, Kommoss, S, Le, ND, Martin, SG, Menon, U, Modugno, F, Pharoah, PDP, Schildkraut, JM, Sieh, W, Staebler, A, Sundfeldt, K, Swerdlow, AJ, Ramus, SJ, Brenton, JD, Kobel, M, Kang, E-Y, Weir, A, Rambau, PF, Lee, C-H, Nelson, GS, Ghatage, P, Meagher, NS, Riggan, MJ, Alsop, J, Anglesio, MS, Beckmann, MW, Bisinotto, C, Boisen, M, Boros, J, Brand, AH, Brooks-Wilson, A, Carney, ME, Coulson, P, Courtney-Brooks, M, Cushing-Haugen, KL, Cybulski, C, Deen, S, El-Bahrawy, MA, Elishaev, E, Erber, R, Fereday, S, Fischer, A, Gayther, SA, Barquin-Garcia, A, Gentry-Maharaj, A, Gilks, CB, Gronwald, H, Grube, M, Harnett, PR, Harris, HR, Hartkopf, AD, Hartmann, A, Hein, A, Hendley, J, Hernandez, BY, Huang, Y, Jakubowska, A, Jimenez-Linan, M, Jones, ME, Kennedy, CJ, Kluz, T, Koziak, JM, Lesnock, J, Lester, J, Lubinski, J, Longacre, TA, Lycke, M, Mateoiu, C, McCauley, BM, McGuire, V, Ney, B, Olawaiye, A, Orsulic, S, Osorio, A, Paz-Ares, L, Ramon Y Cajal, T, Rothstein, JH, Ruebner, M, Schoemaker, MJ, Shah, M, Sharma, R, Sherman, ME, Shvetsov, YB, Singh, N, Steed, H, Storr, SJ, Talhouk, A, Traficante, N, Wang, C, Whittemore, AS, Widschwendter, M, Wilkens, LR, Winham, SJ, Benitez, J, Berchuck, A, Bowtell, DD, Candido dos Reis, FJ, Campbell, I, Cook, LS, DeFazio, A, Doherty, JA, Fasching, PA, Fortner, RT, Garcia, MJ, Goodman, MT, Goode, EL, Gronwald, J, Huntsman, DG, Karlan, BY, Kelemen, LE, Kommoss, S, Le, ND, Martin, SG, Menon, U, Modugno, F, Pharoah, PDP, Schildkraut, JM, Sieh, W, Staebler, A, Sundfeldt, K, Swerdlow, AJ, Ramus, SJ, and Brenton, JD
Abstract: Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36-3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11-2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC.
Published: 2023

6. P130 - RETRACTED: Metastatic Prostate cancer (mPCa) and Homologous Recombination Deficiency (HRD) in daily practice: experience of 6 years in a tertiary hospital.

Author: Gavira, J., Tapia, J.C., Romano, A., Anguera, G., Aguado, M., Piedra, A., Bosma, F., Sanchez, S., Sanz, J., Molina, M.A., Martin, C., Algaba, F., Arce, Y., Ramon y Cajal, T., and Maroto, P.
Published: 2023
Full Text: View/download PDF

7. 284P Clinical and molecular characteristics of early-stage triple-negative breast cancer (eTNBC) patients with germline pathogenic variants in homologous recombination repair genes

Author: Hernandez, A. Rodriguez, Conte, B., Maristany, F. Braso, Pastor, B., Fratini, B., Walbaum, B., Potrony, M., Moreno, L., Grau, E., Torres, E. Sanfeliu, Saez, O. Martinez, Solis, E. Segui, Bravo, R. Gómez, Fructuoso, I. Garcia, Losada, M.J. Vidal, Ramon y Cajal, T., Munoz, M., Balaguer, F., Prat, A., and Adamo, B.
Published: 2024
Full Text: View/download PDF

8. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.

Author: Bancroft E.K., Page E.C., Brook M.N., Thomas S., Taylor N., Pope J., McHugh J., Jones A.-B., Karlsson Q., Merson S., Ong K.R., Hoffman J., Huber C., Maehle L., Grindedal E.M., Stormorken A., Evans D.G., Rothwell J., Lalloo F., Brady A.F., Bartlett M., Snape K., Hanson H., James P., McKinley J., Mascarenhas L., Syngal S., Ukaegbu C., Side L., Thomas T., Barwell J., Teixeira M.R., Izatt L., Suri M., Macrae F.A., Poplawski N., Chen-Shtoyerman R., Ahmed M., Musgrave H., Nicolai N., Greenhalgh L., Brewer C., Pachter N., Spigelman A.D., Azzabi A., Helfand B.T., Halliday D., Buys S., Ramon Y Cajal T., Donaldson A., Cooney K.A., Harris M., McGrath J., Davidson R., Taylor A., Cooke P., Myhill K., Hogben M., Aaronson N.K., Ardern-Jones A., Bangma C.H., Castro E., Dearnaley D., Dias A., Dudderidge T., Eccles D.M., Green K., Eyfjord J., Falconer A., Foster C.S., Gronberg H., Hamdy F.C., Johannsson O., Khoo V., Lilja H., Lindeman G.J., Lubinski J., Axcrona K., Mikropoulos C., Mitra A.V., Moynihan C., Ni Raghallaigh H., Rennert G., Collier R., Offman J., Kote-Jarai Z., Eeles R.A., Bancroft E.K., Page E.C., Brook M.N., Thomas S., Taylor N., Pope J., McHugh J., Jones A.-B., Karlsson Q., Merson S., Ong K.R., Hoffman J., Huber C., Maehle L., Grindedal E.M., Stormorken A., Evans D.G., Rothwell J., Lalloo F., Brady A.F., Bartlett M., Snape K., Hanson H., James P., McKinley J., Mascarenhas L., Syngal S., Ukaegbu C., Side L., Thomas T., Barwell J., Teixeira M.R., Izatt L., Suri M., Macrae F.A., Poplawski N., Chen-Shtoyerman R., Ahmed M., Musgrave H., Nicolai N., Greenhalgh L., Brewer C., Pachter N., Spigelman A.D., Azzabi A., Helfand B.T., Halliday D., Buys S., Ramon Y Cajal T., Donaldson A., Cooney K.A., Harris M., McGrath J., Davidson R., Taylor A., Cooke P., Myhill K., Hogben M., Aaronson N.K., Ardern-Jones A., Bangma C.H., Castro E., Dearnaley D., Dias A., Dudderidge T., Eccles D.M., Green K., Eyfjord J., Falconer A., Foster C.S., Gronberg H., Hamdy F.C., Johannsson O., Khoo V., Lilja H., Lindeman G.J., Lubinski J., Axcrona K., Mikropoulos C., Mitra A.V., Moynihan C., Ni Raghallaigh H., Rennert G., Collier R., Offman J., Kote-Jarai Z., and Eeles R.A.
Abstract: BACKGROUND: Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and endometrial cancer. Data are emerging that pathogenic variants in mismatch repair genes increase the risk of early-onset aggressive prostate cancer. The IMPACT study is prospectively assessing prostate-specific antigen (PSA) screening in men with germline mismatch repair pathogenic variants. Here, we report the usefulness of PSA screening, prostate cancer incidence, and tumour characteristics after the first screening round in men with and without these germline pathogenic variants. METHOD(S): The IMPACT study is an international, prospective study. Men aged 40-69 years without a previous prostate cancer diagnosis and with a known germline pathogenic variant in the MLH1, MSH2, or MSH6 gene, and age-matched male controls who tested negative for a familial pathogenic variant in these genes were recruited from 34 genetic and urology clinics in eight countries, and underwent a baseline PSA screening. Men who had a PSA level higher than 3.0 ng/mL were offered a transrectal, ultrasound-guided, prostate biopsy and a histopathological analysis was done. All participants are undergoing a minimum of 5 years' annual screening. The primary endpoint was to determine the incidence, stage, and pathology of screening-detected prostate cancer in carriers of pathogenic variants compared with non-carrier controls. We used Fisher's exact test to compare the number of cases, cancer incidence, and positive predictive values of the PSA cutoff and biopsy between carriers and non-carriers and the differences between disease types (ie, cancer vs no cancer, clinically significant cancer vs no cancer). We assessed screening outcomes and tumour characteristics by pathogenic variant status. Here we present results from the first round of PSA screening in the IMPACT study. This
Published: 2022

9. 139P Breast cancer risk estimation (CanRisk tool) and perception in unaffected women with family history of breast cancer

Author: Ramon y Cajal, T., primary, Lopez-Fernandez, À., additional, Pardo, M., additional, Darder, E., additional, Perez, E., additional, Costal, A., additional, Teule, A., additional, Perez, A., additional, Torres, M., additional, Alfonso, R., additional, Vallmajó, A., additional, Tuset Der-Abrain, N., additional, Cruellas Lapena, M., additional, Espinosa-Bravo, M., additional, Diez, O., additional, Lázaro, C., additional, Feliubadaló, L., additional, Llort Pursals, G., additional, Brunet Vidal, J.M., additional, and Balmaña, J., additional
Published: 2022
Full Text: View/download PDF

10. PD-0759 Immune and cell cycle differentially expressed pathways underlie late skin radiotherapy toxicity

Author: Aguado Flor, E., primary, Fuentes-Raspall, M.J., additional, Gonzalo, R., additional, Alonso, C., additional, Ramon y Cajal, T., additional, Fisas, D., additional, Seoane, A., additional, Sánchez Pla, Á., additional, Giralt, J., additional, Díez, O., additional, and Gutiérrez-Enríquez, S., additional
Published: 2021
Full Text: View/download PDF

11. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.

Author: Bancroft, EK, Page, EC, Brook, MN, Thomas, S, Taylor, N, Pope, J, McHugh, J, Jones, A-B, Karlsson, Q, Merson, S, Ong, KR, Hoffman, J, Huber, C, Maehle, L, Grindedal, EM, Stormorken, A, Evans, DG, Rothwell, J, Lalloo, F, Brady, AF, Bartlett, M, Snape, K, Hanson, H, James, P, McKinley, J, Mascarenhas, L, Syngal, S, Ukaegbu, C, Side, L, Thomas, T, Barwell, J, Teixeira, MR, Izatt, L, Suri, M, Macrae, FA, Poplawski, N, Chen-Shtoyerman, R, Ahmed, M, Musgrave, H, Nicolai, N, Greenhalgh, L, Brewer, C, Pachter, N, Spigelman, AD, Azzabi, A, Helfand, BT, Halliday, D, Buys, S, Ramon Y Cajal, T, Donaldson, A, Cooney, KA, Harris, M, McGrath, J, Davidson, R, Taylor, A, Cooke, P, Myhill, K, Hogben, M, Aaronson, NK, Ardern-Jones, A, Bangma, CH, Castro, E, Dearnaley, D, Dias, A, Dudderidge, T, Eccles, DM, Green, K, Eyfjord, J, Falconer, A, Foster, CS, Gronberg, H, Hamdy, FC, Johannsson, O, Khoo, V, Lilja, H, Lindeman, GJ, Lubinski, J, Axcrona, K, Mikropoulos, C, Mitra, AV, Moynihan, C, Ni Raghallaigh, H, Rennert, G, Collier, R, IMPACT Study Collaborators, Offman, J, Kote-Jarai, Z, Eeles, RA, Bancroft, EK, Page, EC, Brook, MN, Thomas, S, Taylor, N, Pope, J, McHugh, J, Jones, A-B, Karlsson, Q, Merson, S, Ong, KR, Hoffman, J, Huber, C, Maehle, L, Grindedal, EM, Stormorken, A, Evans, DG, Rothwell, J, Lalloo, F, Brady, AF, Bartlett, M, Snape, K, Hanson, H, James, P, McKinley, J, Mascarenhas, L, Syngal, S, Ukaegbu, C, Side, L, Thomas, T, Barwell, J, Teixeira, MR, Izatt, L, Suri, M, Macrae, FA, Poplawski, N, Chen-Shtoyerman, R, Ahmed, M, Musgrave, H, Nicolai, N, Greenhalgh, L, Brewer, C, Pachter, N, Spigelman, AD, Azzabi, A, Helfand, BT, Halliday, D, Buys, S, Ramon Y Cajal, T, Donaldson, A, Cooney, KA, Harris, M, McGrath, J, Davidson, R, Taylor, A, Cooke, P, Myhill, K, Hogben, M, Aaronson, NK, Ardern-Jones, A, Bangma, CH, Castro, E, Dearnaley, D, Dias, A, Dudderidge, T, Eccles, DM, Green, K, Eyfjord, J, Falconer, A, Foster, CS, Gronberg, H, Hamdy, FC, Johannsson, O, Khoo, V, Lilja, H, Lindeman, GJ, Lubinski, J, Axcrona, K, Mikropoulos, C, Mitra, AV, Moynihan, C, Ni Raghallaigh, H, Rennert, G, Collier, R, IMPACT Study Collaborators, Offman, J, Kote-Jarai, Z, and Eeles, RA
Abstract: BACKGROUND: Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and endometrial cancer. Data are emerging that pathogenic variants in mismatch repair genes increase the risk of early-onset aggressive prostate cancer. The IMPACT study is prospectively assessing prostate-specific antigen (PSA) screening in men with germline mismatch repair pathogenic variants. Here, we report the usefulness of PSA screening, prostate cancer incidence, and tumour characteristics after the first screening round in men with and without these germline pathogenic variants. METHODS: The IMPACT study is an international, prospective study. Men aged 40-69 years without a previous prostate cancer diagnosis and with a known germline pathogenic variant in the MLH1, MSH2, or MSH6 gene, and age-matched male controls who tested negative for a familial pathogenic variant in these genes were recruited from 34 genetic and urology clinics in eight countries, and underwent a baseline PSA screening. Men who had a PSA level higher than 3·0 ng/mL were offered a transrectal, ultrasound-guided, prostate biopsy and a histopathological analysis was done. All participants are undergoing a minimum of 5 years' annual screening. The primary endpoint was to determine the incidence, stage, and pathology of screening-detected prostate cancer in carriers of pathogenic variants compared with non-carrier controls. We used Fisher's exact test to compare the number of cases, cancer incidence, and positive predictive values of the PSA cutoff and biopsy between carriers and non-carriers and the differences between disease types (ie, cancer vs no cancer, clinically significant cancer vs no cancer). We assessed screening outcomes and tumour characteristics by pathogenic variant status. Here we present results from the first round of PSA screening in the IMPACT study. This s
Published: 2021

12. Comprehensive Constitutional Genetic and Epigenetic Characterization of Lynch-Like Individuals

Author: Damaso, E, Gonzalez-Acosta, M, Vargas-Parra, G, Navarro, M, Balmana, J, Ramon y Cajal, T, Tuset, N, Thompson, BA, Marin, F, Fernandez, A, Gomez, C, Velasco, A, Solanes, A, Iglesias, S, Urgel, G, Lopez, C, del Valle, J, Campos, O, Santacana, M, Matias-Guiu, X, Lazaro, C, Valle, L, Brunet, J, Pineda, M, Capella, G, Damaso, E, Gonzalez-Acosta, M, Vargas-Parra, G, Navarro, M, Balmana, J, Ramon y Cajal, T, Tuset, N, Thompson, BA, Marin, F, Fernandez, A, Gomez, C, Velasco, A, Solanes, A, Iglesias, S, Urgel, G, Lopez, C, del Valle, J, Campos, O, Santacana, M, Matias-Guiu, X, Lazaro, C, Valle, L, Brunet, J, Pineda, M, and Capella, G
Abstract: The causal mechanism for cancer predisposition in Lynch-like syndrome (LLS) remains unknown. Our aim was to elucidate the constitutional basis of mismatch repair (MMR) deficiency in LLS patients throughout a comprehensive (epi)genetic analysis. One hundred and fifteen LLS patients harboring MMR-deficient tumors and no germline MMR mutations were included. Mutational analysis of 26 colorectal cancer (CRC)-associated genes was performed. Pathogenicity of MMR variants was assessed by splicing and multifactorial likelihood analyses. Genome-wide methylome analysis was performed by the Infinium Human Methylation 450K Bead Chip. The multigene panel analysis revealed the presence of two MMR gene truncating mutations not previously found. Of a total of 15 additional MMR variants identified, five -present in 6 unrelated individuals- were reclassified as pathogenic. In addition, 13 predicted deleterious variants in other CRC-predisposing genes were found in 12 probands. Methylome analysis detected one constitutional MLH1 epimutation, but no additional differentially methylated regions were identified in LLS compared to LS patients or cancer-free individuals. In conclusion, the use of an ad-hoc designed gene panel combined with pathogenicity assessment of variants allowed the identification of deleterious MMR mutations as well as new LLS candidate causal genes. Constitutional epimutations in non-LS-associated genes are not responsible for LLS.
Published: 2020

13. Prognostic gene expression signature for high-grade serous ovarian cancer

Author: Millstein, J, Budden, T, Goode, EL, Anglesio, MS, Talhouk, A, Intermaggio, MP, Leong, HS, Chen, S, Elatre, W, Gilks, B, Nazeran, T, Volchek, M, Bentley, RC, Wang, C, Chiu, DS, Kommoss, S, Leung, SCY, Senz, J, Lum, A, Chow, V, Sudderuddin, H, Mackenzie, R, George, J, Fereday, S, Hendley, J, Traficante, N, Steed, H, Koziak, JM, Kobel, M, McNeish, IA, Goranova, T, Ennis, D, Macintyre, G, De Silva, DS, Ramon y Cajal, T, Garcia-Donas, J, Hernando Polo, S, Rodriguez, GC, Cushing-Haugen, KL, Harris, HR, Greene, CS, Zelaya, RA, Behrens, S, Fortner, RT, Sinn, P, Herpel, E, Lester, J, Lubinski, J, Oszurek, O, Toloczko, A, Cybulski, C, Menkiszak, J, Pearce, CL, Pike, MC, Tseng, C, Alsop, J, Rhenius, V, Song, H, Jimenez-Linan, M, Piskorz, AM, Gentry-Maharaj, A, Karpinskyj, C, Widschwendter, M, Singh, N, Kennedy, CJ, Sharma, R, Harnett, PR, Gao, B, Johnatty, SE, Sayer, R, Boros, J, Winham, SJ, Keeney, GL, Kaufmann, SH, Larson, MC, Luk, H, Hernandez, BY, Thompson, PJ, Wilkens, LR, Carney, ME, Trabert, B, Lissowska, J, Brinton, L, Sherman, ME, Bodelon, C, Hinsley, S, Lewsley, LA, Glasspool, R, Banerjee, SN, Stronach, EA, Haluska, P, Ray-Coquard, I, Mahner, S, Winterhoff, B, Slamon, D, Levine, DA, Kelemen, LE, Benitez, J, Chang-Claude, J, Gronwald, J, Wu, AH, Menon, U, Goodman, MT, Schildkraut, JM, Wentzensen, N, Brown, R, Berchuck, A, Chenevix-Trench, G, DeFazio, A, Gayther, SA, Garcia, MJ, Henderson, MJ, Rossing, MA, Beeghly-Fadiel, A, Fasching, PA, Orsulic, S, Karlan, BY, Konecny, GE, Huntsman, DG, Bowtell, DD, Brenton, JD, Doherty, JA, Pharoah, PDP, Ramus, SJ, Millstein, J, Budden, T, Goode, EL, Anglesio, MS, Talhouk, A, Intermaggio, MP, Leong, HS, Chen, S, Elatre, W, Gilks, B, Nazeran, T, Volchek, M, Bentley, RC, Wang, C, Chiu, DS, Kommoss, S, Leung, SCY, Senz, J, Lum, A, Chow, V, Sudderuddin, H, Mackenzie, R, George, J, Fereday, S, Hendley, J, Traficante, N, Steed, H, Koziak, JM, Kobel, M, McNeish, IA, Goranova, T, Ennis, D, Macintyre, G, De Silva, DS, Ramon y Cajal, T, Garcia-Donas, J, Hernando Polo, S, Rodriguez, GC, Cushing-Haugen, KL, Harris, HR, Greene, CS, Zelaya, RA, Behrens, S, Fortner, RT, Sinn, P, Herpel, E, Lester, J, Lubinski, J, Oszurek, O, Toloczko, A, Cybulski, C, Menkiszak, J, Pearce, CL, Pike, MC, Tseng, C, Alsop, J, Rhenius, V, Song, H, Jimenez-Linan, M, Piskorz, AM, Gentry-Maharaj, A, Karpinskyj, C, Widschwendter, M, Singh, N, Kennedy, CJ, Sharma, R, Harnett, PR, Gao, B, Johnatty, SE, Sayer, R, Boros, J, Winham, SJ, Keeney, GL, Kaufmann, SH, Larson, MC, Luk, H, Hernandez, BY, Thompson, PJ, Wilkens, LR, Carney, ME, Trabert, B, Lissowska, J, Brinton, L, Sherman, ME, Bodelon, C, Hinsley, S, Lewsley, LA, Glasspool, R, Banerjee, SN, Stronach, EA, Haluska, P, Ray-Coquard, I, Mahner, S, Winterhoff, B, Slamon, D, Levine, DA, Kelemen, LE, Benitez, J, Chang-Claude, J, Gronwald, J, Wu, AH, Menon, U, Goodman, MT, Schildkraut, JM, Wentzensen, N, Brown, R, Berchuck, A, Chenevix-Trench, G, DeFazio, A, Gayther, SA, Garcia, MJ, Henderson, MJ, Rossing, MA, Beeghly-Fadiel, A, Fasching, PA, Orsulic, S, Karlan, BY, Konecny, GE, Huntsman, DG, Bowtell, DD, Brenton, JD, Doherty, JA, Pharoah, PDP, and Ramus, SJ
Abstract: BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust prognostic signature for OS in patients with HGSOC. PATIENTS AND METHODS: Expression of 513 genes, selected from a meta-analysis of 1455 tumours and other candidates, was measured using NanoString technology from formalin-fixed paraffin-embedded tumour tissue collected from 3769 women with HGSOC from multiple studies. Elastic net regularization for survival analysis was applied to develop a prognostic model for 5-year OS, trained on 2702 tumours from 15 studies and evaluated on an independent set of 1067 tumours from six studies. RESULTS: Expression levels of 276 genes were associated with OS (false discovery rate < 0.05) in covariate-adjusted single-gene analyses. The top five genes were TAP1, ZFHX4, CXCL9, FBN1 and PTGER3 (P < 0.001). The best performing prognostic signature included 101 genes enriched in pathways with treatment implications. Each gain of one standard deviation in the gene expression score conferred a greater than twofold increase in risk of death [hazard ratio (HR) 2.35, 95% confidence interval (CI) 2.02-2.71; P < 0.001]. Median survival [HR (95% CI)] by gene expression score quintile was 9.5 (8.3 to -), 5.4 (4.6-7.0), 3.8 (3.3-4.6), 3.2 (2.9-3.7) and 2.3 (2.1-2.6) years. CONCLUSION: The OTTA-SPOT (Ovarian Tumor Tissue Analysis consortium - Stratified Prognosis of Ovarian Tumours) gene expression signature may improve risk stratification in clinical trials by identifying patients who are least likely to achieve 5-year survival. The identified novel genes associated with the outcome may also yield opportunities for the development of targeted therapeutic approaches.
Published: 2020

14. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study

Author: Mitra, Anita V., Bancroft, Elizabeth K., Barbachano, Yolanda, Page, Elizabeth C., Foster, C. S., Jameson, C., Mitchell, G., Lindeman, G. J., Stapleton, A., Suthers, G., Evans, D. G., Cruger, D., Blanco, I., Mercer, C., Kirk, J., Maehle, L., Hodgson, S., Walker, L., Izatt, L., Douglas, F., Tucker, K., Dorkins, H., Clowes, V., Male, A., Donaldson, A., Brewer, C., Doherty, R., Bulman, B., Osther, P. J., Salinas, M., Eccles, D., Axcrona, K., Jobson, I., Newcombe, B., Cybulski, C., Rubinstein, W. S., Buys, S., Townshend, S., Friedman, E., Domchek, S., Ramon y Cajal, T., Spigelman, A., Teo, S. H., Nicolai, N., Aaronson, N., Ardern-Jones, A., Bangma, C., Dearnaley, D., Eyfjord, J., Falconer, A., Grönberg, H., Hamdy, F., Johannsson, O., Khoo, V., Kote-Jarai, Z., Lilja, H., Lubinski, J., Melia, J., Moynihan, C., Peock, S., Rennert, G., Schröder, F., Sibley, P., Suri, M., Wilson, P., Bignon, Y. J., Strom, S., Tischkowitz, M., Liljegren, A., Ilencikova, D., Abele, A., Kyriacou, K., van Asperen, C., Kiemeney, L., Easton, D. F., and Eeles, Rosalind A.
Published: 2011
Full Text: View/download PDF

15. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.

Author: Teixeira M.R., Rhiem K., Izatt L., Tripathi V., Cardoso M., Foulkes W.D., Aprikian A., van Randeraad H., Davidson R., Longmuir M., Ruijs M.W.G., Adank M., Williams R., Andrews L., Murphy D.G., Halliday D., Walker L., Liljegren A., Carlsson S., Azzabi A., Jobson I., Morton C., Shackleton K., Snape K., Hanson H., Harris M., Tischkowitz M., Taylor A., Kirk J., Susman R., Chen-Shtoyerman R., Spigelman A., Pachter N., Ahmed M., Ramon y Cajal T., Zgajnar J., Brewer C., Gadea N., Brady A.F., van Os T., Gallagher D., Johannsson O., Donaldson A., Barwell J., Nicolai N., Friedman E., Obeid E., Greenhalgh L., Murthy V., Copakova L., Saya S., McGrath J., Cooke P., Ronlund K., Richardson K., Henderson A., Teo S.H., Arun B., Kast K., Dias A., Aaronson N.K., Ardern-Jones A., Bangma C.H., Castro E., Dearnaley D., Eccles D.M., Tricker K., Eyfjord J., Falconer A., Foster C., Gronberg H., Hamdy F.C., Stefansdottir V., Khoo V., Lindeman G.J., Lubinski J., Axcrona K., Mikropoulos C., Mitra A., Moynihan C., Rennert G., Suri M., Wilson P., Dudderidge T., Offman J., Kote-Jarai Z., Vickers A., Lilja H., Eeles R.A., Helderman van den Enden A.T.J.M., Page E.C., Bancroft E.K., Brook M.N., Assel M., Hassan Al Battat M., Thomas S., Taylor N., Chamberlain A., Pope J., Raghallaigh H.N., Evans D.G., Rothwell J., Maehle L., Grindedal E.M., James P., Mascarenhas L., McKinley J., Side L., Thomas T., van Asperen C., Vasen H., Kiemeney L.A., Ringelberg J., Jensen T.D., Osther P.J.S., Helfand B.T., Genova E., Oldenburg R.A., Cybulski C., Wokolorczyk D., Ong K.-R., Huber C., Lam J., Taylor L., Salinas M., Feliubadalo L., Oosterwijk J.C., van Zelst-Stams W., Cook J., Rosario D.J., Domchek S., Powers J., Buys S., O'Toole K., Ausems M.G.E.M., Schmutzler R.K., Teixeira M.R., Rhiem K., Izatt L., Tripathi V., Cardoso M., Foulkes W.D., Aprikian A., van Randeraad H., Davidson R., Longmuir M., Ruijs M.W.G., Adank M., Williams R., Andrews L., Murphy D.G., Halliday D., Walker L., Liljegren A., Carlsson S., Azzabi A., Jobson I., Morton C., Shackleton K., Snape K., Hanson H., Harris M., Tischkowitz M., Taylor A., Kirk J., Susman R., Chen-Shtoyerman R., Spigelman A., Pachter N., Ahmed M., Ramon y Cajal T., Zgajnar J., Brewer C., Gadea N., Brady A.F., van Os T., Gallagher D., Johannsson O., Donaldson A., Barwell J., Nicolai N., Friedman E., Obeid E., Greenhalgh L., Murthy V., Copakova L., Saya S., McGrath J., Cooke P., Ronlund K., Richardson K., Henderson A., Teo S.H., Arun B., Kast K., Dias A., Aaronson N.K., Ardern-Jones A., Bangma C.H., Castro E., Dearnaley D., Eccles D.M., Tricker K., Eyfjord J., Falconer A., Foster C., Gronberg H., Hamdy F.C., Stefansdottir V., Khoo V., Lindeman G.J., Lubinski J., Axcrona K., Mikropoulos C., Mitra A., Moynihan C., Rennert G., Suri M., Wilson P., Dudderidge T., Offman J., Kote-Jarai Z., Vickers A., Lilja H., Eeles R.A., Helderman van den Enden A.T.J.M., Page E.C., Bancroft E.K., Brook M.N., Assel M., Hassan Al Battat M., Thomas S., Taylor N., Chamberlain A., Pope J., Raghallaigh H.N., Evans D.G., Rothwell J., Maehle L., Grindedal E.M., James P., Mascarenhas L., McKinley J., Side L., Thomas T., van Asperen C., Vasen H., Kiemeney L.A., Ringelberg J., Jensen T.D., Osther P.J.S., Helfand B.T., Genova E., Oldenburg R.A., Cybulski C., Wokolorczyk D., Ong K.-R., Huber C., Lam J., Taylor L., Salinas M., Feliubadalo L., Oosterwijk J.C., van Zelst-Stams W., Cook J., Rosario D.J., Domchek S., Powers J., Buys S., O'Toole K., Ausems M.G.E.M., and Schmutzler R.K.
Abstract: Background: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. Objective(s): To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status. Design, setting, and participants: Men aged 40-69 yr with a germline pathogenic BRCA1/2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3 yr, and if PSA > 3.0 ng/ml, men were offered prostate biopsy. Outcome measurements and statistical analysis: PSA levels, PrCa incidence, and tumour characteristics were evaluated. Statistical analyses included Poisson regression offset by person-year follow-up, chi-square tests for proportion t tests for means, and Kruskal-Wallis for medians. Results and limitations: A total of 3027 patients (2932 unique individuals) were recruited (919 BRCA1 carriers, 709 BRCA1 noncarriers, 902 BRCA2 carriers, and 497 BRCA2 noncarriers). After 3 yr of screening, 527 men had PSA > 3.0 ng/ml, 357 biopsies were performed, and 112 PrCa cases were diagnosed (31 BRCA1 carriers, 19 BRCA1 noncarriers, 47 BRCA2 carriers, and 15 BRCA2 noncarriers). Higher compliance with biopsy was observed in BRCA2 carriers compared with noncarriers (73% vs 60%). Cancer incidence rate per 1000 person years was higher in BRCA2 carriers than in noncarriers (19.4 vs 12.0; p = 0.03); BRCA2 carriers were diagnosed at a younger age (61 vs 64 yr; p = 0.04) and were more likely to have clinically significant disease than BRCA2 noncarriers (77% vs 40%; p = 0.01). No differences in age or tumour characteristics were detected between BRCA1 carriers and BRCA1 noncarriers. The 4 kallikrein marker model discriminated better (area under the curve [AUC] = 0.73) for clinically significant cancer at
Published: 2019

16. Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations

Author: Bancroft, EK, Saya, S, Page, EC, Myhill, K, Thomas, S, Pope, J, Chamberlain, A, Hart, R, Glover, W, Cook, J, Rosario, DJ, Helfand, BT, Selkirk, CH, Davidson, R, Longmuir, M, Eccles, DM, Gadea, N, Brewer, C, Barwell, J, Salinas, M, Greenhalgh, L, Tischkowitz, M, Henderson, A, Evans, DG, Buys, SS, Eeles, RA, Aaronson, NK, Eeles, R, Bancroft, E, Page, E, Kote-Jarai, Z, Ardern-Jones, A, Bangma, C, Castro, E, Dearnaley, D, Falconer, A, Foster, C, Gronberg, H, Hamdy, FC, Johannsson, OT, Khoo, V, Eccles, D, Lilja, H, Evans, G, Eyfjord, J, Lubinski, J, Maehle, L, Mikropoulos, C, Millner, A, Mitra, A, Offman, J, Moynihan, C, Rennert, G, Suri, M, Dias, A, Taylor, N, D'Mello, L, James, P, Mitchell, G, Shanley, S, Richardson, K, McKinley, J, Petelin, L, Murphy, M, Mascarenhas, L, Murphy, D, Lam, J, Taylor, L, Miller, C, Stapleton, A, Chong, M, Suthers, G, Poplawski, N, Tucker, K, Andrews, L, Duffy, J, Millard, R, Ward, R, Williams, R, Stricker, P, Kirk, J, Bowman, M, Patel, M, Harris, M, O'Connell, S, Hunt, C, Smyth, C, Frydenberg, M, Lindeman, G, Shackleton, K, Morton, C, Susman, R, McGaughran, J, Boon, M, Pachter, N, Townshend, S, Schofield, L, Nicholls, C, Spigelman, A, Gleeson, M, Amor, D, Burke, J, Patterson, B, Swindle, P, Scott, R, Foulkes, W, Boshari, T, Aprikian, A, Jensen, T, Bojeson, A, Osther, P, Skytte, A-B, Cruger, D, Tondering, MK, Gerdes, A-M, Schmutzler, R, Rhiem, K, Wihler, P, Kast, K, Griebsch, C, Johannsson, O, Stefansdottir, V, Murthy, V, Sarin, R, Awatagiri, K, Ghonge, S, Kowtal, P, Mulgund, G, Gallagher, D, Bambury, R, Farrell, M, Gallagher, F, Kiernan, I, Friedman, E, Chen-Shtoyerman, R, Basevitch, A, Leibovici, D, Melzer, E, Ben-Yehoshua, SJ, Nicolai, N, Radice, P, Valdagni, R, Magnani, T, Gay, S, Teo, SH, Tan, HM, Yoon, S-Y, Thong, MK, Vasen, H, Ringleberg, J, van Asperen, C, Kiemeney, B, van Zelst-Stams, W, Ausems, MGEM, van der Luijt, RB, van Os, T, Ruijs, MWG, Adank, MA, Oldenburg, RA, Helderman-van den Enden, APTJM, Caanen, BAH, Oosterwijk, JC, Moller, P, Brennhovd, B, Medvik, H, Hanslien, E, Grindedal, EM, Cybulski, C, Wokolorczyk, D, Teixeira, M, Maia, S, Peixoto, A, Henrique, R, Oliveira, J, Goncalves, N, Araujo, L, Seixas, M, Souto, JP, Nogueira, P, Copakova, L, Zgajnar, J, Krajc, M, Vrecar, A, Capella, G, Ramon y Cajal, T, Fisas, D, Mora, J, Esquena, S, Balmana, J, Morote, J, Liljegren, A, Hjalm-Eriksson, M, Ekdahl, K-J, Carlsson, S, George, A, Kemp, Z, Wiggins, J, Moss, C, Van As, N, Thompson, A, Ogden, C, Woodhouse, C, Kumar, P, Bulman, B, Rothwell, J, Tricker, K, Wise, G, Mercer, C, McBride, D, Costello, P, Pearce, A, Torokwa, A, Paterson, J, Clowes, V, Taylor, A, Newcombe, B, Walker, L, Halliday, D, Stayner, B, Fleming-Brown, D, Snape, K, Hanson, H, Hodgson, S, Brice, G, Homfray, T, Hammond, C, Kohut, K, Anjum, U, Dearing, A, Mencias, M, Potter, A, Renton, C, Searle, A, Hill, K, Goodman, S, Garcia, L, Devlin, G, Everest, S, Nadolski, M, Douglas, F, Jobson, I, Paez, E, Donaldson, A, Tomkins, S, Langman, C, Jacobs, C, Pichert, G, Shaw, A, Kulkarni, A, Tripathi, V, Rose, S, Compton, C, Watson, M, Reinholtz, C, Brady, A, Dorkins, H, Melville, A, Kosicka-Slawinska, M, Cummings, C, Kiesel, V, Bartlett, M, Randhawa, K, Ellery, N, Side, L, Male, A, Simon, K, Rees, K, Tidey, L, Gurasashvili, J, Nevitt, L, Ingram, S, Howell, A, Rosario, D, Catto, J, Howson, J, Ong, K-R, Chapman, C, Cole, T, Heaton, T, Hoffman, J, Burgess, L, Huber, C, Islam, F, Watt, C, Duncan, A, Kockelbergh, R, Mzazi, S, Dineen, A, Sattar, A, Kaemba, B, Sidat, Z, Patel, N, Siguake, K, Birt, A, Poultney, U, Umez-Eronini, N, Mom, J, Sutton, V, Cornford, P, Bermingham, N, Yesildag, P, Treherne, K, Griffiths, J, Cogley, L, Gott, H, Rubinstein, WS, Hulick, P, McGuire, M, Shevrin, D, Kaul, K, Weissman, S, Newlin, A, Vogel, K, Weiss, S, Hook, N, Buys, S, Goldgar, D, Conner, T, Venne, V, Stephenson, R, Dechet, C, Domchek, S, Powers, J, Rustgi, N, Strom, S, Arun, B, Davis, JW, Yamamura, Y, Obeid, E, Giri, V, Gross, L, Bealin, L, Cooney, K, Stoffel, E, Okoth, L, Bancroft, EK, Saya, S, Page, EC, Myhill, K, Thomas, S, Pope, J, Chamberlain, A, Hart, R, Glover, W, Cook, J, Rosario, DJ, Helfand, BT, Selkirk, CH, Davidson, R, Longmuir, M, Eccles, DM, Gadea, N, Brewer, C, Barwell, J, Salinas, M, Greenhalgh, L, Tischkowitz, M, Henderson, A, Evans, DG, Buys, SS, Eeles, RA, Aaronson, NK, Eeles, R, Bancroft, E, Page, E, Kote-Jarai, Z, Ardern-Jones, A, Bangma, C, Castro, E, Dearnaley, D, Falconer, A, Foster, C, Gronberg, H, Hamdy, FC, Johannsson, OT, Khoo, V, Eccles, D, Lilja, H, Evans, G, Eyfjord, J, Lubinski, J, Maehle, L, Mikropoulos, C, Millner, A, Mitra, A, Offman, J, Moynihan, C, Rennert, G, Suri, M, Dias, A, Taylor, N, D'Mello, L, James, P, Mitchell, G, Shanley, S, Richardson, K, McKinley, J, Petelin, L, Murphy, M, Mascarenhas, L, Murphy, D, Lam, J, Taylor, L, Miller, C, Stapleton, A, Chong, M, Suthers, G, Poplawski, N, Tucker, K, Andrews, L, Duffy, J, Millard, R, Ward, R, Williams, R, Stricker, P, Kirk, J, Bowman, M, Patel, M, Harris, M, O'Connell, S, Hunt, C, Smyth, C, Frydenberg, M, Lindeman, G, Shackleton, K, Morton, C, Susman, R, McGaughran, J, Boon, M, Pachter, N, Townshend, S, Schofield, L, Nicholls, C, Spigelman, A, Gleeson, M, Amor, D, Burke, J, Patterson, B, Swindle, P, Scott, R, Foulkes, W, Boshari, T, Aprikian, A, Jensen, T, Bojeson, A, Osther, P, Skytte, A-B, Cruger, D, Tondering, MK, Gerdes, A-M, Schmutzler, R, Rhiem, K, Wihler, P, Kast, K, Griebsch, C, Johannsson, O, Stefansdottir, V, Murthy, V, Sarin, R, Awatagiri, K, Ghonge, S, Kowtal, P, Mulgund, G, Gallagher, D, Bambury, R, Farrell, M, Gallagher, F, Kiernan, I, Friedman, E, Chen-Shtoyerman, R, Basevitch, A, Leibovici, D, Melzer, E, Ben-Yehoshua, SJ, Nicolai, N, Radice, P, Valdagni, R, Magnani, T, Gay, S, Teo, SH, Tan, HM, Yoon, S-Y, Thong, MK, Vasen, H, Ringleberg, J, van Asperen, C, Kiemeney, B, van Zelst-Stams, W, Ausems, MGEM, van der Luijt, RB, van Os, T, Ruijs, MWG, Adank, MA, Oldenburg, RA, Helderman-van den Enden, APTJM, Caanen, BAH, Oosterwijk, JC, Moller, P, Brennhovd, B, Medvik, H, Hanslien, E, Grindedal, EM, Cybulski, C, Wokolorczyk, D, Teixeira, M, Maia, S, Peixoto, A, Henrique, R, Oliveira, J, Goncalves, N, Araujo, L, Seixas, M, Souto, JP, Nogueira, P, Copakova, L, Zgajnar, J, Krajc, M, Vrecar, A, Capella, G, Ramon y Cajal, T, Fisas, D, Mora, J, Esquena, S, Balmana, J, Morote, J, Liljegren, A, Hjalm-Eriksson, M, Ekdahl, K-J, Carlsson, S, George, A, Kemp, Z, Wiggins, J, Moss, C, Van As, N, Thompson, A, Ogden, C, Woodhouse, C, Kumar, P, Bulman, B, Rothwell, J, Tricker, K, Wise, G, Mercer, C, McBride, D, Costello, P, Pearce, A, Torokwa, A, Paterson, J, Clowes, V, Taylor, A, Newcombe, B, Walker, L, Halliday, D, Stayner, B, Fleming-Brown, D, Snape, K, Hanson, H, Hodgson, S, Brice, G, Homfray, T, Hammond, C, Kohut, K, Anjum, U, Dearing, A, Mencias, M, Potter, A, Renton, C, Searle, A, Hill, K, Goodman, S, Garcia, L, Devlin, G, Everest, S, Nadolski, M, Douglas, F, Jobson, I, Paez, E, Donaldson, A, Tomkins, S, Langman, C, Jacobs, C, Pichert, G, Shaw, A, Kulkarni, A, Tripathi, V, Rose, S, Compton, C, Watson, M, Reinholtz, C, Brady, A, Dorkins, H, Melville, A, Kosicka-Slawinska, M, Cummings, C, Kiesel, V, Bartlett, M, Randhawa, K, Ellery, N, Side, L, Male, A, Simon, K, Rees, K, Tidey, L, Gurasashvili, J, Nevitt, L, Ingram, S, Howell, A, Rosario, D, Catto, J, Howson, J, Ong, K-R, Chapman, C, Cole, T, Heaton, T, Hoffman, J, Burgess, L, Huber, C, Islam, F, Watt, C, Duncan, A, Kockelbergh, R, Mzazi, S, Dineen, A, Sattar, A, Kaemba, B, Sidat, Z, Patel, N, Siguake, K, Birt, A, Poultney, U, Umez-Eronini, N, Mom, J, Sutton, V, Cornford, P, Bermingham, N, Yesildag, P, Treherne, K, Griffiths, J, Cogley, L, Gott, H, Rubinstein, WS, Hulick, P, McGuire, M, Shevrin, D, Kaul, K, Weissman, S, Newlin, A, Vogel, K, Weiss, S, Hook, N, Buys, S, Goldgar, D, Conner, T, Venne, V, Stephenson, R, Dechet, C, Domchek, S, Powers, J, Rustgi, N, Strom, S, Arun, B, Davis, JW, Yamamura, Y, Obeid, E, Giri, V, Gross, L, Bealin, L, Cooney, K, Stoffel, E, and Okoth, L
Abstract: OBJECTIVES: To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi-national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic germline mutation in the BRCA1 or BRCA2 genes. PARTICPANTS AND METHODS: Men enrolled in the IMPACT study were invited to complete a questionnaire at collaborating sites prior to each annual screening visit. The questionnaire included sociodemographic characteristics and the following measures: the Hospital Anxiety and Depression Scale (HADS), Impact of Event Scale (IES), 36-item short-form health survey (SF-36), Memorial Anxiety Scale for Prostate Cancer, Cancer Worry Scale-Revised, risk perception and knowledge. The results of the baseline questionnaire are presented. RESULTS: A total of 432 men completed questionnaires: 98 and 160 had mutations in BRCA1 and BRCA2 genes, respectively, and 174 were controls (familial mutation negative). Participants' perception of PCa risk was influenced by genetic status. Knowledge levels were high and unrelated to genetic status. Mean scores for the HADS and SF-36 were within reported general population norms and mean IES scores were within normal range. IES mean intrusion and avoidance scores were significantly higher in BRCA1/BRCA2 carriers than in controls and were higher in men with increased PCa risk perception. At the multivariate level, risk perception contributed more significantly to variance in IES scores than genetic status. CONCLUSION: This is the first study to report the psychosocial profile of men with BRCA1/BRCA2 mutations undergoing PCa screening. No clinically concerning levels of general or cancer-specific distress or poor quality of life were detected in the cohort as a whole. A small subset of participants reported higher levels of distress, suggesting the need for healthcare professionals offering PCa screening to identify these risk factors and offer additional information and support t
Published: 2019

17. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

Author: Page, EC, Bancroft, EK, Brook, MN, Assel, M, Al Battat, MH, Thomas, S, Taylor, N, Chamberlain, A, Pope, J, Ni Raghallaigh, H, Evans, DG, Rothwell, J, Maehle, L, Grindedal, EM, James, P, Mascarenhas, L, McKinley, J, Side, L, Thomas, T, van Asperen, C, Vasen, H, Kiemeney, LA, Ringelberg, J, Jensen, TD, Osther, PJS, Helfand, BT, Genova, E, Oldenburg, RA, Cybulski, C, Wokolorczyk, D, Ong, K-R, Huber, C, Lam, J, Taylor, L, Salinas, M, Feliubadalo, L, Oosterwijk, JC, van Zelst-Stams, W, Cook, J, Rosario, DJ, Domchek, S, Powers, J, Buys, S, O'Toole, K, Ausems, MGEM, Schmutzler, RK, Rhiem, K, Izatt, L, Tripathi, V, Teixeira, MR, Cardoso, M, Foulkes, WD, Aprikian, A, van Randeraad, H, Davidson, R, Longmuir, M, Ruijs, MWG, Helderman van den Enden, ATJM, Adank, M, Williams, R, Andrews, L, Murphy, DG, Halliday, D, Walker, L, Liljegren, A, Carlsson, S, Azzabi, A, Jobson, I, Morton, C, Shackleton, K, Snape, K, Hanson, H, Harris, M, Tischkowitz, M, Taylor, A, Kirk, J, Susman, R, Chen-Shtoyerman, R, Spigelman, A, Pachter, N, Ahmed, M, Ramon y Cajal, T, Zgajnar, J, Brewer, C, Gadea, N, Brady, AF, van Os, T, Gallagher, D, Johannsson, O, Donaldson, A, Barwell, J, Nicolai, N, Friedman, E, Obeid, E, Greenhalgh, L, Murthy, V, Copakova, L, Saya, S, McGrath, J, Cooke, P, Ronlund, K, Richardson, K, Henderson, A, Teo, SH, Arun, B, Kast, K, Dias, A, Aaronson, NK, Ardern-Jones, A, Bangma, CH, Castro, E, Dearnaley, D, Eccles, DM, Tricker, K, Eyfjord, J, Falconer, A, Foster, C, Gronberg, H, Hamdy, FC, Stefansdottir, V, Khoo, V, Lindeman, GJ, Lubinski, J, Axcrona, K, Mikropoulos, C, Mitra, A, Moynihan, C, Rennert, G, Suri, M, Wilson, P, Dudderidge, T, Offman, J, Kote-Jarai, Z, Vickers, A, Lilja, H, Eeles, RA, Page, EC, Bancroft, EK, Brook, MN, Assel, M, Al Battat, MH, Thomas, S, Taylor, N, Chamberlain, A, Pope, J, Ni Raghallaigh, H, Evans, DG, Rothwell, J, Maehle, L, Grindedal, EM, James, P, Mascarenhas, L, McKinley, J, Side, L, Thomas, T, van Asperen, C, Vasen, H, Kiemeney, LA, Ringelberg, J, Jensen, TD, Osther, PJS, Helfand, BT, Genova, E, Oldenburg, RA, Cybulski, C, Wokolorczyk, D, Ong, K-R, Huber, C, Lam, J, Taylor, L, Salinas, M, Feliubadalo, L, Oosterwijk, JC, van Zelst-Stams, W, Cook, J, Rosario, DJ, Domchek, S, Powers, J, Buys, S, O'Toole, K, Ausems, MGEM, Schmutzler, RK, Rhiem, K, Izatt, L, Tripathi, V, Teixeira, MR, Cardoso, M, Foulkes, WD, Aprikian, A, van Randeraad, H, Davidson, R, Longmuir, M, Ruijs, MWG, Helderman van den Enden, ATJM, Adank, M, Williams, R, Andrews, L, Murphy, DG, Halliday, D, Walker, L, Liljegren, A, Carlsson, S, Azzabi, A, Jobson, I, Morton, C, Shackleton, K, Snape, K, Hanson, H, Harris, M, Tischkowitz, M, Taylor, A, Kirk, J, Susman, R, Chen-Shtoyerman, R, Spigelman, A, Pachter, N, Ahmed, M, Ramon y Cajal, T, Zgajnar, J, Brewer, C, Gadea, N, Brady, AF, van Os, T, Gallagher, D, Johannsson, O, Donaldson, A, Barwell, J, Nicolai, N, Friedman, E, Obeid, E, Greenhalgh, L, Murthy, V, Copakova, L, Saya, S, McGrath, J, Cooke, P, Ronlund, K, Richardson, K, Henderson, A, Teo, SH, Arun, B, Kast, K, Dias, A, Aaronson, NK, Ardern-Jones, A, Bangma, CH, Castro, E, Dearnaley, D, Eccles, DM, Tricker, K, Eyfjord, J, Falconer, A, Foster, C, Gronberg, H, Hamdy, FC, Stefansdottir, V, Khoo, V, Lindeman, GJ, Lubinski, J, Axcrona, K, Mikropoulos, C, Mitra, A, Moynihan, C, Rennert, G, Suri, M, Wilson, P, Dudderidge, T, Offman, J, Kote-Jarai, Z, Vickers, A, Lilja, H, and Eeles, RA
Abstract: BACKGROUND: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. OBJECTIVE: To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status. DESIGN, SETTING, AND PARTICIPANTS: Men aged 40-69 yr with a germline pathogenic BRCA1/2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3 yr, and if PSA > 3.0 ng/ml, men were offered prostate biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PSA levels, PrCa incidence, and tumour characteristics were evaluated. Statistical analyses included Poisson regression offset by person-year follow-up, chi-square tests for proportion t tests for means, and Kruskal-Wallis for medians. RESULTS AND LIMITATIONS: A total of 3027 patients (2932 unique individuals) were recruited (919 BRCA1 carriers, 709 BRCA1 noncarriers, 902 BRCA2 carriers, and 497 BRCA2 noncarriers). After 3 yr of screening, 527 men had PSA > 3.0 ng/ml, 357 biopsies were performed, and 112 PrCa cases were diagnosed (31 BRCA1 carriers, 19 BRCA1 noncarriers, 47 BRCA2 carriers, and 15 BRCA2 noncarriers). Higher compliance with biopsy was observed in BRCA2 carriers compared with noncarriers (73% vs 60%). Cancer incidence rate per 1000 person years was higher in BRCA2 carriers than in noncarriers (19.4 vs 12.0; p = 0.03); BRCA2 carriers were diagnosed at a younger age (61 vs 64 yr; p = 0.04) and were more likely to have clinically significant disease than BRCA2 noncarriers (77% vs 40%; p = 0.01). No differences in age or tumour characteristics were detected between BRCA1 carriers and BRCA1 noncarriers. The 4 kallikrein marker model discriminated better (area under the curve [AUC] = 0.73) for clinically significant cancer at
Published: 2019

18. Abstract P5-09-04: Impact of premenopausal RRSO on breast cancer risk in BRCA1/2 mutation carriers: Maximizing bias-reduction

Author: Stjepanovic, N, primary, Villacampa, G, additional, Nead, K, additional, Torres, S, additional, Gomez, L, additional, Nathanson, KL, additional, Teule, A, additional, Brunet, J, additional, Ramon y Cajal, T, additional, Llort, G, additional, Dienstmann, R, additional, Rue, M, additional, Domchek, S, additional, and Balmana, J, additional
Published: 2019
Full Text: View/download PDF

19. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

Author: Block, MS, Vierkant, RA, Rambau, PF, Winham, SJ, Wagner, P, Traficante, N, Toloczko, A, Tiezzi, DG, Taran, FA, Sinn, P, Sieh, W, Sharma, R, Rothstein, JH, Ramon y Cajal, T, Paz-Ares, L, Oszurek, O, Orsulic, S, Ness, RB, Nelson, G, Modugno, F, Menkiszak, J, McGuire, V, McCauley, BM, Mack, M, Lubinski, J, Longacre, TA, Li, Z, Lester, J, Kennedy, CJ, Kalli, KR, Jung, AY, Johnatty, SE, Jimenez-Linan, M, Jensen, A, Intermaggio, MP, Hung, J, Herpel, E, Hernandez, BY, Hartkopf, AD, Harnett, PR, Ghatage, P, Garcia-Bueno, JM, Gao, B, Fereday, S, Eilber, U, Edwards, RP, de Sousa, CB, de Andrade, JM, Chudecka-Glaz, A, Chenevix-Trench, G, Cazorla, A, Brucker, SY, Alsop, J, Whittemore, AS, Steed, H, Staebler, A, Moysich, KB, Menon, U, Koziak, JM, Kommoss, S, Kjaer, SK, Kelemen, LE, Karlan, BY, Huntsman, DG, Hogdall, E, Gronwald, J, Goodman, MT, Gilks, B, Jose Garcia, M, Fasching, PA, de Fazio, A, Deen, S, Chang-Claude, J, dos Reis, FJC, Campbell, IG, Brenton, JD, Bowtell, DD, Benitez, J, Pharoah, PDP, Kobel, M, Ramus, SJ, Goode, EL, Block, MS, Vierkant, RA, Rambau, PF, Winham, SJ, Wagner, P, Traficante, N, Toloczko, A, Tiezzi, DG, Taran, FA, Sinn, P, Sieh, W, Sharma, R, Rothstein, JH, Ramon y Cajal, T, Paz-Ares, L, Oszurek, O, Orsulic, S, Ness, RB, Nelson, G, Modugno, F, Menkiszak, J, McGuire, V, McCauley, BM, Mack, M, Lubinski, J, Longacre, TA, Li, Z, Lester, J, Kennedy, CJ, Kalli, KR, Jung, AY, Johnatty, SE, Jimenez-Linan, M, Jensen, A, Intermaggio, MP, Hung, J, Herpel, E, Hernandez, BY, Hartkopf, AD, Harnett, PR, Ghatage, P, Garcia-Bueno, JM, Gao, B, Fereday, S, Eilber, U, Edwards, RP, de Sousa, CB, de Andrade, JM, Chudecka-Glaz, A, Chenevix-Trench, G, Cazorla, A, Brucker, SY, Alsop, J, Whittemore, AS, Steed, H, Staebler, A, Moysich, KB, Menon, U, Koziak, JM, Kommoss, S, Kjaer, SK, Kelemen, LE, Karlan, BY, Huntsman, DG, Hogdall, E, Gronwald, J, Goodman, MT, Gilks, B, Jose Garcia, M, Fasching, PA, de Fazio, A, Deen, S, Chang-Claude, J, dos Reis, FJC, Campbell, IG, Brenton, JD, Bowtell, DD, Benitez, J, Pharoah, PDP, Kobel, M, Ramus, SJ, and Goode, EL
Abstract: OBJECTIVE: To evaluate myeloid differentiation primary response gene 88 (MyD88) and Toll-like receptor 4 (TLR4) expression in relation to clinical features of epithelial ovarian cancer, histologic subtypes, and overall survival. PATIENTS AND METHODS: We conducted centralized immunohistochemical staining, semi-quantitative scoring, and survival analysis in 5263 patients participating in the Ovarian Tumor Tissue Analysis consortium. Patients were diagnosed between January 1, 1978, and December 31, 2014, including 2865 high-grade serous ovarian carcinomas (HGSOCs), with more than 12,000 person-years of follow-up time. Tissue microarrays were stained for MyD88 and TLR4, and staining intensity was classified using a 2-tiered system for each marker (weak vs strong). RESULTS: Expression of MyD88 and TLR4 was similar in all histotypes except clear cell ovarian cancer, which showed reduced expression compared with other histotypes (P<.001 for both). In HGSOC, strong MyD88 expression was modestly associated with shortened overall survival (hazard ratio [HR], 1.13; 95% CI, 1.01-1.26; P=.04) but was also associated with advanced stage (P<.001). The expression of TLR4 was not associated with survival. In low-grade serous ovarian cancer (LGSOC), strong expression of both MyD88 and TLR4 was associated with favorable survival (HR [95% CI], 0.49 [0.29-0.84] and 0.44 [0.21-0.89], respectively; P=.009 and P=.02, respectively). CONCLUSION: Results are consistent with an association between strong MyD88 staining and advanced stage and poorer survival in HGSOC and demonstrate correlation between strong MyD88 and TLR4 staining and improved survival in LGSOC, highlighting the biological differences between the 2 serous histotypes.
Published: 2018

20. IDENTIFICATION OF CLINICAL, GENETIC AND ENDOSCOPIC PREDICTORS OF INCIDENT COLORECTAL CANCER IN LYNCH SYNDROME UNDER COLONOSCOPY SCREENING

Author: Sanchez Garcia, A, additional, Navarro, M, additional, Moreno, L, additional, Ocaña, T, additional, Rodríguez-Moranta, F, additional, Rodríguez-Alonso, L, additional, Soriano, A, additional, Ramon y Cajal, T, additional, Llort, G, additional, Yagüe, C, additional, Picó, MD, additional, Jover, R, additional, Lopez-Fernandez, A, additional, Martinez Castro, E, additional, Alvarez, C, additional, Bessa, X, additional, Rivas, L, additional, Cubiellas, J, additional, Rodriguez-Alcalde, D, additional, Dacal, A, additional, Herraiz, M, additional, Garau, C, additional, Bujanda, L, additional, Cid, L, additional, Poves, C, additional, Garzon, M, additional, Pizarro, A, additional, Salces, I, additional, Ponce, M, additional, Carrillo-Palau, M, additional, Aguirre, E, additional, Saperas, E, additional, Suarez, A, additional, Piñol, V, additional, Lleuger, R, additional, Martinez-Bauer, E, additional, Romero, C, additional, Gisbert, A, additional, Jung, G, additional, Carballal, S, additional, Rivero, L, additional, Pellisé, M, additional, Balmaña, J, additional, Brunet, J, additional, Castells, A, additional, Capellà, G, additional, Moreira, L, additional, Serra, M, additional, and Balaguer, F, additional
Published: 2018
Full Text: View/download PDF

21. 734P Kidney manifestations in patients with hereditary leiomyomatosis and renal cell cancer syndrome (LHRCC) in Spain

Author: Sanchez, A.B., Teule, A., Lastra, E., Balmana, J., Robles, L., García, J.D.D., Ramón y Cajal, T., Llort, G., Fonfria, M., Robledo, M., Castillejo, A., Duran, M., Zuñiga, A., Gómez, L., Garcés, E. Grau, López, A., Bosquet-Sanz, M., Barberá, V., and Soto, J.L.
Published: 2020
Full Text: View/download PDF

22. P003 Implementation of High Throughput Parallel Sequencing in a Diagnostic Setting: Multiplexed Amplicon Sequencing of the Breast Cancer Genes BRCA1 and 2

Author: Zogopoulos G, Tomi Pastinen, Sivanandan K, Vaca F, Kinoshita T, Johannes B, Leguis E, Jansen-van der Weide M, Learn L, Godlewski D, Ed Saunders, Montserrat Rué, Vaisman A, de Bock G, Ángel Segura, Sabbaghian N, Mohammad Amin Kerachian, Pelletier S, Metcalfe K, Lilge L, Stockle E, Cheng S, Burger C, Woike A, Michelle Guy, Ragone A, Y. J. Bignon, Bronkhorst Y, Patricia N. Tonin, Lima M, Mieke Kriege, Karsan A, Zweemer R, Prady C, Beattie M, Panchal S, Kathleen Claes, van Zon P, Diane Provencher, Ummels A, Kang I, Shumak R, Arcusa Â, Yosr Hamdi, Alonso Mc, Dolman L, Houssami N, Olivier Delattre, Yannick Bidet, Claude Houdayer, Mercedes Durán, Ganschow P, Isabel Chirivella, Domingo S, Rebsamen M, Giustina Simone, Orland Diez, Chapman J, An tSaoir C, Jeanna McCuaig, Blayney J, Bosdet I, Treacy R, Esther Darder, Ando J, Luc Dehaspe, García-Casado Z, Duffy J, Harkin D, Z Kote-Jarai, Kasamatsu T, Ulf Kristoffersson, Membrez, Priston M, Noreau-Heisz D, Trivedi A, Begoña Graña, Ghadirian P, Ashuryk O, Consol López, Wenzel L, Vogel R, Joseph G, Poll A, Kennedy R, Patton S, Pérez C, Mónica Cornet, Panighetti A, Cassart P, Burke K, Mes-Masson A, Llacuachaqui M, Marc Tischkowitz, Wong N, Arcand S, Kotsopoulos J, Meschino W, Hall A, Marles S, Docking R, Haroun I, Marie Plante, Rachel Laframboise, Daniel Sinnett, Luce J, Sekiguchi I, Edenir Inêz Palmero, de Winter J, Christopher J. Lord, Hamel N, Pruski-Clark J, Lee D, Rusnak A, Carson N, Marta Santamariña, Knoppers B, Oakhill K, Bruce R. Rosen, Pierre O. Chappuis, Bruce Poppe, Stanislaw C, Catts Z, Brood M, van der Wall E, Yip C, Christine Walsh, Hoodfar E, Pressman A, Andrulis I, Alicia Barroso, D. Leongamornlert, Gillian Mitchell, Akira Hirasawa, Shen Z, Sameer Parpia, Horgan M, van Echtelt J, Chun K, Lubinski J, Rebecca Sutphen, Terespolsky D, Richard D, McDyer F, Floquet A, Lambo R, Bathurst L, Brown G, Kidd M, Nicolas Sevenet, Mourits M, Vencken P, Tatiana Popova, Garcia N, Armel S, van Amstel H, Valentini A, Ellen Warner, Hofland N, Hanna D, Kim J, Osann K, Enmore M, Loranger K, Sulivan I, J. Oliveira, Meijers H, Jansen R, Edmundo Carvalho Mauad, Kirkpatrick R, Danilo V Viana, Ian G. Campbell, Mil S, E J Sawyer, J. Balmaña, Samra Turajlic, Graham G, Alonso C, Inanc Birol, Sinclair F, van Tuil M, Pascual Bolufer, Micheli R, Andrew R. Green, Junyent N, Whittaker J, Monnerat C, Rhéaume J, Livingston D, Chan S, L. Ramadan, Lee R, Katarzyna Durda, De Leeneer K, Grados C, Côté C, Kyle B. Matchett, Robert Winqvist, Bonner D, Brunella Pilato, Mohd Taib N, Judy Garber, Kleiderman E, Murakami S, Sharifi N, Kimberley Hill, Desbiens C, Robert Royer, Jasperson K, Hsieh S, De Summa S, Dominique Stoppa-Lyonnet, de Lima J, Stuart McIntosh, Shakeri M, Wendy Kohlmann, Albert-Green A, de Hullu J, Pasick R, Avard D, Pathania S, van der Groep P, Laura Fachal, Bruno Zeitouni, Susan M. Domchek, Davey S, Richard Marais, Powell C, Hans J. J. P. Gille, Greenberg R, Kamata H, Cina, Gaarenstroom K, Lakhal Chaieb M, Kavanagh L, Gaelle Benais-Pont, Sun P, Jansen L, Matthew Parker, Barjhoux L, Russ H, Simon J. Furney, Willems A, Robb L, David E. Goldgar, Young S, Natalia Campacci, Mark G. Thomas, Doug Easton, Klugman S, Barrault M, Calvo N, Adriana C. Flora, Littell R, Narod S, Fragoso, N. Bosch, Finch A, Paul M. Wilkerson, Teo S, Tomasz Huzarski, Manuel Salto-Tellez, Moseley M, Davis S, Olga M. Sinilnikova, Iturbe A, Joan Brunet, Tierney M, Tsai E, Navarro de Souza A, Leclerc M, Lorenzo Manti, Gutiérrez-Enríquez S, Milewski B, Simon S. McDade, Kaplan C, Buckley N, Eva Esteban-Cardeñosa, Richter S, Shimizu C, Li J, Elena Castro, Iwanka Kozarewa, Harley I, Atocha Romero, Carlos E. Andrade, Carole Verny-Pierre, Barouk E, Vian D, Montserrat Baiget, Chan J, Sandra Bonache, Andrew Y Shuen, van der Merwe N, Kaklewski K, Mohar A, Tamura C, Heale E, Rooyadeh M, van Asperen C, Gemma Llort, Alan Mackay, Denroche R, Seelaus C, Zbuk K, McCluggage W, van der Luijt R, Maaike P.G. Vreeswijk, Edelweiss M, Crossan G, Arseneau J, Ambus I, Verheul H, Rodrigo Augusto Depieri Michelli, Juul T. Wijnen, Gross-Lester J, Britta Weigelt, Pedro Pérez-Segura, Richard A. Moore, Cornelissen C, Larouche G, McAlpine J, Daniel Nava Rodrigues, Trim L, Furnival J, Elser C, Muszyńka M, Adriana Lasa, Tuya Pal, Greuter. M, Ng K, Dorval M, Bresee C, Reimnitz G, Gaëtan MacGrogan, Perry Maxwell, Barnadas A, Hwang E, Powell B, Knapke S, Griskevicius. L, Alvarez R, Mester J, Anne-Bine Skytte, Eladio Velasco, Vidal S, Australie K, Leunen K, Ben-Yishay M, Van Houdt J, Phuah S, Amy E Taylor, Pinto R, Fonseca T, Champine M, Gammon A, Hollema H, Menko F, Feng B, David Olmos, Chong G, Tomasz Byrski, Patrick J. Morrison, Gregoire J, André Lopes Carvalho, Don B. Plewes, Rabeneck L, Carrol J, Alan Ashworth, Terlinge A, A Jakubowska, Odette Mariani, Setareh Moghadasi, Reitsma W, Rothenmund H, Herrera L, Anna Tenés, Angel Izquierdo, Asunción Torres, Stawicka M, Goh C, Hirst M, Drummond J, Osorio A, Ostrovsky R, Jeffrey N. Weitzel, Gareth W. Irwin, Fehniger J, Sugano K, Spriggs E, Dęniak T, Volenik A, Thorne H, Piccinin C, Amie Blanco, Jinno H, Robert A. Holt, Stephen B. Fox, Julia J. Gorski, Gilpin C, Herschorn S, Vega A, E. Page, Hamet P, McKenna D, Fabrice Bonnet, Yoshida T, Kienan I. Savage, Petzel S, Elizabeth Bancroft, Schneider S, Warwick L, Stewart S, William D. Foulkes, Colizza K, Bell K, Demsky R, Malgorzata Tymrakiewicz, Caldés T, Fons G, Bowen D, Côté S, Clouston D, Kitagawa Y, Gordon Glendon, Jenny Lester, Kinney A, Nelson E, Silke Hollants, Macrae L, Cajal T, Andrew J. Mungall, Ferrell B, Creighton B, Bressler L, Uy P, Makishima K, Haffaf Z, Ramūnas Janavičius, Einstein G, Zakalik D, Chiarelli A, Cantu D, Croce S, Kalloger S, Lin F, Ian O. Ellis, Benedito Mauro Rossi, R A Wilkinson, Mulligan J, Murphy J, Vadaparampil S, Smith E, Slangen B, Loiselle C, Iqbal J, Palma L, Cooper K, Jorge S. Reis-Filho, Chen. L, Quinten Waisfisz, Haneda E, Banks P, Vermeulen K, Visser B, Montalbán G, McCabe N, Honeyford J, Naseri S, Ng J, Ali A, Sandrine Viala, Mensa I, Kamarainen O, Guerra C, Mazzola E, David A. Schwartz, Marjanka K. Schmidt, Simon R, Fergus J. Couch, Margreet G. E. M. Ausems, Anne Vincent-Salomon, Olinski R, Zewald R, Moreno R, Semple J, McPherson J, Lamers E, Kharbanda A, Kessler L, Biemans D, Au A, Bordeleau L, Jean Feunteun, Mar Infante, Mullan P, Rudaitis, Molenda A, Rachael Natrajan, Pawar, Boman B, Kok T, Andrew A. Brown, Geller M, Monfared N, Bart J, Murata P, Crawford N, Butterfield Y, Bargalló J, Katherine L. Tucker, Cook-Wiens G, Rhodes A, Elodie Manié, Rubio E, Oram L, Shandiz F, Hayden R, Crawford B, Parmigiani G, Harkin P, Müller C, Grant M, Maryou B. Lambros, Thong M, Grzegorz Sukiennicki, Wouts J, Haddock P, Ramon y Cajal T, Kenneth C. Anderson, Michel Longy, Batiste W, Carroll J, Matte C, Hojyo T, Zhao Y, Caroline Seynaeve, Wai P, Simard J, Hurley K, Bolton D, Karlan B, Javier Benítez, Miriam Masas, Tołczko-Grabarek A, de Dueñas E, Geneviève Michils, Moncoutier, Nancy Uhrhammer, MacDonald D, Keyserlingk J, Osher D, Gilks C, Christopher T. Elliott, Scharf L, Gabram-Mendola S, Grondin K, Dohany L, van Diest P, Joris Vermeesch, Jan C. Oosterwijk, M’Baïlara K, DePuit M, Jacek Gronwald, Stefania Tommasi, de la Hoya M, Bouchard K, Black L, Lui M, Soucy P, Rosalind A. Eeles, Gert Matthijs, Graham T, Andrea Eisen, Bacha O, Alvaro N.A. Monteiro, Yoon S, Caron T, Smith D, Marc-Henri Stern, Hampson E, Kurz R, Gaasbeek W, Mundt E, Angela Velasco, Quinn J, Jocelyne Chiquette, Marquez T, Adam B. Murphy, Bakker J, Neus Gadea, Anita Grigoriadis, Aoki D, Dean S, Looi L, Paradiso A, Agostina Stradella, K. Govindasami, Lovell N, Eva Tomiak, Siesling S, Belanger M, Feilotter H, Knight J, Emmanuel Barillot, Huang M, Raquel Andrés, Kang P, Somerman C, Gackowski D, Rimel B, Nakamura S, McClellan K, Barrros E, Henriette Roed Nielsen, Rui Manuel Reis, Greening S, Ayme A, Carmen Guillen, de Vries E, and Katarzyna Jaworska
Subjects: Oncology, Education and Communication, medicine.medical_specialty, endocrine system diseases, medicine.diagnostic_test, business.industry, Psycho-Oncology, medicine.disease, Meeting Abstracts, Transcriptome, Basic Research, Clinical Management, Germline mutation, Breast cancer, Applied Research, Internal medicine, Mutation (genetic algorithm), medicine, Genetic Counselling, Human genome, skin and connective tissue diseases, business, Ovarian cancer, Comparative genomic hybridization, Fluorescence in situ hybridization
Abstract: Background: Germline mutation screening of BRCA1 and BRCA2 genes is performed in suspected familial breast cancer cases, but a causative mutation is found in only 30% of patients. The development of additional methods to identify good candidates for BRCA1 and BRCA2 analysis would therefore increase the efficacy of diagnostic mutation screening. With this in mind, we developed a study to determine molecular signatures of BRCA1—or BRCA2—mutated breast cancers. Materials and Methods: Array-cgh (comparative genomic hybridization) and transcriptomic analysis were performed on a series of 103 familial breast cancers. The series included 7 breast cancers with a BRCA1 mutation and 5 breast cancers with a BRCA2 mutation. The remaining 91 cases were obtained from 73 families selected on the basis of at least 3 affected first-degree relatives or at least 2 affected first-degree relatives with breast cancer at an average age of 45 years. Array-cgh analyses were performed on a 4407 BAC-array (CIT-V8) manufactured by IntegraGen. Transcriptomic analyses were performed using an Affymetrix Human Genome U133 Plus 2.0 chip. Results: Using supervised clustering analyses we identified two transcriptomic signatures: one for BRCA1-mutated breast cancers consisting of 600 probe sets and another for BRCA2-mutated breast cancers also consisting of 600 probes sets. We also defined cgh-array signatures, based on the presence of specific genomic rearrangements, one for BRCA1-mutated breast cancers and one for BRCA2-mutated breast cancers. Conclusions: This study identified molecular signatures of breast cancers with BRCA1 or BRCA2 germline mutations. Genes present in these signatures could be exploited to find new markers for such breast cancers. We also identified specific genomic rearrangements in these breast cancers, which could be screened for in a diagnostic setting using fluorescence in situ hybridization, thus improving patient selection for BRCA1 and BRCA2 molecular genetic analysis.
Published: 2009

23. Multi-gene panels: new clinical experience in hereditary breast and ovarian cancer

Author: Ramon y Cajal, T., primary, Lasa, A., additional, Llort, G., additional, Lopez, C., additional, Yagüe, C., additional, Cornet, M., additional, Gisbert, A., additional, Fisas, D., additional, Calvo, N., additional, Vethencourt, A., additional, Barba, A., additional, Quero, S., additional, Martinez, E., additional, Hernan, I., additional, Ruiz, A., additional, Arcusa, A., additional, Saigi, E., additional, Barnadas, A., additional, and Surralles, J., additional
Published: 2017
Full Text: View/download PDF

24. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

Author: Rebbeck, TR, Mitra, N, Wan, F, Sinilnikova, OM, Healey, S, McGuffog, L, Chenevix-Trench, G, Easton, DF, Antoniou, AC, Nathanson, KL, Laitman, Y, Kushnir, A, Paluch-Shimon, S, Berger, R, Zidan, J, Friedman, E, Ehrencrona, H, Stenmark-Askmalm, M, Einbeigi, Z, Loman, N, Harbst, K, Rantala, J, Melin, B, Huo, D, Olopade, OI, Seldon, J, Ganz, PA, Nussbaum, RL, Chan, SB, Odunsi, K, Gayther, SA, Domchek, SM, Arun, BK, Lu, KH, Mitchell, G, Karlan, BY, Walsh, C, Lester, J, Godwin, AK, Pathak, H, Ross, E, Daly, MB, Whittemore, AS, John, EM, Miron, A, Terry, MB, Chung, WK, Goldgar, DE, Buys, SS, Janavičius, R, Tihomirova, L, Tung, N, Dorfling, CM, Van Rensburg, EJ, Steele, L, Neuhausen, SL, Ding, YC, Ejlertsen, B, Gerdes, AM, Hansen, TVO, Ramon Y Cajal, T, Osorio, A, Benitez, J, Godino, J, Tejada, MI, Duran, M, Weitzel, JN, Bobolis, KA, Sand, SR, Fontaine, A, Savarese, A, Pasini, B, Peissel, B, Bonanni, B, Zaffaroni, D, Vignolo-Lutati, F, Scuvera, G, Giannini, G, Bernard, L, Genuardi, M, Radice, P, Dolcetti, R, Manoukian, S, Pensotti, V, Gismondi, V, Yannoukakos, D, Fostira, F, Garber, J, Torres, D, and Rashid, MU
Subjects: endocrine system diseases, skin and connective tissue diseases
Abstract: Importance: Limited information about the relationship between specific mutations in BRCA1 or BRCA2 (BRCA1/2) and cancer risk exists. Objective: To identify mutation-specific cancer risks for carriers of BRCA1/2. Design, Setting, and Participants: Observational study ofwomen whowere ascertained between 1937 and 2011 (median, 1999) and found to carry disease-associated BRCA1 or BRCA2 mutations. The international sample comprised 19 581 carriers of BRCA1 mutations and 11 900 carriers of BRCA2 mutations from 55 centers in 33 countries on 6 continents.We estimated hazard ratios for breast and ovarian cancer based on mutation type, function, and nucleotide position.We also estimated RHR, the ratio of breast vs ovarian cancer hazard ratios. A value of RHR greater than 1 indicated elevated breast cancer risk; a value of RHR less than 1 indicated elevated ovarian cancer risk. Exposures: Mutations of BRCA1 or BRCA2. Main Outcomes and Measures: Breast and ovarian cancer risks. Results: Among BRCA1 mutation carriers, 9052 women (46%) were diagnosed with breast cancer, 2317 (12%) with ovarian cancer, 1041 (5%) with breast and ovarian cancer, and 7171 (37%) without cancer. Among BRCA2 mutation carriers, 6180 women (52%) were diagnosed with breast cancer, 682 (6%) with ovarian cancer, 272 (2%) with breast and ovarian cancer, and 4766 (40%) without cancer. In BRCA1, we identified 3 breast cancer cluster regions (BCCRs) located at c.179 to c.505 (BCCR1; RHR = 1.46; 95%CI, 1.22-1.74; P = 2 × 10-6), c.4328 to c.4945 (BCCR2; RHR = 1.34; 95%CI, 1.01-1.78; P = .04), and c. 5261 to c.5563 (BCCR2', RHR = 1.38; 95%CI, 1.22-1.55; P = 6 × 10-9).We also identified an ovarian cancer cluster region (OCCR) from c.1380 to c.4062 (approximately exon 11) with RHR = 0.62 (95%CI, 0.56-0.70; P = 9 × 10-17). In BRCA2, we observed multiple BCCRs spanning c.1 to c.596 (BCCR1; RHR = 1.71; 95%CI, 1.06-2.78; P = .03), c.772 to c.1806 (BCCR1'; RHR = 1.63; 95%CI, 1.10-2.40; P = .01), and c.7394 to c.8904 (BCCR2; RHR = 2.31; 95%CI, 1.69-3.16; P = .00002).We also identified 3 OCCRs: the first (OCCR1) spanned c.3249 to c.5681 that was adjacent to c.5946delT (6174delT; RHR = 0.51; 95%CI, 0.44-0.60; P = 6 × 10-17). The second OCCR spanned c.6645 to c.7471 (OCCR2; RHR = 0.57; 95%CI, 0.41-0.80; P = .001). Mutations conferring nonsense-mediated decay were associated with differential breast or ovarian cancer risks and an earlier age of breast cancer diagnosis for both BRCA1 and BRCA2 mutation carriers. Conclusions and Relevance: Breast and ovarian cancer risks varied by type and location of BRCA1/2 mutations. With appropriate validation, these data may have implications for risk assessment and cancer prevention decision making for carriers of BRCA1 and BRCA2 mutations.
Published: 2015

25. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

Author: Rebbeck, T.R., Mitra, N., Wan, F., Sinilnikova, O.M., Healey, S., McGuffog, L., Mazoyer, S., Chenevix-Trench, G., Easton, D.F., Antoniou, A.C., Nathanson, K.L., Laitman, Y., Kushnir, A., Paluch-Shimon, S., Berger, R., Zidan, J., Friedman, E., Ehrencrona, H., Stenmark-Askmalm, M., Einbeigi, Z., Loman, N., Harbst, K., Rantala, J., Melin, B., Huo, D., Olopade, O.I., Seldon, J., Ganz, P.A., Nussbaum, R.L., Chan, S.B., Odunsi, K., Gayther, S.A., Domchek, S.M., Arun, B.K., Lu, K.H., Mitchell, G., Karlan, B.Y., Walsh, C., Lester, J., Godwin, A.K., Pathak, H., Ross, E., Daly, M.B., Whittemore, A.S., John, E.M., Miron, A., Terry, M.B., Chung, W.K., Goldgar, D.E., Buys, S.S., Janavicius, R., Tihomirova, L., Tung, N., Dorfling, C.M., Rensburg, E.J. van, Steele, L., Neuhausen, S.L., Ding, Y.C., Ejlertsen, B., Gerdes, A.M., Hansen, T., Ramon Y Cajal, T., Osorio, A., Benitez, J., Godino, J., Tejada, M.I., Duran, M., Weitzel, J.N., Bobolis, K.A., Sand, S.R., Fontaine, A., Savarese, A., Pasini, B., Peissel, B., Bonanni, B., Zaffaroni, D., Vignolo-Lutati, F., Scuvera, G., Giannini, G., Bernard, L., Genuardi, M., Radice, P., Dolcetti, R., Manoukian, S., Pensotti, V., Gismondi, V., Yannoukakos, D., Fostira, F., Garber, J., Torres, D., Rashid, M.U., Hamann, U., Peock, S., Frost, D., Platte, R., Evans, D.G., Eeles, R., Davidson, R., Eccles, D., Cole, T., Kets, M., Mensenkamp, A.R., et al., Rebbeck, T.R., Mitra, N., Wan, F., Sinilnikova, O.M., Healey, S., McGuffog, L., Mazoyer, S., Chenevix-Trench, G., Easton, D.F., Antoniou, A.C., Nathanson, K.L., Laitman, Y., Kushnir, A., Paluch-Shimon, S., Berger, R., Zidan, J., Friedman, E., Ehrencrona, H., Stenmark-Askmalm, M., Einbeigi, Z., Loman, N., Harbst, K., Rantala, J., Melin, B., Huo, D., Olopade, O.I., Seldon, J., Ganz, P.A., Nussbaum, R.L., Chan, S.B., Odunsi, K., Gayther, S.A., Domchek, S.M., Arun, B.K., Lu, K.H., Mitchell, G., Karlan, B.Y., Walsh, C., Lester, J., Godwin, A.K., Pathak, H., Ross, E., Daly, M.B., Whittemore, A.S., John, E.M., Miron, A., Terry, M.B., Chung, W.K., Goldgar, D.E., Buys, S.S., Janavicius, R., Tihomirova, L., Tung, N., Dorfling, C.M., Rensburg, E.J. van, Steele, L., Neuhausen, S.L., Ding, Y.C., Ejlertsen, B., Gerdes, A.M., Hansen, T., Ramon Y Cajal, T., Osorio, A., Benitez, J., Godino, J., Tejada, M.I., Duran, M., Weitzel, J.N., Bobolis, K.A., Sand, S.R., Fontaine, A., Savarese, A., Pasini, B., Peissel, B., Bonanni, B., Zaffaroni, D., Vignolo-Lutati, F., Scuvera, G., Giannini, G., Bernard, L., Genuardi, M., Radice, P., Dolcetti, R., Manoukian, S., Pensotti, V., Gismondi, V., Yannoukakos, D., Fostira, F., Garber, J., Torres, D., Rashid, M.U., Hamann, U., Peock, S., Frost, D., Platte, R., Evans, D.G., Eeles, R., Davidson, R., Eccles, D., Cole, T., Kets, M., Mensenkamp, A.R., and et al.
Abstract: Item does not contain fulltext, IMPORTANCE: Limited information about the relationship between specific mutations in BRCA1 or BRCA2 (BRCA1/2) and cancer risk exists. OBJECTIVE: To identify mutation-specific cancer risks for carriers of BRCA1/2. DESIGN, SETTING, AND PARTICIPANTS: Observational study of women who were ascertained between 1937 and 2011 (median, 1999) and found to carry disease-associated BRCA1 or BRCA2 mutations. The international sample comprised 19,581 carriers of BRCA1 mutations and 11,900 carriers of BRCA2 mutations from 55 centers in 33 countries on 6 continents. We estimated hazard ratios for breast and ovarian cancer based on mutation type, function, and nucleotide position. We also estimated RHR, the ratio of breast vs ovarian cancer hazard ratios. A value of RHR greater than 1 indicated elevated breast cancer risk; a value of RHR less than 1 indicated elevated ovarian cancer risk. EXPOSURES: Mutations of BRCA1 or BRCA2. MAIN OUTCOMES AND MEASURES: Breast and ovarian cancer risks. RESULTS: Among BRCA1 mutation carriers, 9052 women (46%) were diagnosed with breast cancer, 2317 (12%) with ovarian cancer, 1041 (5%) with breast and ovarian cancer, and 7171 (37%) without cancer. Among BRCA2 mutation carriers, 6180 women (52%) were diagnosed with breast cancer, 682 (6%) with ovarian cancer, 272 (2%) with breast and ovarian cancer, and 4766 (40%) without cancer. In BRCA1, we identified 3 breast cancer cluster regions (BCCRs) located at c.179 to c.505 (BCCR1; RHR = 1.46; 95% CI, 1.22-1.74; P = 2 x 10(-6)), c.4328 to c.4945 (BCCR2; RHR = 1.34; 95% CI, 1.01-1.78; P = .04), and c. 5261 to c.5563 (BCCR2', RHR = 1.38; 95% CI, 1.22-1.55; P = 6 x 10(-9)). We also identified an ovarian cancer cluster region (OCCR) from c.1380 to c.4062 (approximately exon 11) with RHR = 0.62 (95% CI, 0.56-0.70; P = 9 x 10(-17)). In BRCA2, we observed multiple BCCRs spanning c.1 to c.596 (BCCR1; RHR = 1.71; 95% CI, 1.06-2.78; P = .03), c.772 to c.1806 (BCCR1'; RHR = 1.63; 95% CI, 1.10-2.40; P = .01), and c.73
Published: 2015

26. Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers

Author: Blanco, I., Kuchenbaecker, K., Cuadras, D., Wang, X., Barrowdale, D., Garibay, G.R. de, Librado, P., Sanchez-Gracia, A., Rozas, J., Bonifaci, N., McGuffog, L., Pankratz, V.S., Islam, A., Mateo, F., Berenguer, A., Petit, A., Catala, I., Brunet, J., Feliubadalo, L., Tornero, E., Benitez, J., Osorio, A., Ramon Y Cajal, T., Nevanlinna, H., Aittomaki, K., Arun, B.K., Toland, A.E., Karlan, B.Y., Walsh, C., Lester, J., Greene, M.H., Mai, P.L., Nussbaum, R.L., Andrulis, I.L., Domchek, S.M., Nathanson, K.L., Rebbeck, T.R., Barkardottir, R.B., Jakubowska, A., Lubinski, J., Durda, K., Jaworska-Bieniek, K., Claes, K., Maerken, T. Van, Diez, O., Hansen, T.V., Jonson, L., Gerdes, A.M., Ejlertsen, B., Hoya, M. de la, Caldes, T., Dunning, A.M., Oliver, C., Fineberg, E., Cook, M., Peock, S., McCann, E., Murray, A., Jacobs, C, Pichert, G., Lalloo, F., Chu, C., Dorkins, H., Paterson, J., Ong, K.R., Teixeira, M.R., Hogervorst, F.B., Hout, A.H. van der, Seynaeve, C., Luijt, R.B. van der, Ligtenberg, M.J., Devilee, P., Wijnen, J.T., Rookus, M.A., Meijers-Heijboer, H.E., Blok, M.J., Ouweland, A.M. van den, Aalfs, C.M., Rodriguez, G.C., Phillips, K.A., Piedmonte, M., Nerenstone, S.R., Bae-Jump, V.L., O'Malley, D.M., Ratner, E.S., Schmutzler, R.K., Wappenschmidt, B., Rhiem, K., Engel, C., Meindl, A., Ditsch, N., Arnold, N., Plendl, H.J., Niederacher, D., Sutter, C., Wang-Gohrke, S., Steinemann, D., Preisler-Adams, S., Kast, K., Varon-Mateeva, R., et al., Blanco, I., Kuchenbaecker, K., Cuadras, D., Wang, X., Barrowdale, D., Garibay, G.R. de, Librado, P., Sanchez-Gracia, A., Rozas, J., Bonifaci, N., McGuffog, L., Pankratz, V.S., Islam, A., Mateo, F., Berenguer, A., Petit, A., Catala, I., Brunet, J., Feliubadalo, L., Tornero, E., Benitez, J., Osorio, A., Ramon Y Cajal, T., Nevanlinna, H., Aittomaki, K., Arun, B.K., Toland, A.E., Karlan, B.Y., Walsh, C., Lester, J., Greene, M.H., Mai, P.L., Nussbaum, R.L., Andrulis, I.L., Domchek, S.M., Nathanson, K.L., Rebbeck, T.R., Barkardottir, R.B., Jakubowska, A., Lubinski, J., Durda, K., Jaworska-Bieniek, K., Claes, K., Maerken, T. Van, Diez, O., Hansen, T.V., Jonson, L., Gerdes, A.M., Ejlertsen, B., Hoya, M. de la, Caldes, T., Dunning, A.M., Oliver, C., Fineberg, E., Cook, M., Peock, S., McCann, E., Murray, A., Jacobs, C, Pichert, G., Lalloo, F., Chu, C., Dorkins, H., Paterson, J., Ong, K.R., Teixeira, M.R., Hogervorst, F.B., Hout, A.H. van der, Seynaeve, C., Luijt, R.B. van der, Ligtenberg, M.J., Devilee, P., Wijnen, J.T., Rookus, M.A., Meijers-Heijboer, H.E., Blok, M.J., Ouweland, A.M. van den, Aalfs, C.M., Rodriguez, G.C., Phillips, K.A., Piedmonte, M., Nerenstone, S.R., Bae-Jump, V.L., O'Malley, D.M., Ratner, E.S., Schmutzler, R.K., Wappenschmidt, B., Rhiem, K., Engel, C., Meindl, A., Ditsch, N., Arnold, N., Plendl, H.J., Niederacher, D., Sutter, C., Wang-Gohrke, S., Steinemann, D., Preisler-Adams, S., Kast, K., Varon-Mateeva, R., and et al.
Abstract: Contains fulltext : 154570.PDF (publisher's version ) (Open Access), While interplay between BRCA1 and AURKA-RHAMM-TPX2-TUBG1 regulates mammary epithelial polarization, common genetic variation in HMMR (gene product RHAMM) may be associated with risk of breast cancer in BRCA1 mutation carriers. Following on these observations, we further assessed the link between the AURKA-HMMR-TPX2-TUBG1 functional module and risk of breast cancer in BRCA1 or BRCA2 mutation carriers. Forty-one single nucleotide polymorphisms (SNPs) were genotyped in 15,252 BRCA1 and 8,211 BRCA2 mutation carriers and subsequently analyzed using a retrospective likelihood approach. The association of HMMR rs299290 with breast cancer risk in BRCA1 mutation carriers was confirmed: per-allele hazard ratio (HR) = 1.10, 95% confidence interval (CI) 1.04-1.15, p = 1.9 x 10(-4) (false discovery rate (FDR)-adjusted p = 0.043). Variation in CSTF1, located next to AURKA, was also found to be associated with breast cancer risk in BRCA2 mutation carriers: rs2426618 per-allele HR = 1.10, 95% CI 1.03-1.16, p = 0.005 (FDR-adjusted p = 0.045). Assessment of pairwise interactions provided suggestions (FDR-adjusted pinteraction values > 0.05) for deviations from the multiplicative model for rs299290 and CSTF1 rs6064391, and rs299290 and TUBG1 rs11649877 in both BRCA1 and BRCA2 mutation carriers. Following these suggestions, the expression of HMMR and AURKA or TUBG1 in sporadic breast tumors was found to potentially interact, influencing patients' survival. Together, the results of this study support the hypothesis of a causative link between altered function of AURKA-HMMR-TPX2-TUBG1 and breast carcinogenesis in BRCA1/2 mutation carriers.
Published: 2015

27. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

Author: Rebbeck, R. (Timothy), Mitra, N. (Nandita), Wan, F. (Fei), Sinilnikova, O. (Olga), Healey, S. (Sue), McGuffog, L. (Lesley), Chenevix-Trench, G. (Georgia), Easton, D.F. (Douglas), Antoniou, A.C. (Antonis), Nathanson, K.L. (Katherine), Laitman, Y. (Yael), Kushnir, A. (Anya), Paluch-Shimon, S. (Shani), Berger, R. (Raanan), Zidan, J. (Jamal), Friedman, E. (Eitan), Ehrencrona, H. (Hans), Stenmark-Askmalm, M. (Marie), Einbeigi, Z. (Zakaria), Loman, N. (Niklas), Harbst, K. (Katja), Rantala, J. (Johanna), Melin, B. (Beatrice), Huo, D. (Dezheng), Olopade, O.I. (Olofunmilayo), Seldon, J.L. (Joyce), Ganz, P.A. (Patricia), Nussbaum, R.L. (Robert L.), Chan, S. (Salina), Odunsi, K. (Kunle), Gayther, S.A. (Simon), Domchek, S.M. (Susan), Arun, B.K. (Banu), Lu, K.H. (Karen), Mitchell, G. (Gillian), Karlan, B.Y. (Beth), Walsh, C.S. (Christine), Lester, K.J. (Kathryn), Godwin, A.K. (Andrew), Pathak, S.S., Ross, E.B. (Eric), Daly, M.J. (Mark), Whittemore, A.S. (Alice), John, E.M. (Esther), Miron, A. (Alexander), Terry, M.B. (Mary Beth), Chung, W.K. (Wendy K.), Goldgar, D. (David), Buys, S.S. (Saundra), Janavicius, R. (Ramunas), Tihomirova, L. (Laima), Tung, N. (Nadine), Dorfling, C.M. (Cecilia), Rensburg, E.J. (Elizabeth) van, Steele, L. (Linda), Neuhausen, S.L. (Susan), Ding, Y.C. (Yuan), Ejlertsen, B. (Bent), Gerdes, A-M. (Anne-Marie), Hansen, T.V.O. (Thomas), Ramon Y Cajal, T., Osorio, A. (Ana), Benítez, J. (Javier), Godino, J. (Javier), Tejada, M.I., Duran, M. (Mercedes), Weitzel, J.N. (Jeffrey), Bobolis, K.A. (Kristie A.), Sand, S.R. (Sharon), Fontaine, A. (Annette), Savarese, A. (Antonella), Pasini, B. (Barbara), Peissel, B. (Bernard), Bonnani, B. (Bernardo), Zaffaroni, D. (Daniela), Vignolo-Lutati, F. (Francesca), Scuvera, G. (Giulietta), Giannini, G. (Giuseppe), Bernard, L. (Loris), Genuardi, M. (Maurizio), Radice, P. (Paolo), Dolcetti, R. (Riccardo), Manoukian, S. (Siranoush), Pensotti, V. (Valeria), Gismondi, V. (Viviana), Yannoukakos, D. (Drakoulis), Fostira, F. (Florentia), Garber, J. (Judy), Torres, D. (Diana), Rashid, M.U. (Muhammad), Hamann, U. (Ute), Peock, S. (Susan), Frost, D. (Debra), Platte, R. (Radka), Evans, D.G. (Gareth), Eeles, R. (Rosalind), Davidson, R. (Rosemarie), Eccles, D. (Diana), Cole, T. (Trevor), Cook, J. (Jackie), Brewer, C. (Carole), Hodgson, S. (Shirley), Morrison, P.J. (Patrick), Walker, L.J. (Lisa), Porteous, M.E. (Mary), Kennedy, M.J. (John), Izatt, L. (Louise), Adlard, L., Donaldson, A. (Alan), Ellis, S.D. (Steve), Sharma, P. (Priyanka), Schmutzler, R.K. (Rita), Wapenschmidt, B. (Barbara), Becker, A. (Alexandra), Rhiem, K. (Kerstin), Hahnen, E. (Eric), Engel, C. (Christoph), Meindl, A. (Alfons), Engert, S. (Stefanie), Ditsch, N. (Nina), Arnold, N. (Norbert), Plendl, H. (Hansjoerg), Mundhenke, C. (Christoph), Niederacher, D. (Dieter), Fleisch, M.C. (Markus), Sutter, C. (Christian), Bartram, C.R. (Claus), Dikow, N. (Nicola), Wang-Gohrke, S. (Shan), Gadzicki, D. (Dorothea), Steinemann, D. (Doris), Kast, K. (Karin), Beer, M. (Marit), Varon-Mateeva, R. (Raymonda), Gehrig, P.A. (Paola A.), Weber, B.H.F. (Bernhard), Stoppa-Lyonnet, D. (Dominique), Belotti, M. (Muriel), Gauthier-Villars, M. (Marion), Damiola, F. (Francesca), Boutry-Kryza, N. (N.), Lasset, C. (Christine), Sobol, H. (Hagay), Peyrat, J.-P., Muller, D.W. (Danièle), Fricker, J.P. (Jean Pierre), Collonge-Rame, M.-A., Mortemousque, I. (Isabelle), Nogues, C. (Catherine), Rouleau, E. (Etienne), Isaacs, C. (Claudine), Paepe, A. (Anne) de, Poppe, B. (Bruce), Claes, K. (Kathleen), De Leeneer, K. (Kim), Piedmonte, M. (Marion), Rodriguez, G. (Gustavo), Wakely, K. (Katie), Boggess, J.F. (John), Blank, S.V. (Stephanie), Basil, J. (Jack), Azodi, M. (Masoud), Phillips, K.-A. (Kelly-Anne), Caldes, T. (Trinidad), Hoya, M. (Miguel) de La, Romero, A. (Atocha), Nevanlinna, H. (Heli), Aittomäki, K. (Kristiina), Hout, A.H. (Annemarie) van der, Hogervorst, F.B.L. (Frans), Verhoef, S., Collée, J.M. (Margriet), Seynaeve, C.M. (Caroline), Oosterwijk, J.C. (Jan), Gille, J.J. (Johan), Wijnen, J.T. (Juul), Gómez García, E.B. (Encarna), Kets, C.M. (Marleen), Ausems, M.G.E.M. (Margreet), Aalfs, C.M. (Cora), Devilee, P. (Peter), Mensenkamp, A.R. (Arjen), Kwong, A. (Ava), Olah, E., Papp, J. (Janos), Díez, O. (Orland), Lázaro, C. (Conxi), Darder, E. (Esther), Blanco, I. (Ignacio), Salinas, M., Jakubowska, A. (Anna), Lubinski, J. (Jan), Gronwald, J. (Jacek), Jaworska-Bieniek, K. (Katarzyna), Durda, K. (Katarzyna), Sukiennicki, G. (Grzegorz), Huzarski, T. (Tomasz), Byrski, T. (Tomasz), Cybulski, C. (Cezary), Toloczko-Grabarek, A. (Aleksandra), Złowocka-Perłowska, E. (Elzbieta), Menkiszak, J. (Janusz), Arason, A. (Adalgeir), Barkardottir, R.B. (Rosa), Simard, J. (Jacques), Laframboise, R. (Rachel), Montagna, M. (Marco), Agata, S. (Simona), Alducci, E. (Elisa), Peixoto, A. (Ana), Teixeira, P.J., Spurdle, A.B. (Amanda), Lee, M.H. (Min Hyuk), Park, S.K. (Sue), Kim, S.-W. (Sung-Won), Friebel, M.O.W. (Mark ), Couch, F.J. (Fergus), Lindor, N.M. (Noralane), Pankratz, V.S. (Shane), Guidugli, L. (Lucia), Wang, X. (Xianshu), Tischkowitz, M. (Marc), Foretova, L. (Lenka), Vijai, J. (Joseph), Offit, K. (Kenneth), Robson, M. (Mark), Rau-Murthy, R. (Rohini), Kauff, N. (Noah), Fink-Retter, A. (Anneliese), Singer, C.F. (Christian), Rappaport, C. (Christine), Gschwantler-Kaulich, D. (Daphne), Pfeiler, G. (Georg), Tea, M.-K., Berger, A. (Andreas), Greene, M.H. (Mark), Mai, P.L. (Phuong), Imyanitov, E.N. (Evgeny), Toland, A.E. (Amanda), Senter, L. (Leigha), Bojesen, A. (Anders), Pedersen, I.S. (Inge Sokilde), Skytte, A.-B. (Anne-Bine), Sunde, L. (Lone), Thomassen, M. (Mads), Moeller, S.T. (Sanne Traasdahl), Kruse, T.A. (Torben), Jensen, U.B., Caligo, M.A. (Maria), Aretini, P. (Paolo), Teo, S.-H. (Soo-Hwang), Selkirk, C.G. (Christina), Hulick, P.J. (Peter), Andrulis, I.L. (Irene), Rebbeck, R. (Timothy), Mitra, N. (Nandita), Wan, F. (Fei), Sinilnikova, O. (Olga), Healey, S. (Sue), McGuffog, L. (Lesley), Chenevix-Trench, G. (Georgia), Easton, D.F. (Douglas), Antoniou, A.C. (Antonis), Nathanson, K.L. (Katherine), Laitman, Y. (Yael), Kushnir, A. (Anya), Paluch-Shimon, S. (Shani), Berger, R. (Raanan), Zidan, J. (Jamal), Friedman, E. (Eitan), Ehrencrona, H. (Hans), Stenmark-Askmalm, M. (Marie), Einbeigi, Z. (Zakaria), Loman, N. (Niklas), Harbst, K. (Katja), Rantala, J. (Johanna), Melin, B. (Beatrice), Huo, D. (Dezheng), Olopade, O.I. (Olofunmilayo), Seldon, J.L. (Joyce), Ganz, P.A. (Patricia), Nussbaum, R.L. (Robert L.), Chan, S. (Salina), Odunsi, K. (Kunle), Gayther, S.A. (Simon), Domchek, S.M. (Susan), Arun, B.K. (Banu), Lu, K.H. (Karen), Mitchell, G. (Gillian), Karlan, B.Y. (Beth), Walsh, C.S. (Christine), Lester, K.J. (Kathryn), Godwin, A.K. (Andrew), Pathak, S.S., Ross, E.B. (Eric), Daly, M.J. (Mark), Whittemore, A.S. (Alice), John, E.M. (Esther), Miron, A. (Alexander), Terry, M.B. (Mary Beth), Chung, W.K. (Wendy K.), Goldgar, D. (David), Buys, S.S. (Saundra), Janavicius, R. (Ramunas), Tihomirova, L. (Laima), Tung, N. (Nadine), Dorfling, C.M. (Cecilia), Rensburg, E.J. (Elizabeth) van, Steele, L. (Linda), Neuhausen, S.L. (Susan), Ding, Y.C. (Yuan), Ejlertsen, B. (Bent), Gerdes, A-M. (Anne-Marie), Hansen, T.V.O. (Thomas), Ramon Y Cajal, T., Osorio, A. (Ana), Benítez, J. (Javier), Godino, J. (Javier), Tejada, M.I., Duran, M. (Mercedes), Weitzel, J.N. (Jeffrey), Bobolis, K.A. (Kristie A.), Sand, S.R. (Sharon), Fontaine, A. (Annette), Savarese, A. (Antonella), Pasini, B. (Barbara), Peissel, B. (Bernard), Bonnani, B. (Bernardo), Zaffaroni, D. (Daniela), Vignolo-Lutati, F. (Francesca), Scuvera, G. (Giulietta), Giannini, G. (Giuseppe), Bernard, L. (Loris), Genuardi, M. (Maurizio), Radice, P. (Paolo), Dolcetti, R. (Riccardo), Manoukian, S. (Siranoush), Pensotti, V. (Valeria), Gismondi, V. (Viviana), Yannoukakos, D. (Drakoulis), Fostira, F. (Florentia), Garber, J. (Judy), Torres, D. (Diana), Rashid, M.U. (Muhammad), Hamann, U. (Ute), Peock, S. (Susan), Frost, D. (Debra), Platte, R. (Radka), Evans, D.G. (Gareth), Eeles, R. (Rosalind), Davidson, R. (Rosemarie), Eccles, D. (Diana), Cole, T. (Trevor), Cook, J. (Jackie), Brewer, C. (Carole), Hodgson, S. (Shirley), Morrison, P.J. (Patrick), Walker, L.J. (Lisa), Porteous, M.E. (Mary), Kennedy, M.J. (John), Izatt, L. (Louise), Adlard, L., Donaldson, A. (Alan), Ellis, S.D. (Steve), Sharma, P. (Priyanka), Schmutzler, R.K. (Rita), Wapenschmidt, B. (Barbara), Becker, A. (Alexandra), Rhiem, K. (Kerstin), Hahnen, E. (Eric), Engel, C. (Christoph), Meindl, A. (Alfons), Engert, S. (Stefanie), Ditsch, N. (Nina), Arnold, N. (Norbert), Plendl, H. (Hansjoerg), Mundhenke, C. (Christoph), Niederacher, D. (Dieter), Fleisch, M.C. (Markus), Sutter, C. (Christian), Bartram, C.R. (Claus), Dikow, N. (Nicola), Wang-Gohrke, S. (Shan), Gadzicki, D. (Dorothea), Steinemann, D. (Doris), Kast, K. (Karin), Beer, M. (Marit), Varon-Mateeva, R. (Raymonda), Gehrig, P.A. (Paola A.), Weber, B.H.F. (Bernhard), Stoppa-Lyonnet, D. (Dominique), Belotti, M. (Muriel), Gauthier-Villars, M. (Marion), Damiola, F. (Francesca), Boutry-Kryza, N. (N.), Lasset, C. (Christine), Sobol, H. (Hagay), Peyrat, J.-P., Muller, D.W. (Danièle), Fricker, J.P. (Jean Pierre), Collonge-Rame, M.-A., Mortemousque, I. (Isabelle), Nogues, C. (Catherine), Rouleau, E. (Etienne), Isaacs, C. (Claudine), Paepe, A. (Anne) de, Poppe, B. (Bruce), Claes, K. (Kathleen), De Leeneer, K. (Kim), Piedmonte, M. (Marion), Rodriguez, G. (Gustavo), Wakely, K. (Katie), Boggess, J.F. (John), Blank, S.V. (Stephanie), Basil, J. (Jack), Azodi, M. (Masoud), Phillips, K.-A. (Kelly-Anne), Caldes, T. (Trinidad), Hoya, M. (Miguel) de La, Romero, A. (Atocha), Nevanlinna, H. (Heli), Aittomäki, K. (Kristiina), Hout, A.H. (Annemarie) van der, Hogervorst, F.B.L. (Frans), Verhoef, S., Collée, J.M. (Margriet), Seynaeve, C.M. (Caroline), Oosterwijk, J.C. (Jan), Gille, J.J. (Johan), Wijnen, J.T. (Juul), Gómez García, E.B. (Encarna), Kets, C.M. (Marleen), Ausems, M.G.E.M. (Margreet), Aalfs, C.M. (Cora), Devilee, P. (Peter), Mensenkamp, A.R. (Arjen), Kwong, A. (Ava), Olah, E., Papp, J. (Janos), Díez, O. (Orland), Lázaro, C. (Conxi), Darder, E. (Esther), Blanco, I. (Ignacio), Salinas, M., Jakubowska, A. (Anna), Lubinski, J. (Jan), Gronwald, J. (Jacek), Jaworska-Bieniek, K. (Katarzyna), Durda, K. (Katarzyna), Sukiennicki, G. (Grzegorz), Huzarski, T. (Tomasz), Byrski, T. (Tomasz), Cybulski, C. (Cezary), Toloczko-Grabarek, A. (Aleksandra), Złowocka-Perłowska, E. (Elzbieta), Menkiszak, J. (Janusz), Arason, A. (Adalgeir), Barkardottir, R.B. (Rosa), Simard, J. (Jacques), Laframboise, R. (Rachel), Montagna, M. (Marco), Agata, S. (Simona), Alducci, E. (Elisa), Peixoto, A. (Ana), Teixeira, P.J., Spurdle, A.B. (Amanda), Lee, M.H. (Min Hyuk), Park, S.K. (Sue), Kim, S.-W. (Sung-Won), Friebel, M.O.W. (Mark ), Couch, F.J. (Fergus), Lindor, N.M. (Noralane), Pankratz, V.S. (Shane), Guidugli, L. (Lucia), Wang, X. (Xianshu), Tischkowitz, M. (Marc), Foretova, L. (Lenka), Vijai, J. (Joseph), Offit, K. (Kenneth), Robson, M. (Mark), Rau-Murthy, R. (Rohini), Kauff, N. (Noah), Fink-Retter, A. (Anneliese), Singer, C.F. (Christian), Rappaport, C. (Christine), Gschwantler-Kaulich, D. (Daphne), Pfeiler, G. (Georg), Tea, M.-K., Berger, A. (Andreas), Greene, M.H. (Mark), Mai, P.L. (Phuong), Imyanitov, E.N. (Evgeny), Toland, A.E. (Amanda), Senter, L. (Leigha), Bojesen, A. (Anders), Pedersen, I.S. (Inge Sokilde), Skytte, A.-B. (Anne-Bine), Sunde, L. (Lone), Thomassen, M. (Mads), Moeller, S.T. (Sanne Traasdahl), Kruse, T.A. (Torben), Jensen, U.B., Caligo, M.A. (Maria), Aretini, P. (Paolo), Teo, S.-H. (Soo-Hwang), Selkirk, C.G. (Christina), Hulick, P.J. (Peter), and Andrulis, I.L. (Irene)
Abstract: Importance: Limited information about the relationship between specific mutations in BRCA1 or BRCA2 (BRCA1/2) and cancer risk exists. Objective: To identify mutation-specific cancer risks for carriers of BRCA1/2. Design, Setting, and Participants: Observational study ofwomen whowere ascertained between 1937 and 2011 (median, 1999) and found to carry disease-associated BRCA1 or BRCA2 mutations. The international sample comprised 19 581 carriers of BRCA1 mutations and 11 900 carriers of BRCA2 mutations from 55 centers in 33 countries on 6 continents.We estimated hazard ratios for breast and ovarian cancer based on mutation type, function, and nucleotide position.We also estimated RHR, the ratio of breast vs ovarian cancer hazard ratios. A value of RHR greater than 1 indicated elevated breast cancer risk; a value of RHR less than 1 indicated elevated ovarian cancer risk. Exposures: Mutations of BRCA1 or BRCA2. Main Outcomes and Measures: Breast and ovarian cancer risks. Results: Among BRCA1 mutation carriers, 9052 women (46%) were diagnosed with breast cancer, 2317 (12%) with ovarian cancer, 1041 (5%) with breast and ovarian cancer, and 7171 (37%) without cancer. Among BRCA2 mutation carriers, 6180 women (52%) were diagnosed with breast cancer, 682 (6%) with ovarian cancer, 272 (2%) with breast and ovarian cancer, and 4766 (40%) without cancer. In BRCA1, we identified 3 breast cancer cluster regions (BCCRs) located at c.179 to c.505 (BCCR1; RHR = 1.46; 95%CI, 1.22-1.74; P = 2 × 10-6), c.4328 to c.4945 (BCCR2; RHR = 1.34; 95%CI, 1.01-1.78; P = .04), and c. 5261 to c.5563 (BCCR2', RHR = 1.38; 95%CI, 1.22-1.55; P = 6 × 10-9).We also identified an ovarian cancer cluster region (OCCR) from c.1380 to c.4062 (approximately exon 11) with RHR = 0.62 (95%CI, 0.56-0.70; P = 9 × 10-17). In BRCA2, we observed multiple BCCRs spanning c.1 to c.596 (BCCR1; RHR = 1.71; 95%CI, 1.06-2.78; P = .03), c.772 to c.1806 (BCCR1'; RHR = 1.63; 95%CI, 1.10-2.40; P = .01), and c.7394 to
Published: 2015
Full Text: View/download PDF

28. Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients

Author: Kamieniak, MM, Rico, D, Milne, RL, Munoz-Repeto, I, Ibanez, K, Grillo, MA, Domingo, S, Borrego, S, Cazorla, A, Garcia-Bueno, JM, Hernando, S, Garcia-Donas, J, Hernandez-Agudo, E, Ramon y Cajal, T, Robles-Diaz, L, Marquez-Rodas, I, Cusido, M, Saez, R, Lacambra-Calvet, C, Osorio, A, Urioste, M, Cigudosa, JC, Paz-Ares, L, Palacios, J, Benitez, J, Garcia, MJ, Kamieniak, MM, Rico, D, Milne, RL, Munoz-Repeto, I, Ibanez, K, Grillo, MA, Domingo, S, Borrego, S, Cazorla, A, Garcia-Bueno, JM, Hernando, S, Garcia-Donas, J, Hernandez-Agudo, E, Ramon y Cajal, T, Robles-Diaz, L, Marquez-Rodas, I, Cusido, M, Saez, R, Lacambra-Calvet, C, Osorio, A, Urioste, M, Cigudosa, JC, Paz-Ares, L, Palacios, J, Benitez, J, and Garcia, MJ
Abstract: Standard treatments for advanced high-grade serous ovarian carcinomas (HGSOCs) show significant side-effects and provide only short-term survival benefits due to disease recurrence. Thus, identification of novel prognostic and predictive biomarkers is urgently needed. We have used 42 paraffin-embedded HGSOCs, to evaluate the utility of DNA copy number alterations, as potential predictors of clinical outcome. Copy number-based unsupervised clustering stratified HGSOCs into two clusters of different immunohistopathological features and survival outcome (HR = 0.15, 95%CI = 0.03-0.81; Padj = 0.03). We found that loss at 6q24.2-26 was significantly associated with the cluster of longer survival independently from other confounding factors (HR = 0.06, 95%CI = 0.01-0.43, Padj = 0.005). The prognostic value of this deletion was validated in two independent series, one consisting of 36 HGSOCs analyzed by fluorescent in situ hybridization (P = 0.04) and another comprised of 411 HGSOCs from the Cancer Genome Atlas study (TCGA) (HR = 0.67, 95%CI = 0.48-0.93, Padj = 0.019). In addition, we confirmed the association of low expression of the genes from the region with longer survival in 799 HGSOCs (HR = 0.74, 95%CI = 0.61-0.90, log-rank P = 0.002) and 675 high-FIGO stage HGSOCs (HR = 0.76, 95%CI = 0.61-0.96, log-rank P = 0.02) available from the online tool KM-plotter. Finally, by integrating copy number, RNAseq and survival data of 296 HGSOCs from TCGA we propose a few candidate genes that can potentially explain the association. Altogether our findings indicate that the 6q24.2-26 deletion is an independent marker of favorable outcome in HGSOCs with potential clinical value as it can be analyzed by FISH on tumor sections and guide the selection of patients towards more conservative therapeutic strategies in order to reduce side-effects and improve quality of life.
Published: 2015

29. Mammographic Density and Breast Cancer in BRCA1/BRCA2 Carriers.

Author: Pollan, M., primary, Ramon y Cajal, T., additional, Chirivella, I., additional, Miranda, J., additional, Teule, A., additional, Brunet, J., additional, Sanchez-Heras, A. B., additional, Llort, G., additional, Balmañà, J., additional, Carvajal, V., additional, Hernandez-Agudo, E., additional, Juan-Fita, M. J., additional, Tena-García, I., additional, Robles, L., additional, Guillén, C., additional, Pérez-Segura, P., additional, Luque-Molina, M. S., additional, and Hernando, S., additional
Published: 2015
Full Text: View/download PDF

30. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: Results from the initial screening round of the IMPACT study.

Author: Domchek S., Blanco I., Salinas M., Cook J., Rosario D.J., Buys S., Conner T., Ausems M.G., Ong K.-R., Hoffman J., Powers J., Teixeira M.R., Maia S., Foulkes W.D., Taherian N., Ruijs M., Den Enden A.T.H.-V., Izatt L., Davidson R., Adank M.A., Walker L., Schmutzler R., Tucker K., Kirk J., Hodgson S., Harris M., Douglas F., Lindeman G.J., Zgajnar J., Tischkowitz M., Clowes V.E., Susman R., Ramon Y Cajal T., Patcher N., Gadea N., Spigelman A., Van Os T., Liljegren A., Side L., Brewer C., Brady A.F., Donaldson A., Stefansdottir V., Friedman E., Chen-Shtoyerman R., Amor D.J., Copakova L., Barwell J., Giri V.N., Murthy V., Nicolai N., Teo S.-H., Greenhalgh L., Strom S., Henderson A., McGrath J., Gallagher D., Aaronson N., Ardern-Jones A., Bangma C., Dearnaley D., Costello P., Eyfjord J., Rothwell J., Falconer A., Gronberg H., Hamdy F.C., Johannsson O., Khoo V., Kote-Jarai Z., Lubinski J., Axcrona U., Melia J., McKinley J., Mitra A.V., Moynihan C., Rennert G., Suri M., Wilson P., Killick E., Moss S., Eeles R.A., Bancroft E.K., Page E.C., Castro E., Lilja H., Vickers A., Sjoberg D., Assel M., Foster C.S., Mitchell G., Drew K., Maehle L., Axcrona K., Evans D.G., Bulman B., Eccles D., McBride D., Van Asperen C., Vasen H., Kiemeney L.A., Ringelberg J., Cybulski C., Wokolorczyk D., Selkirk C., Hulick P.J., Bojesen A., Skytte A.-B., Lam J., Taylor L., Oldenburg R., Cremers R., Verhaegh G., Van Zelst-Stams W.A., Oosterwijk J.C., Domchek S., Blanco I., Salinas M., Cook J., Rosario D.J., Buys S., Conner T., Ausems M.G., Ong K.-R., Hoffman J., Powers J., Teixeira M.R., Maia S., Foulkes W.D., Taherian N., Ruijs M., Den Enden A.T.H.-V., Izatt L., Davidson R., Adank M.A., Walker L., Schmutzler R., Tucker K., Kirk J., Hodgson S., Harris M., Douglas F., Lindeman G.J., Zgajnar J., Tischkowitz M., Clowes V.E., Susman R., Ramon Y Cajal T., Patcher N., Gadea N., Spigelman A., Van Os T., Liljegren A., Side L., Brewer C., Brady A.F., Donaldson A., Stefansdottir V., Friedman E., Chen-Shtoyerman R., Amor D.J., Copakova L., Barwell J., Giri V.N., Murthy V., Nicolai N., Teo S.-H., Greenhalgh L., Strom S., Henderson A., McGrath J., Gallagher D., Aaronson N., Ardern-Jones A., Bangma C., Dearnaley D., Costello P., Eyfjord J., Rothwell J., Falconer A., Gronberg H., Hamdy F.C., Johannsson O., Khoo V., Kote-Jarai Z., Lubinski J., Axcrona U., Melia J., McKinley J., Mitra A.V., Moynihan C., Rennert G., Suri M., Wilson P., Killick E., Moss S., Eeles R.A., Bancroft E.K., Page E.C., Castro E., Lilja H., Vickers A., Sjoberg D., Assel M., Foster C.S., Mitchell G., Drew K., Maehle L., Axcrona K., Evans D.G., Bulman B., Eccles D., McBride D., Van Asperen C., Vasen H., Kiemeney L.A., Ringelberg J., Cybulski C., Wokolorczyk D., Selkirk C., Hulick P.J., Bojesen A., Skytte A.-B., Lam J., Taylor L., Oldenburg R., Cremers R., Verhaegh G., Van Zelst-Stams W.A., and Oosterwijk J.C.
Abstract: Background Men with germline breast cancer 1, early onset (BRCA1) or breast cancer 2, early onset (BRCA2) gene mutations have a higher risk of developing prostate cancer (PCa) than noncarriers. IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls) is an international consortium of 62 centres in 20 countries evaluating the use of targeted PCa screening in men with BRCA1/2 mutations. Objective To report the first year's screening results for all men at enrolment in the study. Design, setting and participants We recruited men aged 40-69 yr with germline BRCA1/2 mutations and a control group of men who have tested negative for a pathogenic BRCA1 or BRCA2 mutation known to be present in their families. All men underwent prostate-specific antigen (PSA) testing at enrolment, and those men with PSA >3 ng/ml were offered prostate biopsy. Outcome measurements and statistical analysis PSA levels, PCa incidence, and tumour characteristics were evaluated. The Fisher exact test was used to compare the number of PCa cases among groups and the differences among disease types. Results and limitations We recruited 2481 men (791 BRCA1 carriers, 531 BRCA1 controls; 731 BRCA2 carriers, 428 BRCA2 controls). A total of 199 men (8%) presented with PSA >3.0 ng/ml, 162 biopsies were performed, and 59 PCas were diagnosed (18 BRCA1 carriers, 10 BRCA1 controls; 24 BRCA2 carriers, 7 BRCA2 controls); 66% of the tumours were classified as intermediate- or high-risk disease. The positive predictive value (PPV) for biopsy using a PSA threshold of 3.0 ng/ml in BRCA2 mutation carriers was 48% - double the PPV reported in population screening studies. A significant difference in detecting intermediate- or high-risk disease was observed in BRCA2 carriers. Ninety-five percent of the men were white, thus the results cannot be generalised to all ethnic groups. Conclusions The IMPACT screening network will be useful for
Published: 2014

31. DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

Author: Osorio, A. (Ana), Milne, R.L. (Roger), Kuchenbaecker, K.B. (Karoline), Vaclová, T. (Tereza), Pita, G. (Guillermo), Alonso, M.R. (Rosario), Peterlongo, P. (Paolo), Blanco, I. (Ignacio), Hoya, M. (Miguel) de La, Durán, M. (Mercedes), Díez, O. (Orland), Ramon Y Cajal, T., Konstantopoulou, I. (I.), Martínez-Bouzas, C. (Cristina), Andrés Conejero, R. (Raquel), Soucy, P. (Penny), McGuffog, L. (Lesley), Barrowdale, D. (Daniel), Lee, A. (Andrew), Arver, B. (Brita Wasteson), Rantala, J. (Johanna), Loman, N. (Niklas), Ehrencrona, H. (Hans), Olopade, O.I. (Olofunmilayo), Beattie, M.S. (Mary), Domchek, S.M. (Susan), Nathanson, K.L. (Katherine), Rebbeck, R. (Timothy), Arun, B.K. (Banu), Karlan, B.Y. (Beth), Walsh, C.S. (Christine), Lester, K.J. (Kathryn), John, E.M. (Esther), Whittemore, A.S. (Alice), Daly, M.B. (Mary), Southey, M.C. (Melissa), Hopper, J.L. (John), Terry, M.-B. (Mary-Beth), Buys, S.S. (Saundra), Janavicius, R. (Ramunas), Dorfling, C.M. (Cecilia), Rensburg, E.J. (Elizabeth) van, Steele, L. (Linda), Neuhausen, S.L. (Susan), Ding, Y.C. (Yuan), Hansen, T.V.O. (Thomas), Jønson, L. (Lars), Ejlertsen, B. (Bent), Gerdes, A-M. (Anne-Marie), Infante, J. (Jon), Herráez, B. (Belén), Moreno, L.T. (Leticia Thais), Weitzel, J.N. (Jeffrey), Herzog, J. (Josef), Weeman, K. (Kisa), Manoukian, S. (Siranoush), Peissel, B. (Bernard), Zaffaroni, D. (D.), Scuvera, G. (Giulietta), Bonnani, B. (Bernardo), Mariette, F. (F.), Volorio, S. (Sara), Viel, A. (Alessandra), Varesco, L. (Liliana), Papi, L. (Laura), Ottini, L. (Laura), Tibiletti, M.G. (Maria Grazia), Radice, P. (Paolo), Yannoukakos, D. (Drakoulis), Garber, J., Ellis, S.D. (Steve), Frost, D. (Debra), Platte, R. (Radka), Fineberg, E. (Elena), Evans, D.G. (Gareth), Lalloo, F. (Fiona), Izatt, L. (Louise), Eeles, R. (Rosalind), Adlard, J.W. (Julian), Davidson, R. (Rosemarie), Cole, T.J. (Trevor), Eccles, D. (Diana), Cook, J. (Jackie), Hodgson, S.V. (Shirley), Brewer, C. (Carole), Tischkowitz, M. (Marc), Douglas, F. (Fiona), Porteous, M.E. (Mary), Side, L. (Lucy), Walker, L.J. (Lisa), Morrison, P.J. (Patrick), Donaldson, A. (Alan), Kennedy, J. (John), Foo, C. (Claire), Godwin, A.K. (Andrew), Schmutzler, R.K. (Rita), Wapenschmidt, B. (Barbara), Rhiem, K. (Kerstin), Engel, C. (Christoph), Meindl, A. (Alfons), Ditsch, N. (Nina), Arnold, N. (Norbert), Plendl, H. (Hansjoerg), Niederacher, D. (Dieter), Sutter, C. (Christian), Wang-Gohrke, S. (Shan), Steinemann, D. (Doris), Preisler-Adams, S. (Sabine), Kast, K. (Karin), Varon-Mateeva, R. (Raymonda), Gehrig, P.A. (Paola A.), Stoppa-Lyonnet, D. (Dominique), Sinilnikova, O. (Olga), Mazoyer, S. (Sylvie), Damiola, F. (Francesca), Poppe, B. (Bruce), Claes, K. (Kathleen), Piedmonte, M. (Marion), Tucker, K. (Kathryn), Backes, F.J. (Floor), Rodríguez, P.M., Brewster, W. (Wendy), Wakeley, K. (Katie), Rutherford, T. (Thomas), Caldes, T. (Trinidad), Nevanlinna, H. (Heli), Aittomäki, K. (Kristiina), Rookus, M.A. (Matti), Os, T.A.M. (Theo) van, Kolk, L.E. (Lizet) van der, Lange, J.L. (J.) de, Meijers-Heijboer, E.J. (Hanne), Hout, A.H. (Annemarie) van der, Asperen, C.J. (Christi) van, Gómez García, E.B. (Encarna), Hoogerbrugge, N. (Nicoline), Collée, J.M. (Margriet), Deurzen, C.H.M. (Carolien) van, Luijt, R.B. (Rob) van der, Devilee, P. (Peter), Olah, E. (Edith), Lázaro, C. (Conxi), Teulé, A. (A.), Menéndez, M. (Mireia), Jakubowska, A. (Anna), Cybulski, C. (Cezary), Gronwald, J. (Jacek), Lubinski, J. (Jan), Durda, K. (Katarzyna), Jaworska-Bieniek, K. (Katarzyna), Johannson, O.T. (Oskar), Maugard, C., Montagna, M. (Marco), Tognazzo, S. (Silvia), Teixeira, P.J., Healey, S. (Sue), Olswold, C. (Curtis), Guidugli, L. (Lucia), Lindor, N.M. (Noralane), Slager, S. (Susan), Szabo, C. (Csilla), Vijai, J. (Joseph), Robson, M. (Mark), Kauff, N. (Noah), Zhang, L. (Lingling), Rau-Murthy, R. (Rohini), Fink-Retter, A. (Anneliese), Singer, C.F. (Christian), Rappaport, C. (Christine), Geschwantler Kaulich, D. (Daphne), Pfeiler, G. (Georg), Tea, M.-K., Berger, A. (Annemarie), Phelan, C. (Catherine), Greene, M.H. (Mark), Mai, P.L. (Phuong), Lejbkowicz, F. (Flavio), Andrulis, I.L. (Irene), Mulligan, A.M. (Anna Marie), Glendon, G. (Gord), Toland, A.E. (Amanda), Bojesen, S.E. (Stig), Pedersen, I.S. (Inge Sokilde), Sunde, L. (Lone), Thomassen, M. (Mads), Kruse, T.A. (Torben), Jensen, U.B., Friedman, E. (Eitan), Laitman, Y. (Yael), Shimon, S.P. (Shani Paluch), Simard, J. (Jacques), Easton, D.F. (Douglas), Offit, K. (Kenneth), Couch, F.J. (Fergus), Chenevix-Trench, G. (Georgia), Antoniou, A.C. (Antonis), Benítez, J. (Javier), Osorio, A. (Ana), Milne, R.L. (Roger), Kuchenbaecker, K.B. (Karoline), Vaclová, T. (Tereza), Pita, G. (Guillermo), Alonso, M.R. (Rosario), Peterlongo, P. (Paolo), Blanco, I. (Ignacio), Hoya, M. (Miguel) de La, Durán, M. (Mercedes), Díez, O. (Orland), Ramon Y Cajal, T., Konstantopoulou, I. (I.), Martínez-Bouzas, C. (Cristina), Andrés Conejero, R. (Raquel), Soucy, P. (Penny), McGuffog, L. (Lesley), Barrowdale, D. (Daniel), Lee, A. (Andrew), Arver, B. (Brita Wasteson), Rantala, J. (Johanna), Loman, N. (Niklas), Ehrencrona, H. (Hans), Olopade, O.I. (Olofunmilayo), Beattie, M.S. (Mary), Domchek, S.M. (Susan), Nathanson, K.L. (Katherine), Rebbeck, R. (Timothy), Arun, B.K. (Banu), Karlan, B.Y. (Beth), Walsh, C.S. (Christine), Lester, K.J. (Kathryn), John, E.M. (Esther), Whittemore, A.S. (Alice), Daly, M.B. (Mary), Southey, M.C. (Melissa), Hopper, J.L. (John), Terry, M.-B. (Mary-Beth), Buys, S.S. (Saundra), Janavicius, R. (Ramunas), Dorfling, C.M. (Cecilia), Rensburg, E.J. (Elizabeth) van, Steele, L. (Linda), Neuhausen, S.L. (Susan), Ding, Y.C. (Yuan), Hansen, T.V.O. (Thomas), Jønson, L. (Lars), Ejlertsen, B. (Bent), Gerdes, A-M. (Anne-Marie), Infante, J. (Jon), Herráez, B. (Belén), Moreno, L.T. (Leticia Thais), Weitzel, J.N. (Jeffrey), Herzog, J. (Josef), Weeman, K. (Kisa), Manoukian, S. (Siranoush), Peissel, B. (Bernard), Zaffaroni, D. (D.), Scuvera, G. (Giulietta), Bonnani, B. (Bernardo), Mariette, F. (F.), Volorio, S. (Sara), Viel, A. (Alessandra), Varesco, L. (Liliana), Papi, L. (Laura), Ottini, L. (Laura), Tibiletti, M.G. (Maria Grazia), Radice, P. (Paolo), Yannoukakos, D. (Drakoulis), Garber, J., Ellis, S.D. (Steve), Frost, D. (Debra), Platte, R. (Radka), Fineberg, E. (Elena), Evans, D.G. (Gareth), Lalloo, F. (Fiona), Izatt, L. (Louise), Eeles, R. (Rosalind), Adlard, J.W. (Julian), Davidson, R. (Rosemarie), Cole, T.J. (Trevor), Eccles, D. (Diana), Cook, J. (Jackie), Hodgson, S.V. (Shirley), Brewer, C. (Carole), Tischkowitz, M. (Marc), Douglas, F. (Fiona), Porteous, M.E. (Mary), Side, L. (Lucy), Walker, L.J. (Lisa), Morrison, P.J. (Patrick), Donaldson, A. (Alan), Kennedy, J. (John), Foo, C. (Claire), Godwin, A.K. (Andrew), Schmutzler, R.K. (Rita), Wapenschmidt, B. (Barbara), Rhiem, K. (Kerstin), Engel, C. (Christoph), Meindl, A. (Alfons), Ditsch, N. (Nina), Arnold, N. (Norbert), Plendl, H. (Hansjoerg), Niederacher, D. (Dieter), Sutter, C. (Christian), Wang-Gohrke, S. (Shan), Steinemann, D. (Doris), Preisler-Adams, S. (Sabine), Kast, K. (Karin), Varon-Mateeva, R. (Raymonda), Gehrig, P.A. (Paola A.), Stoppa-Lyonnet, D. (Dominique), Sinilnikova, O. (Olga), Mazoyer, S. (Sylvie), Damiola, F. (Francesca), Poppe, B. (Bruce), Claes, K. (Kathleen), Piedmonte, M. (Marion), Tucker, K. (Kathryn), Backes, F.J. (Floor), Rodríguez, P.M., Brewster, W. (Wendy), Wakeley, K. (Katie), Rutherford, T. (Thomas), Caldes, T. (Trinidad), Nevanlinna, H. (Heli), Aittomäki, K. (Kristiina), Rookus, M.A. (Matti), Os, T.A.M. (Theo) van, Kolk, L.E. (Lizet) van der, Lange, J.L. (J.) de, Meijers-Heijboer, E.J. (Hanne), Hout, A.H. (Annemarie) van der, Asperen, C.J. (Christi) van, Gómez García, E.B. (Encarna), Hoogerbrugge, N. (Nicoline), Collée, J.M. (Margriet), Deurzen, C.H.M. (Carolien) van, Luijt, R.B. (Rob) van der, Devilee, P. (Peter), Olah, E. (Edith), Lázaro, C. (Conxi), Teulé, A. (A.), Menéndez, M. (Mireia), Jakubowska, A. (Anna), Cybulski, C. (Cezary), Gronwald, J. (Jacek), Lubinski, J. (Jan), Durda, K. (Katarzyna), Jaworska-Bieniek, K. (Katarzyna), Johannson, O.T. (Oskar), Maugard, C., Montagna, M. (Marco), Tognazzo, S. (Silvia), Teixeira, P.J., Healey, S. (Sue), Olswold, C. (Curtis), Guidugli, L. (Lucia), Lindor, N.M. (Noralane), Slager, S. (Susan), Szabo, C. (Csilla), Vijai, J. (Joseph), Robson, M. (Mark), Kauff, N. (Noah), Zhang, L. (Lingling), Rau-Murthy, R. (Rohini), Fink-Retter, A. (Anneliese), Singer, C.F. (Christian), Rappaport, C. (Christine), Geschwantler Kaulich, D. (Daphne), Pfeiler, G. (Georg), Tea, M.-K., Berger, A. (Annemarie), Phelan, C. (Catherine), Greene, M.H. (Mark), Mai, P.L. (Phuong), Lejbkowicz, F. (Flavio), Andrulis, I.L. (Irene), Mulligan, A.M. (Anna Marie), Glendon, G. (Gord), Toland, A.E. (Amanda), Bojesen, S.E. (Stig), Pedersen, I.S. (Inge Sokilde), Sunde, L. (Lone), Thomassen, M. (Mads), Kruse, T.A. (Torben), Jensen, U.B., Friedman, E. (Eitan), Laitman, Y. (Yael), Shimon, S.P. (Shani Paluch), Simard, J. (Jacques), Easton, D.F. (Douglas), Offit, K. (Kenneth), Couch, F.J. (Fergus), Chenevix-Trench, G. (Georgia), Antoniou, A.C. (Antonis), and Benítez, J. (Javier)
Abstract: Single Nucleotide Polymorphisms (SNPs) in genes involved in the DNA Base Excision Repair (BER) pathway could be associated with cancer risk in carriers of mutations in the high-penetrance susceptibility genes BRCA1 and BRCA2, given the relation of synthetic lethality that exists between one of the components of the BER pathway, PARP1 (poly ADP ribose polymerase), and both BRCA1 and BRCA2. In the present study, we have performed a comprehensive analysis of 18 genes involved in BER using a tagging SNP approach in a large series of BRCA1 and BRCA2 mutation carriers. 144 SNPs were analyzed in a two stage study involving 23,463 carriers from the CIMBA consortium (the Consortium of Investigators of Modifiers of BRCA1 and BRCA2). Eleven SNPs showed evidence of association with breast and/or ovarian cancer at p<0.05 in the combined analysis. Four of the five genes for which strongest evidence of association was observed were DNA glycosylases. The strongest evidence was for rs1466785 in the NEIL2 (endonuclease VIII-like 2) gene (HR: 1.09, 95% CI (1.03-1.1
Published: 2014
Full Text: View/download PDF

32. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: Results from the initial screening round of the IMPACT study

Author: Bancroft, E.K. (Elizabeth), Page, E. (Elizabeth), Castro, E. (Elena), Lilja, H. (Hans), Vickers, A.J. (Andrew), Sjoberg, D. (Daniel), Assel, M. (Matthias), Foster, C.S. (Christopher), Mitchell, G. (Gillian), Drew, K. (Kate), Maehle, L., Axcrona, K., Evans, D.G. (Gareth), Bulman, B., Eccles, D. (Diana), McBride, D. (Donna), Asperen, C.J. (Christi) van, Vasen, H. (Hans), Kiemeney, L.A.L.M. (Bart), Ringelberg, J. (Janneke), Cybulski, C. (Cezary), Wokolorczyk, D. (Dominika), Selkirk, C.G. (Christina), Hulick, P.J. (Peter), Bojesen, S.E. (Stig), Skytte, A.-B. (Anne-Bine), Lam, J. (Jimmy), Taylor, L. (Lorne), Oldenburg, R.A. (Rogier), Cremers, R.G.H.M. (Ruben), Verhaegh, G. (Gerald), Zelst-Stams, W.A. van, Oosterwijk, J.C. (Jan), Blanco, I. (Ignacio), Salinas, M., Cook, J. (Jackie), Rosario, K. (Karyna), Buys, S.S. (Saundra), Conner, T. (Tom), Ausems, M.G.E.M. (Margreet), Ong, K.-R. (Kai-Ren), Hoffman, J. (Jonathan), Domchek, S.M. (Susan), Powers, J. (Jacquelyn), Teixeira, P.J., Maia, S. (Sofia), Foulkes, W.D. (William), Taherian, N. (Nassim), Ruijs, M.W.G. (Marielle), Enden, A.T.H.-V. (Apollonia T. Helderman-Van) den, Izatt, L. (Louise), Davidson, R. (Rosemarie), Adank, M.A. (Muriel), Walker, L.J. (Lisa), Schmutzler, R.K. (Rita), Tucker, K. (Kathryn), Kirk, J. (Judy), Hodgson, S.V. (Shirley), Harris, M. (Marion), Douglas, F. (Fiona), Lindeman, G.J. (Geoffrey), Zgajnar, J. (Janez), Tischkowitz, M. (Marc), Clowes, V., Susman, R. (Rachel), Ramon Y Cajal, T., Patcher, N. (Nicholas), Gadea, N. (Neus), Spigelman, A., Os, T.A.M. (Theo) van, Liljegren, A. (Annelie), Side, L. (Lucy), Brewer, C. (Carole), Brady, A.F. (Angela), Donaldson, A. (Alan), Stefansdottir, V. (Vigdis), Friedman, E. (Eitan), Chen-Shtoyerman, R. (Rakefet), Amor, D. (David), Copakova, L. (Lucia), Barwell, J. (Julian), Giri, V.N. (Veda), Murthy, A.C. (Adeline C.), Nicolai, N. (Nicola), Teo, S.-H. (Soo-Hwang), Greenhalgh, T. (Trisha), Strom, S., Henderson, A. (Alex), McGrath, J. (John), Gallagher, D. (David), Aaronson, N.K. (Neil), Ardern-Jones, A. (Audrey), Bangma, C.H. (Chris), Dearnaley, D. (David), Costello, A. (Anthony), Eyfjord, J., Rothwell, J. (Jeanette), Falconer, A., Grönberg, H. (Henrik), Hamdy, F. (Freddie), Johannson, O.T. (Oskar), Khoo, V., Kote-Jarai, Z., Lubinski, J. (Jan), Melia, J., McKinley, E.T. (Enid), Mitra, A. (Anita), Moynihan, C., Rennert, G. (Gad), Suri, M. (Mohnish), Wilson, P., Killick, S.R., Moss, S.M. (Sue), Eeles, R. (Rosalind), Bancroft, E.K. (Elizabeth), Page, E. (Elizabeth), Castro, E. (Elena), Lilja, H. (Hans), Vickers, A.J. (Andrew), Sjoberg, D. (Daniel), Assel, M. (Matthias), Foster, C.S. (Christopher), Mitchell, G. (Gillian), Drew, K. (Kate), Maehle, L., Axcrona, K., Evans, D.G. (Gareth), Bulman, B., Eccles, D. (Diana), McBride, D. (Donna), Asperen, C.J. (Christi) van, Vasen, H. (Hans), Kiemeney, L.A.L.M. (Bart), Ringelberg, J. (Janneke), Cybulski, C. (Cezary), Wokolorczyk, D. (Dominika), Selkirk, C.G. (Christina), Hulick, P.J. (Peter), Bojesen, S.E. (Stig), Skytte, A.-B. (Anne-Bine), Lam, J. (Jimmy), Taylor, L. (Lorne), Oldenburg, R.A. (Rogier), Cremers, R.G.H.M. (Ruben), Verhaegh, G. (Gerald), Zelst-Stams, W.A. van, Oosterwijk, J.C. (Jan), Blanco, I. (Ignacio), Salinas, M., Cook, J. (Jackie), Rosario, K. (Karyna), Buys, S.S. (Saundra), Conner, T. (Tom), Ausems, M.G.E.M. (Margreet), Ong, K.-R. (Kai-Ren), Hoffman, J. (Jonathan), Domchek, S.M. (Susan), Powers, J. (Jacquelyn), Teixeira, P.J., Maia, S. (Sofia), Foulkes, W.D. (William), Taherian, N. (Nassim), Ruijs, M.W.G. (Marielle), Enden, A.T.H.-V. (Apollonia T. Helderman-Van) den, Izatt, L. (Louise), Davidson, R. (Rosemarie), Adank, M.A. (Muriel), Walker, L.J. (Lisa), Schmutzler, R.K. (Rita), Tucker, K. (Kathryn), Kirk, J. (Judy), Hodgson, S.V. (Shirley), Harris, M. (Marion), Douglas, F. (Fiona), Lindeman, G.J. (Geoffrey), Zgajnar, J. (Janez), Tischkowitz, M. (Marc), Clowes, V., Susman, R. (Rachel), Ramon Y Cajal, T., Patcher, N. (Nicholas), Gadea, N. (Neus), Spigelman, A., Os, T.A.M. (Theo) van, Liljegren, A. (Annelie), Side, L. (Lucy), Brewer, C. (Carole), Brady, A.F. (Angela), Donaldson, A. (Alan), Stefansdottir, V. (Vigdis), Friedman, E. (Eitan), Chen-Shtoyerman, R. (Rakefet), Amor, D. (David), Copakova, L. (Lucia), Barwell, J. (Julian), Giri, V.N. (Veda), Murthy, A.C. (Adeline C.), Nicolai, N. (Nicola), Teo, S.-H. (Soo-Hwang), Greenhalgh, T. (Trisha), Strom, S., Henderson, A. (Alex), McGrath, J. (John), Gallagher, D. (David), Aaronson, N.K. (Neil), Ardern-Jones, A. (Audrey), Bangma, C.H. (Chris), Dearnaley, D. (David), Costello, A. (Anthony), Eyfjord, J., Rothwell, J. (Jeanette), Falconer, A., Grönberg, H. (Henrik), Hamdy, F. (Freddie), Johannson, O.T. (Oskar), Khoo, V., Kote-Jarai, Z., Lubinski, J. (Jan), Melia, J., McKinley, E.T. (Enid), Mitra, A. (Anita), Moynihan, C., Rennert, G. (Gad), Suri, M. (Mohnish), Wilson, P., Killick, S.R., Moss, S.M. (Sue), and Eeles, R. (Rosalind)
Abstract: Background Men with germline breast cancer 1, early onset (BRCA1) or breast cancer 2, early onset (BRCA2) gene mutations have a higher risk of developing prostate cancer (PCa) than noncarriers. IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls) is an international consortium of 62 centres in 20 countries evaluating the use of targeted PCa screening in men with BRCA1/2 mutations. Objective To report the first year's screening results for all men at enrolment in the study. Design, setting and participants We recruited men aged 40-69 yr with germline BRCA1/2 mutations and a control group of men who have tested negative for a pathogenic BRCA1 or BRCA2 mutation known to be present in their families. All men underwent prostate-specific antigen (PSA) testing at enrolment, and those men with PSA >3 ng/ml were offered prostate biopsy. Outcome measurements and statistical analysis PSA levels, PCa incidence, and tumour characteristics were evaluated. The Fisher exact test was used to compare the number of PCa cases among groups and the differences among disease types. Results and limitations We recruited 2481 men (791 BRCA1 carriers, 531 BRCA1 controls; 731 BRCA2 carriers, 428 BRCA2 controls). A total of 199 men (8%) presented with PSA >3.0 ng/ml, 162 biopsies were performed, and 59 PCas were diagnosed (18 BRCA1 carriers, 10 BRCA1 controls; 24 BRCA2 carriers, 7 BRCA2 controls); 66% of the tumours were classified as intermediate- or high
Published: 2014
Full Text: View/download PDF

33. 1417P - Multi-gene panels: new clinical experience in hereditary breast and ovarian cancer

Author: Ramon y Cajal, T., Lasa, A., Llort, G., Lopez, C., Yagüe, C., Cornet, M., Gisbert, A., Fisas, D., Calvo, N., Vethencourt, A., Barba, A., Quero, S., Martinez, E., Hernan, I., Ruiz, A., Arcusa, A., Saigi, E., Barnadas, A., and Surralles, J.
Published: 2017
Full Text: View/download PDF

34. PO-0958: Radiogenomics: role of non-coding RNA genes in increased radiotherapy sensitivity

Author: Duran-Lozano, L., Reyes, V., Mollà, M., Fuentes-Raspall, M.J., Altabas, M., Ramón y Cajal, T., Barnadas, A., Diez, O., Giralt, J., and Gutiérrez-Enríquez, S.
Published: 2017
Full Text: View/download PDF

35. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers

Author: Antoniou, A.C., Kartsonaki, C., Sinilnikova, O.M., Soucy, P., McGuffog, L., Healey, S., Lee, A., Peterlongo, P., Manoukian, S., Peissel, B., Zaffaroni, D., Cattaneo, E., Barile, M., Pensotti, V., Pasini, B., Dolcetti, R., Giannini, G., Putignano, A.L., Varesco, L., Radice, P., Mai, P.L., Greene, M.H., Andrulis, I.L., Glendon, G., Ozcelik, H., Thomassen, M., Gerdes, A.M., Kruse, T.A., Birk Jensen, U., Cruger, D.G., Caligo, M.A., Laitman, Y., Milgrom, R., Kaufman, B., Paluch-Shimon, S., Friedman, E., Loman, N., Harbst, K., Lindblom, A., Arver, B., Ehrencrona, H., Melin, B., Nathanson, K.L., Domchek, S.M., Rebbeck, T., Jakubowska, A., Lubinski, J., Gronwald, J., Huzarski, T., Byrski, T., Cybulski, C., Gorski, B., Osorio, A., Ramon Y Cajal, T., Fostira, F., Andres, R., Benitez, J., Hamann, U., Hogervorst, F.B.L., Rookus, M.A., Hooning, M.J., Nelen, M.R., Luijt, R.B. van der, Os, T.A. van, Asperen, C.J. van, Devilee, P., Meijers-Heijboer, H.E., Garcia, E.B., Peock, S., Cook, M., Frost, D., Platte, R., Leyland, J., Evans, D.G., Lalloo, F., Eeles, R., Izatt, L., Adlard, J., Davidson, R., Eccles, D., Ong, K.R., Cook, J., Douglas, F., Paterson, J., Kennedy, M.J., Miedzybrodzka, Z., Godwin, A., Stoppa-Lyonnet, D., Buecher, B., Belotti, M., Tirapo, C., Mazoyer, S., Barjhoux, L., Lasset, C., Leroux, D., Faivre, L., Bronner, M., Prieur, F., Nogues, C., Rouleau, E., et al., Antoniou, A.C., Kartsonaki, C., Sinilnikova, O.M., Soucy, P., McGuffog, L., Healey, S., Lee, A., Peterlongo, P., Manoukian, S., Peissel, B., Zaffaroni, D., Cattaneo, E., Barile, M., Pensotti, V., Pasini, B., Dolcetti, R., Giannini, G., Putignano, A.L., Varesco, L., Radice, P., Mai, P.L., Greene, M.H., Andrulis, I.L., Glendon, G., Ozcelik, H., Thomassen, M., Gerdes, A.M., Kruse, T.A., Birk Jensen, U., Cruger, D.G., Caligo, M.A., Laitman, Y., Milgrom, R., Kaufman, B., Paluch-Shimon, S., Friedman, E., Loman, N., Harbst, K., Lindblom, A., Arver, B., Ehrencrona, H., Melin, B., Nathanson, K.L., Domchek, S.M., Rebbeck, T., Jakubowska, A., Lubinski, J., Gronwald, J., Huzarski, T., Byrski, T., Cybulski, C., Gorski, B., Osorio, A., Ramon Y Cajal, T., Fostira, F., Andres, R., Benitez, J., Hamann, U., Hogervorst, F.B.L., Rookus, M.A., Hooning, M.J., Nelen, M.R., Luijt, R.B. van der, Os, T.A. van, Asperen, C.J. van, Devilee, P., Meijers-Heijboer, H.E., Garcia, E.B., Peock, S., Cook, M., Frost, D., Platte, R., Leyland, J., Evans, D.G., Lalloo, F., Eeles, R., Izatt, L., Adlard, J., Davidson, R., Eccles, D., Ong, K.R., Cook, J., Douglas, F., Paterson, J., Kennedy, M.J., Miedzybrodzka, Z., Godwin, A., Stoppa-Lyonnet, D., Buecher, B., Belotti, M., Tirapo, C., Mazoyer, S., Barjhoux, L., Lasset, C., Leroux, D., Faivre, L., Bronner, M., Prieur, F., Nogues, C., Rouleau, E., and et al.
Abstract: Item does not contain fulltext, Two single nucleotide polymorphisms (SNPs) at 6q25.1, near the ESR1 gene, have been implicated in the susceptibility to breast cancer for Asian (rs2046210) and European women (rs9397435). A genome-wide association study in Europeans identified two further breast cancer susceptibility variants: rs11249433 at 1p11.2 and rs999737 in RAD51L1 at 14q24.1. Although previously identified breast cancer susceptibility variants have been shown to be associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers, the involvement of these SNPs to breast cancer susceptibility in mutation carriers is currently unknown. To address this, we genotyped these SNPs in BRCA1 and BRCA2 mutation carriers from 42 studies from the Consortium of Investigators of Modifiers of BRCA1/2. In the analysis of 14 123 BRCA1 and 8053 BRCA2 mutation carriers of European ancestry, the 6q25.1 SNPs (r(2) = 0.14) were independently associated with the risk of breast cancer for BRCA1 mutation carriers [hazard ratio (HR) = 1.17, 95% confidence interval (CI): 1.11-1.23, P-trend = 4.5 x 10(-9) for rs2046210; HR = 1.28, 95% CI: 1.18-1.40, P-trend = 1.3 x 10(-8) for rs9397435], but only rs9397435 was associated with the risk for BRCA2 carriers (HR = 1.14, 95% CI: 1.01-1.28, P-trend = 0.031). SNP rs11249433 (1p11.2) was associated with the risk of breast cancer for BRCA2 mutation carriers (HR = 1.09, 95% CI: 1.02-1.17, P-trend = 0.015), but was not associated with breast cancer risk for BRCA1 mutation carriers (HR = 0.97, 95% CI: 0.92-1.02, P-trend = 0.20). SNP rs999737 (RAD51L1) was not associated with breast cancer risk for either BRCA1 or BRCA2 mutation carriers (P-trend = 0.27 and 0.30, respectively). The identification of SNPs at 6q25.1 associated with breast cancer risk for BRCA1 mutation carriers will lead to a better understanding of the biology of tumour development in these women.
Published: 2011

36. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.

Author: Mitra, A.V., Bancroft, E.K., Barbachano, Y., Page, E.C., Foster, C.S., Jameson, C., Mitchell, G., Lindeman, G.J., Stapleton, A., Suthers, G., Evans, D.G., Cruger, D., Blanco, I., Mercer, C., Kirk, J., Maehle, L., Hodgson, S., Walker, L., Izatt, L., Douglas, F., Tucker, K., Dorkins, H., Clowes, V., Male, A., Donaldson, A., Brewer, C., Doherty, R., Bulman, B., Osther, P.J., Salinas, M., Eccles, D., Axcrona, K., Jobson, I., Newcombe, B., Cybulski, C., Rubinstein, W.S., Buys, S., Townshend, S., Friedman, E., Domchek, S., Ramon Y Cajal, T., Spigelman, A., Teo, S.H., Nicolai, N., Aaronson, N., Ardern-Jones, A., Bangma, C., Dearnaley, D., Eyfjord, J., Falconer, A., Gronberg, H., Hamdy, F., Johannsson, O., Khoo, V., Kote-Jarai, Z., Lilja, H., Lubinski, J., Melia, J., Moynihan, C., Peock, S., Rennert, G., Schroder, F., Sibley, P., Suri, M., Wilson, P.H., Bignon, Y.J., Strom, S., Tischkowitz, M., Liljegren, A., Ilencikova, D., Abele, A., Kyriacou, K., Asperen, C. van, Kiemeney, L.A.L.M., Easton, D.F., Eeles, R.A., Mitra, A.V., Bancroft, E.K., Barbachano, Y., Page, E.C., Foster, C.S., Jameson, C., Mitchell, G., Lindeman, G.J., Stapleton, A., Suthers, G., Evans, D.G., Cruger, D., Blanco, I., Mercer, C., Kirk, J., Maehle, L., Hodgson, S., Walker, L., Izatt, L., Douglas, F., Tucker, K., Dorkins, H., Clowes, V., Male, A., Donaldson, A., Brewer, C., Doherty, R., Bulman, B., Osther, P.J., Salinas, M., Eccles, D., Axcrona, K., Jobson, I., Newcombe, B., Cybulski, C., Rubinstein, W.S., Buys, S., Townshend, S., Friedman, E., Domchek, S., Ramon Y Cajal, T., Spigelman, A., Teo, S.H., Nicolai, N., Aaronson, N., Ardern-Jones, A., Bangma, C., Dearnaley, D., Eyfjord, J., Falconer, A., Gronberg, H., Hamdy, F., Johannsson, O., Khoo, V., Kote-Jarai, Z., Lilja, H., Lubinski, J., Melia, J., Moynihan, C., Peock, S., Rennert, G., Schroder, F., Sibley, P., Suri, M., Wilson, P.H., Bignon, Y.J., Strom, S., Tischkowitz, M., Liljegren, A., Ilencikova, D., Abele, A., Kyriacou, K., Asperen, C. van, Kiemeney, L.A.L.M., Easton, D.F., and Eeles, R.A.
Abstract: 01 januari 2011, Contains fulltext : 97398.pdf (publisher's version ) (Closed access), OBJECTIVE: To evaluate the role of targeted prostate cancer screening in men with BRCA1 or BRCA2 mutations, an international study, IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls), was established. This is the first multicentre screening study targeted at men with a known genetic predisposition to prostate cancer. A preliminary analysis of the data is reported. PATIENTS AND METHODS: Men aged 40-69 years from families with BRCA1 or BRCA2 mutations were offered annual prostate specific antigen (PSA) testing, and those with PSA > 3 ng/mL, were offered a prostate biopsy. Controls were men age-matched (+/- 5 years) who were negative for the familial mutation. RESULTS: In total, 300 men were recruited (205 mutation carriers; 89 BRCA1, 116 BRCA2 and 95 controls) over 33 months. At the baseline screen (year 1), 7.0% (21/300) underwent a prostate biopsy. Prostate cancer was diagnosed in ten individuals, a prevalence of 3.3%. The positive predictive value of PSA screening in this cohort was 47.6% (10/21). One prostate cancer was diagnosed at year 2. Of the 11 prostate cancers diagnosed, nine were in mutation carriers, two in controls, and eight were clinically significant. CONCLUSIONS: The present study shows that the positive predictive value of PSA screening in BRCA mutation carriers is high and that screening detects clinically significant prostate cancer. These results support the rationale for continued screening in such men.
Published: 2011

37. Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2 (CIMBA)

Author: Osorio, A. (Ana), Milne, R.L. (Roger), Pita, G. (Guillermo), Peterlongo, P. (Paolo), Heikinen, T. (Tuomas), Simard, J. (Jacques), Chenevix-Trench, G. (Georgia), Spurdle, A.B. (Amanda), Beesley, J. (Jonathan), Chen, X.C. (X. C.), Healey, S. (Sue), Neuhausen, S.L. (Susan), Ding, Y.C. (Yuan), Couch, F.J. (Fergus), Wang, X. (Xing), Lindor, N.M. (Noralane), Manoukian, S. (Siranoush), Barile, M. (Monica), Viel, A. (Alessandra), Tizzoni, L. (Laura), Szabo, C. (Csilla), Foretova, L. (Lenka), Zikan, M. (Michal), Claes, K. (Kathleen), Greene, M.H. (Mark), Mai, P.L. (Phuong), Rennert, G. (Gad), Lejbkowicz, F. (Flavio), Barnett-Griness, O. (Ofra), Andrulis, I.L. (Irene), Ozcelik, H. (Hilmi), Weerasooriya, N. (Nayana), Gerdes, A-M. (Anne-Marie), Thomassen, M. (Mads), Cruger, D. (Dorthe), Caligo, M.A. (Maria), Friedman, E. (Eitan), Kaufman, B. (Bella), Laitman, Y. (Yael), Cohen, S. (Shimrit), Kontorovich, T. (Tair), Gershoni-Baruch, R., Dagan, E. (Efrat), Jernström, H. (H.), Askmalm, M.S. (Marie), Arver, B. (Brita Wasteson), Malmer, B. (Beatrice), Domchek, S.M. (Susan), Nathanson, K.L. (Katherine), Brunet, J. (Joan), Ramon Y Cajal, T., Yannoukakos, D. (Drakoulis), Hamann, U. (Ute), Hogervorst, F.B.L. (Frans), Verhoef, S., Garcíla, E.B.G. (E.B. Gómez), Wijnen, J.T. (Juul), Ouweland, A.M.W. (Ans) van den, Easton, D.F. (Douglas), Peock, S. (Susan), Cook, M. (Margaret), Oliver, C.T. (Clare), Frost, D. (Debra), Luccarini, C. (Craig), Evans, D.G. (Gareth), Lalloo, F. (Fiona), Eeles, R. (Rosalind), Pichert, G. (Gabriella), Cook, J. (Jackie), Hodgson, S.V. (Shirley), Morrison, P.J. (Patrick), Douglas, F. (Fiona), Godwin, A.K. (Andrew), Sinilnikova, O. (Olga), Barjhoux, L. (Laure), Stoppa-Lyonnet, D. (Dominique), Moncoutier, V. (Virginie), Giraud, S. (Sophie), Cassini, C. (C.), Faivre, L. (Laurence), Révillion, F. (Françoise), Peyrat, J.-P., Muller, D.W. (Danièle), Fricker, J.P. (Jean Pierre), Lynch, H. (Henry), John, E.M. (Esther), Buys, S.S. (Saundra), Daly, M.B. (Mary), Hopper, J.L. (John), Terry, M.-B. (Mary-Beth), Miron, A. (Alexander), Yassin, Y. (Yosuf), Goldgar, D. (David), Singer, C.F. (Christian), Gschwantler-Kaulich, D. (Daphne), Pfeiler, G. (Georg), Spiess, E. (Eberhard), Hansen, T.V.O. (Thomas), Johannson, O.T. (Oskar), Kircchoff, T. (Tomas), Offit, K. (Kenneth), Kosarin, K. (Kristi), Piedmonte, M. (Marion), Rodriguez, G.C. (Gustavo), Wakeley, K. (Katie), Boggess, J.F. (John), Basil, J. (Jack), Schwartz, P.E. (Peter), Blank, S.V. (Stephanie), Toland, A.E. (Amanda), Montagna, M. (Marco), Casella, C. (Cinzia), Imyanitov, E.N. (Evgeny), Allavena, A. (Anna), Schmutzler, R.K. (Rita), Versmold, B. (Beatrix), Engel, C. (Christoph), Meindl, A. (Alfons), Ditsch, N. (Nina), Arnold, N. (Norbert), Niederacher, D. (Dieter), Deiler, H. (H.), Fiebig, B. (Britta), Varon-Mateeva, R. (Raymonda), Schaefer, D. (D.), Froster, U.G. (U.), Caldes, T. (Trinidad), Hoya, M. (Miguel) de La, McGuffog, L. (Lesley), Antoniou, A.C. (Antonis), Nevanlinna, H. (Heli), Radice, P. (Paolo), Benítez, J. (Javier), Osorio, A. (Ana), Milne, R.L. (Roger), Pita, G. (Guillermo), Peterlongo, P. (Paolo), Heikinen, T. (Tuomas), Simard, J. (Jacques), Chenevix-Trench, G. (Georgia), Spurdle, A.B. (Amanda), Beesley, J. (Jonathan), Chen, X.C. (X. C.), Healey, S. (Sue), Neuhausen, S.L. (Susan), Ding, Y.C. (Yuan), Couch, F.J. (Fergus), Wang, X. (Xing), Lindor, N.M. (Noralane), Manoukian, S. (Siranoush), Barile, M. (Monica), Viel, A. (Alessandra), Tizzoni, L. (Laura), Szabo, C. (Csilla), Foretova, L. (Lenka), Zikan, M. (Michal), Claes, K. (Kathleen), Greene, M.H. (Mark), Mai, P.L. (Phuong), Rennert, G. (Gad), Lejbkowicz, F. (Flavio), Barnett-Griness, O. (Ofra), Andrulis, I.L. (Irene), Ozcelik, H. (Hilmi), Weerasooriya, N. (Nayana), Gerdes, A-M. (Anne-Marie), Thomassen, M. (Mads), Cruger, D. (Dorthe), Caligo, M.A. (Maria), Friedman, E. (Eitan), Kaufman, B. (Bella), Laitman, Y. (Yael), Cohen, S. (Shimrit), Kontorovich, T. (Tair), Gershoni-Baruch, R., Dagan, E. (Efrat), Jernström, H. (H.), Askmalm, M.S. (Marie), Arver, B. (Brita Wasteson), Malmer, B. (Beatrice), Domchek, S.M. (Susan), Nathanson, K.L. (Katherine), Brunet, J. (Joan), Ramon Y Cajal, T., Yannoukakos, D. (Drakoulis), Hamann, U. (Ute), Hogervorst, F.B.L. (Frans), Verhoef, S., Garcíla, E.B.G. (E.B. Gómez), Wijnen, J.T. (Juul), Ouweland, A.M.W. (Ans) van den, Easton, D.F. (Douglas), Peock, S. (Susan), Cook, M. (Margaret), Oliver, C.T. (Clare), Frost, D. (Debra), Luccarini, C. (Craig), Evans, D.G. (Gareth), Lalloo, F. (Fiona), Eeles, R. (Rosalind), Pichert, G. (Gabriella), Cook, J. (Jackie), Hodgson, S.V. (Shirley), Morrison, P.J. (Patrick), Douglas, F. (Fiona), Godwin, A.K. (Andrew), Sinilnikova, O. (Olga), Barjhoux, L. (Laure), Stoppa-Lyonnet, D. (Dominique), Moncoutier, V. (Virginie), Giraud, S. (Sophie), Cassini, C. (C.), Faivre, L. (Laurence), Révillion, F. (Françoise), Peyrat, J.-P., Muller, D.W. (Danièle), Fricker, J.P. (Jean Pierre), Lynch, H. (Henry), John, E.M. (Esther), Buys, S.S. (Saundra), Daly, M.B. (Mary), Hopper, J.L. (John), Terry, M.-B. (Mary-Beth), Miron, A. (Alexander), Yassin, Y. (Yosuf), Goldgar, D. (David), Singer, C.F. (Christian), Gschwantler-Kaulich, D. (Daphne), Pfeiler, G. (Georg), Spiess, E. (Eberhard), Hansen, T.V.O. (Thomas), Johannson, O.T. (Oskar), Kircchoff, T. (Tomas), Offit, K. (Kenneth), Kosarin, K. (Kristi), Piedmonte, M. (Marion), Rodriguez, G.C. (Gustavo), Wakeley, K. (Katie), Boggess, J.F. (John), Basil, J. (Jack), Schwartz, P.E. (Peter), Blank, S.V. (Stephanie), Toland, A.E. (Amanda), Montagna, M. (Marco), Casella, C. (Cinzia), Imyanitov, E.N. (Evgeny), Allavena, A. (Anna), Schmutzler, R.K. (Rita), Versmold, B. (Beatrix), Engel, C. (Christoph), Meindl, A. (Alfons), Ditsch, N. (Nina), Arnold, N. (Norbert), Niederacher, D. (Dieter), Deiler, H. (H.), Fiebig, B. (Britta), Varon-Mateeva, R. (Raymonda), Schaefer, D. (D.), Froster, U.G. (U.), Caldes, T. (Trinidad), Hoya, M. (Miguel) de La, McGuffog, L. (Lesley), Antoniou, A.C. (Antonis), Nevanlinna, H. (Heli), Radice, P. (Paolo), and Benítez, J. (Javier)
Abstract: Background: In this study we aimed to evaluate the role of a SNP in intron 1 of the ERCC4 gene (rs744154), previously reported to be associated with a reduced risk of breast cancer in the general population, as a breast cancer risk modifier in BRCA1 and BRCA2 mutation carriers. Methods: We have genotyped rs744154 in 9408 BRCA1 and 5632 BRCA2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and assessed its association with breast cancer risk using a retrospective weighted cohort approach. Results: We found no evidence of association with breast cancer risk for BRCA1 (per-allele HR: 0.98, 95% CI: 0.93-1.04, P0.5) or BRCA2 (per-allele HR: 0.97, 95% CI: 0.89-1.06, P0.5) mutation carriers. Conclusion: Thi
Published: 2009
Full Text: View/download PDF

38. Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA).

Author: Osorio, A., Milne, R.L., Pita, G., Peterlongo, P., Heikkinen, T., Simard, J., Chenevix-Trench, G., Spurdle, A.B., Beesley, J., Chen, X., Healey, S., Neuhausen, S.L., Ding, Y.C., Couch, F.J., Wang, X., Lindor, N., Manoukian, S., Barile, M., Viel, A., Tizzoni, L., Szabo, C.I., Foretova, L., Zikan, M., Claes, K., Greene, M.H., Mai, P., Rennert, G., Lejbkowicz, F., Barnett-Griness, O., Andrulis, I.L., Ozcelik, H., Weerasooriya, N., Gerdes, A.M., Thomassen, M., Cruger, D.G., Caligo, M.A., Friedman, E., Kaufman, B., Laitman, Y., Cohen, S., Kontorovich, T., Gershoni-Baruch, R., Dagan, E., Jernstrom, H., Askmalm, M.S., Arver, B., Malmer, B., Domchek, S.M., Nathanson, K.L., Brunet, J., Ramon Y Cajal, T., Yannoukakos, D., Hamann, U., Hogervorst, F.B.L., Verhoef, S., Gomez Garcia, E.B., Wijnen, J.T., Ouweland, A.M.W. van den, Easton, D.F., Peock, S., Cook, M., Oliver, C.T., Frost, D., Luccarini, C., Evans, D.G., Lalloo, F., Eeles, R., Pichert, G., Cook, J., Hodgson, S., Morrison, P.J., Douglas, F., Godwin, A.K., Sinilnikova, O.M., Barjhoux, L., Stoppa-Lyonnet, D., Moncoutier, V., Giraud, S., Cassini, C., Olivier-Faivre, L., Revillion, F., Peyrat, J.P., Muller, D., Fricker, J.P., Lynch, H.T., John, E.M., Buys, S., Daly, M., Hopper, J.L., Terry, M.B., Miron, A., Yassin, Y., Goldgar, D., Singer, C.F., Gschwantler-Kaulich, D., Pfeiler, G., Spiess, A.C., Hansen, T.V., Johannsson, O.T., Osorio, A., Milne, R.L., Pita, G., Peterlongo, P., Heikkinen, T., Simard, J., Chenevix-Trench, G., Spurdle, A.B., Beesley, J., Chen, X., Healey, S., Neuhausen, S.L., Ding, Y.C., Couch, F.J., Wang, X., Lindor, N., Manoukian, S., Barile, M., Viel, A., Tizzoni, L., Szabo, C.I., Foretova, L., Zikan, M., Claes, K., Greene, M.H., Mai, P., Rennert, G., Lejbkowicz, F., Barnett-Griness, O., Andrulis, I.L., Ozcelik, H., Weerasooriya, N., Gerdes, A.M., Thomassen, M., Cruger, D.G., Caligo, M.A., Friedman, E., Kaufman, B., Laitman, Y., Cohen, S., Kontorovich, T., Gershoni-Baruch, R., Dagan, E., Jernstrom, H., Askmalm, M.S., Arver, B., Malmer, B., Domchek, S.M., Nathanson, K.L., Brunet, J., Ramon Y Cajal, T., Yannoukakos, D., Hamann, U., Hogervorst, F.B.L., Verhoef, S., Gomez Garcia, E.B., Wijnen, J.T., Ouweland, A.M.W. van den, Easton, D.F., Peock, S., Cook, M., Oliver, C.T., Frost, D., Luccarini, C., Evans, D.G., Lalloo, F., Eeles, R., Pichert, G., Cook, J., Hodgson, S., Morrison, P.J., Douglas, F., Godwin, A.K., Sinilnikova, O.M., Barjhoux, L., Stoppa-Lyonnet, D., Moncoutier, V., Giraud, S., Cassini, C., Olivier-Faivre, L., Revillion, F., Peyrat, J.P., Muller, D., Fricker, J.P., Lynch, H.T., John, E.M., Buys, S., Daly, M., Hopper, J.L., Terry, M.B., Miron, A., Yassin, Y., Goldgar, D., Singer, C.F., Gschwantler-Kaulich, D., Pfeiler, G., Spiess, A.C., Hansen, T.V., and Johannsson, O.T.
Abstract: Contains fulltext : 80736.pdf (publisher's version ) (Closed access), BACKGROUND: In this study we aimed to evaluate the role of a SNP in intron 1 of the ERCC4 gene (rs744154), previously reported to be associated with a reduced risk of breast cancer in the general population, as a breast cancer risk modifier in BRCA1 and BRCA2 mutation carriers. METHODS: We have genotyped rs744154 in 9408 BRCA1 and 5632 BRCA2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and assessed its association with breast cancer risk using a retrospective weighted cohort approach. RESULTS: We found no evidence of association with breast cancer risk for BRCA1 (per-allele HR: 0.98, 95% CI: 0.93-1.04, P = 0.5) or BRCA2 (per-allele HR: 0.97, 95% CI: 0.89-1.06, P = 0.5) mutation carriers. CONCLUSION: This SNP is not a significant modifier of breast cancer risk for mutation carriers, though weak associations cannot be ruled out.
Published: 2009

39. Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)

Author: Osorio, A, Milne, RL, Pita, G, Peterlongo, P, Heikkinen, T, Simard, J, Chenevix-Trench, G, Spurdle, AB, Beesley, J, Chen, X, Healey, S, Neuhausen, SL, Ding, YC, Couch, FJ, Wang, X, Lindor, N, Manoukian, S, Barile, M, Viel, A, Tizzoni, L, Szabo, CI, Foretova, L, Zikan, M, Claes, K, Greene, MH, Mai, P, Rennert, G, Lejbkowicz, F, Barnett-Griness, O, Andrulis, IL, Ozcelik, H, Weerasooriya, N, Gerdes, A-M, Thomassen, M, Cruger, DG, Caligo, MA, Friedman, E, Kaufman, B, Laitman, Y, Cohen, S, Kontorovich, T, Gershoni-Baruch, R, Dagan, E, Jernstrom, H, Askmalm, MS, Arver, B, Malmer, B, Domchek, SM, Nathanson, KL, Brunet, J, Ramon y Cajal, T, Yannoukakos, D, Hamann, U, Hogervorst, FBL, Verhoef, S, Gomez Garcia, EB, Wijnen, JT, van den Ouweland, A, Easton, DF, Peock, S, Cook, M, Oliver, CT, Frost, D, Luccarini, C, Evans, DG, Lalloo, F, Eeles, R, Pichert, G, Cook, J, Hodgson, S, Morrison, PJ, Douglas, F, Godwin, AK, Sinilnikova, OM, Barjhoux, L, Stoppa-Lyonnet, D, Moncoutier, V, Giraud, S, Cassini, C, Olivier-Faivre, L, Revillion, F, Peyrat, J-P, Muller, D, Fricker, J-P, Lynch, HT, John, EM, Buys, S, Daly, M, Hopper, JL, Terry, MB, Miron, A, Yassin, Y, Goldgar, D, Singer, CF, Gschwantler-Kaulich, D, Pfeiler, G, Spiess, A-C, Hansen, TVO, Johannsson, OT, Kirchhoff, T, Offit, K, Kosarin, K, Piedmonte, M, Rodriguez, GC, Wakeley, K, Boggess, JF, Basil, J, Schwartz, PE, Blank, SV, Toland, AE, Montagna, M, Casella, C, Imyanitov, EN, Allavena, A, Schmutzler, RK, Versmold, B, Engel, C, Meindl, A, Ditsch, N, Arnold, N, Niederacher, D, Deissler, H, Fiebig, B, Varon-Mateeva, R, Schaefer, D, Froster, UG, Caldes, T, de la Hoya, M, McGuffog, L, Antoniou, AC, Nevanlinna, H, Radice, P, Benitez, J, Osorio, A, Milne, RL, Pita, G, Peterlongo, P, Heikkinen, T, Simard, J, Chenevix-Trench, G, Spurdle, AB, Beesley, J, Chen, X, Healey, S, Neuhausen, SL, Ding, YC, Couch, FJ, Wang, X, Lindor, N, Manoukian, S, Barile, M, Viel, A, Tizzoni, L, Szabo, CI, Foretova, L, Zikan, M, Claes, K, Greene, MH, Mai, P, Rennert, G, Lejbkowicz, F, Barnett-Griness, O, Andrulis, IL, Ozcelik, H, Weerasooriya, N, Gerdes, A-M, Thomassen, M, Cruger, DG, Caligo, MA, Friedman, E, Kaufman, B, Laitman, Y, Cohen, S, Kontorovich, T, Gershoni-Baruch, R, Dagan, E, Jernstrom, H, Askmalm, MS, Arver, B, Malmer, B, Domchek, SM, Nathanson, KL, Brunet, J, Ramon y Cajal, T, Yannoukakos, D, Hamann, U, Hogervorst, FBL, Verhoef, S, Gomez Garcia, EB, Wijnen, JT, van den Ouweland, A, Easton, DF, Peock, S, Cook, M, Oliver, CT, Frost, D, Luccarini, C, Evans, DG, Lalloo, F, Eeles, R, Pichert, G, Cook, J, Hodgson, S, Morrison, PJ, Douglas, F, Godwin, AK, Sinilnikova, OM, Barjhoux, L, Stoppa-Lyonnet, D, Moncoutier, V, Giraud, S, Cassini, C, Olivier-Faivre, L, Revillion, F, Peyrat, J-P, Muller, D, Fricker, J-P, Lynch, HT, John, EM, Buys, S, Daly, M, Hopper, JL, Terry, MB, Miron, A, Yassin, Y, Goldgar, D, Singer, CF, Gschwantler-Kaulich, D, Pfeiler, G, Spiess, A-C, Hansen, TVO, Johannsson, OT, Kirchhoff, T, Offit, K, Kosarin, K, Piedmonte, M, Rodriguez, GC, Wakeley, K, Boggess, JF, Basil, J, Schwartz, PE, Blank, SV, Toland, AE, Montagna, M, Casella, C, Imyanitov, EN, Allavena, A, Schmutzler, RK, Versmold, B, Engel, C, Meindl, A, Ditsch, N, Arnold, N, Niederacher, D, Deissler, H, Fiebig, B, Varon-Mateeva, R, Schaefer, D, Froster, UG, Caldes, T, de la Hoya, M, McGuffog, L, Antoniou, AC, Nevanlinna, H, Radice, P, and Benitez, J
Abstract: BACKGROUND: In this study we aimed to evaluate the role of a SNP in intron 1 of the ERCC4 gene (rs744154), previously reported to be associated with a reduced risk of breast cancer in the general population, as a breast cancer risk modifier in BRCA1 and BRCA2 mutation carriers. METHODS: We have genotyped rs744154 in 9408 BRCA1 and 5632 BRCA2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and assessed its association with breast cancer risk using a retrospective weighted cohort approach. RESULTS: We found no evidence of association with breast cancer risk for BRCA1 (per-allele HR: 0.98, 95% CI: 0.93-1.04, P = 0.5) or BRCA2 (per-allele HR: 0.97, 95% CI: 0.89-1.06, P = 0.5) mutation carriers. CONCLUSION: This SNP is not a significant modifier of breast cancer risk for mutation carriers, though weak associations cannot be ruled out.
Published: 2009

40. Comparison of Lynch predictive models for identification of MLH1/MSH2 mutation carriers in a Spanish multicentre clinic- based cohort

Author: Valenzuela, I., primary, Balmaña, J., additional, Rue, M., additional, Blanco, I., additional, Torres, A., additional, Ramon y Cajal, T., additional, Chirivella, I., additional, Guillen, C., additional, Brunet, J., additional, and Tejada, I., additional
Published: 2009
Full Text: View/download PDF

41. Clinical features and outcome in primary breast sarcomas (BS): Analysis of a single-institution experience

Author: Ramon y Cajal, T., primary, Mazarico, J., additional, Lopez Pousa, A., additional, Quintana, M., additional, Sala, N., additional, Altabas, M., additional, Sebio, A., additional, Robert, L., additional, Alonso, C., additional, and Barnadas, A., additional
Published: 2009
Full Text: View/download PDF

42. Effect of Mammography on Breast Cancer Risk in Women with Mutations in BRCA1 or BRCA2

Author: Goldfrank, D., primary, Chuai, S., additional, Bernstein, J. L., additional, Ramon y Cajal, T., additional, Lee, J. B., additional, Alonso, M. C., additional, Diez, O., additional, Baiget, M., additional, Kauff, N. D., additional, Offit, K., additional, and Robson, M., additional
Published: 2006
Full Text: View/download PDF

43. Phase I/II study of oxaliplatin (L-OHP) plus 5-Fluorouracil concurrent with external beam radiotherapy (EBRT) in rectosigmoidcarcinoma

Author: Ramon y Cajal, T., primary, Rayo, S.García, additional, Calvo, E., additional, Aristu, J.J., additional, Villafranca, E., additional, Cañón, R., additional, Moreno, M., additional, Hernández, J.L., additional, and Azinovic, I., additional
Published: 1999
Full Text: View/download PDF

44. 8113 POSTER Anxiety, depression and quality of life in patients undergoing genetic testing for BRCA in a Spanish multicentre cohort (IMASS collaborative group)

Author: Mensa, I., Fortuny, D., Brunet, J., Ramón y Cajal, T., Torres, A., Ramírez, N., and Balmaña, J.
Published: 2007
Full Text: View/download PDF

45. Comprehensive constitutional genetic and epigenetic characterization of lynch-like individuals

Author: Conxi Lázaro, Laura Valle, Silvia Iglesias, Carolina Gómez, Gisela Urgel, Joan Brunet, Matilde Navarro, Ares Solanes, Anna Fernández, Consol López, Judith Balmaña, Fátima Marín, Bryony A. Thompson, Teresa Ramón y Cajal, Maribel González-Acosta, Angela Velasco, Maria Santacana, Jesús del Valle, Gardenia Vargas-Parra, Noemí Tuset, Marta Pineda, Xavier Matias-Guiu, Olga Campos, Gabriel Capellá, Estela Dámaso, Institut Català de la Salut, [Dámaso E] Hereditary Cancer Program, Catalan Institute of Oncology, Insititut d’Investigació Biomèdica de Bellvitge (IDIBELL), ONCOBELL Program, Avinguda de la Gran Via de l’Hospitalet 199-203, L’Hospitalet de Llobregat, Barcelona, Spain. [González-Acosta M, Vargas-Parra G, Navarro M] Hereditary Cancer Program, Catalan Institute of Oncology, Insititut d’Investigació Biomèdica de Bellvitge (IDIBELL), ONCOBELL Program, Avinguda de la Gran Via de l’Hospitalet 199-203, L’Hospitalet de Llobregat, Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. [Balmaña J] High Risk and Cancer Prevention Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Ramon Y Cajal T] Medical Oncology Department, Hospital de Santa Creu i Sant Pau, Carrer de Sant Quintí 89, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: 0301 basic medicine, Cancer Research, Càncer - Prognosi, Mutació, Genetic Phenomena::Genotype::Genetic Predisposition to Disease [PHENOMENA AND PROCESSES], Biology, MLH1, Genetic analysis, lcsh:RC254-282, Article, 03 medical and health sciences, 0302 clinical medicine, Germline mutation, Càncer colorectal, medicine, Genetics, Recte--Càncer, Epigenetics, fenómenos genéticos::genotipo::predisposición genética a la enfermedad [FENÓMENOS Y PROCESOS], next generation sequencing, Gens del càncer, epimutation, Aparell digestiu - Malalties - Aspectes genètics, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::síndromes neoplásicos hereditarios::neoplasias colorrectales hereditarias sin poliposis [ENFERMEDADES], Colorectal cancer, variant of unknown significance, Lynch syndrome, digestive system diseases, mismatch repair, 030104 developmental biology, Differentially methylated regions, Oncology, Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Neoplastic Syndromes, Hereditary::Colorectal Neoplasms, Hereditary Nonpolyposis [DISEASES], MSH2, 030220 oncology & carcinogenesis, DNA methylation, cancer genes panel, methylation, Genètica, Lynch-like syndrome
Abstract: Síndrome de Lynch; Panell de gens del càncer; Epimutació Síndrome de Lynch; Panel de genes del cáncer; Epimutación Lynch syndrome; Cancer genes panel; Epimutation The causal mechanism for cancer predisposition in Lynch-like syndrome (LLS) remains unknown. Our aim was to elucidate the constitutional basis of mismatch repair (MMR) deficiency in LLS patients throughout a comprehensive (epi)genetic analysis. One hundred and fifteen LLS patients harboring MMR-deficient tumors and no germline MMR mutations were included. Mutational analysis of 26 colorectal cancer (CRC)-associated genes was performed. Pathogenicity of MMR variants was assessed by splicing and multifactorial likelihood analyses. Genome-wide methylome analysis was performed by the Infinium Human Methylation 450K Bead Chip. The multigene panel analysis revealed the presence of two MMR gene truncating mutations not previously found. Of a total of 15 additional MMR variants identified, five -present in 6 unrelated individuals- were reclassified as pathogenic. In addition, 13 predicted deleterious variants in other CRC-predisposing genes were found in 12 probands. Methylome analysis detected one constitutional MLH1 epimutation, but no additional differentially methylated regions were identified in LLS compared to LS patients or cancer-free individuals. In conclusion, the use of an ad-hoc designed gene panel combined with pathogenicity assessment of variants allowed the identification of deleterious MMR mutations as well as new LLS candidate causal genes. Constitutional epimutations in non-LS-associated genes are not responsible for LLS. This work was funded by the Spanish Ministry of Economy and Competitiveness and cofunded by FEDER funds -a way to build Europe- (grants SAF2012-33636, SAF2015-68016-R and SAF2016-80888-R), CIBERONC, RTICC Network (RD12/0036/0031 and RD12/0036/0008), the Spanish Association Against Cancer (AECC) (080253), the Government of Catalonia (grant 2014SGR338, 2017SGR1282 and PERIS SLT002/16/0037), Fundación Mutua Madrileña (grant AP114252013). We thank CERCA Programme for institutional support. ED was supported by a grant from the Spanish Ministry of Economy and Competitiveness. The AECC fellowship to MG-A. AF was supported by a grant from the Catalonian Health Department (SLT002/16/00409). FM was supported by CIBERONC. The Mexican National Council for Science and Technology (CONACyT) fellowship to GV.
Published: 2020

46. Open-Source Bioinformatic Pipeline to Improve PMS2 Genetic Testing Using Short-Read NGS Data.

Author: Munté E, Feliubadaló L, Del Valle J, González S, Ramos-Muntada M, Balmaña J, Ramon Y Cajal T, Tuset N, Llort G, Cadiñanos J, Brunet J, Capellá G, Lázaro C, and Pineda M
Subjects: Humans, DNA Mutational Analysis methods, Germ-Line Mutation, Neoplastic Syndromes, Hereditary genetics, Neoplastic Syndromes, Hereditary diagnosis, Mismatch Repair Endonuclease PMS2 genetics, High-Throughput Nucleotide Sequencing methods, Computational Biology methods, Genetic Testing methods
Abstract: The molecular diagnosis of mismatch repair-deficient cancer syndromes is hampered by difficulties in sequencing the PMS2 gene, mainly owing to the PMS2CL pseudogene. Next-generation sequencing short reads cannot be mapped unambiguously by standard pipelines, compromising variant calling accuracy. This study aimed to provide a refined bioinformatic pipeline for PMS2 mutational analysis and explore PMS2 germline pathogenic variant prevalence in an unselected hereditary cancer (HC) cohort. PMS2 mutational analysis was optimized using two cohorts: 192 unselected HC patients for assessing the allelic ratio of paralogous sequence variants, and 13 samples enriched with PMS2 (likely) pathogenic variants screened previously by long-range genomic DNA PCR amplification. Reads were forced to align with the PMS2 reference sequence, except those corresponding to exon 11, where only those intersecting gene-specific invariant positions were considered. Afterward, the refined pipeline's accuracy was validated in a cohort of 40 patients and used to screen 5619 HC patients. Compared with our routine diagnostic pipeline, the PMS2_vaR pipeline showed increased technical sensitivity (0.853 to 0.956, respectively) in the validation cohort, identifying all previously PMS2 pathogenic variants found by long-range genomic DNA PCR amplification. Fifteen HC cohort samples carried a pathogenic PMS2 variant (15 of 5619; 0.285%), doubling the estimated prevalence in the general population. The refined open-source approach improved PMS2 mutational analysis accuracy, allowing its inclusion in the routine next-generation sequencing pipeline streamlining PMS2 screening., Competing Interests: Disclosure Statement None declared., (Copyright © 2024 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

47. SpadaHC: a database to improve the classification of variants in hereditary cancer genes in the Spanish population.

Author: Moreno-Cabrera JM, Feliubadaló L, Pineda M, Prada-Dacasa P, Ramos-Muntada M, Del Valle J, Brunet J, Gel B, Currás-Freixes M, Calsina B, Salazar-Hidalgo ME, Rodríguez-Balada M, Roig B, Fernández-Castillejo S, Durán Domínguez M, Arranz Ledo M, Infante Sanz M, Castillejo A, Dámaso E, Soto JL, de Miguel M, Hidalgo Calero B, Sánchez-Zapardiel JM, Ramon Y Cajal T, Lasa A, Gisbert-Beamud A, López-Novo A, Ruiz-Ponte C, Potrony M, Álvarez-Mora MI, Osorio A, Lorda-Sánchez I, Robledo M, Cascón A, Ruiz A, Spataro N, Hernan I, Borràs E, Moles-Fernández A, Earl J, Cadiñanos J, Sánchez-Heras AB, Bigas A, Capellá G, and Lázaro C
Subjects: Humans, Spain, Genetic Variation, Neoplasms genetics, Genes, Neoplasm, Genetic Predisposition to Disease, Databases, Genetic
Abstract: Accurate classification of genetic variants is crucial for clinical decision-making in hereditary cancer. In Spain, genetic diagnostic laboratories have traditionally approached this task independently due to the lack of a dedicated resource. Here we present SpadaHC, a web-based database for sharing variants in hereditary cancer genes in the Spanish population. SpadaHC is implemented using a three-tier architecture consisting of a relational database, a web tool and a bioinformatics pipeline. Contributing laboratories can share variant classifications and variants from individuals in Variant Calling Format (VCF) format. The platform supports open and restricted access, flexible dataset submissions, automatic pseudo-anonymization, VCF quality control, variant normalization and liftover between genome builds. Users can flexibly explore and search data, receive automatic discrepancy notifications and access SpadaHC population frequencies based on many criteria. In February 2024, SpadaHC included 18 laboratory members, storing 1.17 million variants from 4306 patients and 16 343 laboratory classifications. In the first analysis of the shared data, we identified 84 genetic variants with clinically relevant discrepancies in their classifications and addressed them through a three-phase resolution strategy. This work highlights the importance of data sharing to promote consistency in variant classifications among laboratories, so patients and family members can benefit from more accurate clinical management. Database URL: https://spadahc.ciberisciii.es/., (© The Author(s) 2024. Published by Oxford University Press.)
Published: 2024
Full Text: View/download PDF

48. CTNND1 is involved in germline predisposition to early-onset gastric cancer by affecting cell-to-cell interactions.

Author: Herrera-Pariente C, Bonjoch L, Muñoz J, Fernàndez G, Soares de Lima Y, Mahmood R, Cuatrecasas M, Ocaña T, Lopez-Prades S, Llargués-Sistac G, Domínguez-Rovira X, Llach J, Luzko I, Díaz-Gay M, Lazaro C, Brunet J, Castillo-Manzano C, García-González MA, Lanas A, Carrillo M, Hernández San Gil R, Quintero E, Sala N, Llort G, Aguilera L, Carot L, Diez-Redondo P, Jover R, Ramon Y Cajal T, Cubiella J, Castells A, Balaguer F, Bujanda L, Castellví-Bel S, and Moreira L
Subjects: Humans, Male, Female, Middle Aged, Adult, Cell Communication, Age of Onset, Antigens, CD, Stomach Neoplasms genetics, Stomach Neoplasms pathology, Delta Catenin, Germ-Line Mutation, Genetic Predisposition to Disease, Catenins genetics, Catenins metabolism, Cadherins genetics
Abstract: Background: CDH1 and CTNNA1 remain as the main genes for hereditary gastric cancer. However, they only explain a small fraction of gastric cancer cases with suspected inherited basis. In this study, we aimed to identify new hereditary genes for early-onset gastric cancer patients (EOGC; < 50 years old)., Methods: After germline exome sequencing in 20 EOGC patients and replication of relevant findings by gene-panel sequencing in an independent cohort of 152 patients, CTNND1 stood out as an interesting candidate gene, since its protein product (p120ctn) directly interacts with E-cadherin. We proceeded with functional characterization by generating two knockout CTNND1 cellular models by gene editing and introducing the detected genetic variants using a lentiviral delivery system. We assessed β-catenin and E-cadherin levels, cell detachment, as well as E-cadherin localization and cell-to-cell interaction by spheroid modeling., Results: Three CTNND1 germline variants [c.28_29delinsCT, p.(Ala10Leu); c.1105C > T, p.(Pro369Ser); c.1537A > G, p.(Asn513Asp)] were identified in our EOGC cohorts. Cells encoding CTNND1 variants displayed altered E-cadherin levels and intercellular interactions. In addition, the p.(Pro369Ser) variant, located in a key region in the E-cadherin/p120ctn binding domain, showed E-cadherin mislocalization., Conclusions: Defects in CTNND1 could be involved in germline predisposition to gastric cancer by altering E-cadherin and, consequently, cell-to-cell interactions. In the present study, CTNND1 germline variants explained 2% (3/172) of the cases, although further studies in larger external cohorts are needed., (© 2024. The Author(s).)
Published: 2024
Full Text: View/download PDF

49. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer.

Author: Torres-Esquius S, Llop-Guevara A, Gutiérrez-Enríquez S, Romey M, Teulé À, Llort G, Herrero A, Sánchez-Henarejos P, Vallmajó A, González-Santiago S, Chirivella I, Cano JM, Graña B, Simonetti S, Díaz de Corcuera I, Ramon Y Cajal T, Sanz J, Serrano S, Otero A, Churruca C, Sánchez-Heras AB, Servitja S, Guillén-Ponce C, Brunet J, Denkert C, Serra V, and Balmaña J
Subjects: Adult, Female, Humans, DNA-Binding Proteins genetics, Genetic Predisposition to Disease, Prevalence, Retrospective Studies, Spain epidemiology, Breast Neoplasms genetics, Breast Neoplasms epidemiology, Germ-Line Mutation, Homologous Recombination genetics, Ovarian Neoplasms genetics, Ovarian Neoplasms epidemiology, Rad51 Recombinase genetics
Abstract: Importance: RAD51C and RAD51D are involved in DNA repair by homologous recombination. Germline pathogenic variants (PVs) in these genes are associated with an increased risk of ovarian and breast cancer. Understanding the homologous recombination deficiency (HRD) status of tumors from patients with germline PVs in RAD51C/D could guide therapeutic decision-making and improve survival., Objective: To characterize the clinical and tumor characteristics of germline RAD51C/D PV carriers, including the evaluation of HRD status., Design, Setting, and Participants: This retrospective cohort study included 91 index patients plus 90 relatives carrying germline RAD51C/D PV (n = 181) in Spanish hospitals from January 1, 2014, to December 31, 2021. Genomic and functional HRD biomarkers were assessed in untreated breast and ovarian tumor samples (n = 45) from June 2022 to February 2023., Main Outcomes and Measures: Clinical and pathologic characteristics were assessed using descriptive statistics. Genomic HRD by genomic instability scores, functional HRD by RAD51, and gene-specific loss of heterozygosity were analyzed. Associations between HRD status and tumor subtype, age at diagnosis, and gene-specific loss of heterozygosity in RAD51C/D were investigated using logistic regression or the t test., Results: A total of 9507 index patients were reviewed, and 91 patients (1.0%) were found to carry a PV in RAD51C/D; 90 family members with a germline PV in RAD51C/D were also included. A total of 157 of carriers (86.7%) were women and 181 (55.8%) had received a diagnosis of cancer, mainly breast cancer or ovarian cancer. The most prevalent PVs were c.1026+5_1026+7del (11 of 56 [19.6%]) and c.709C>T (9 of 56 [16.1%]) in RAD51C and c.694C>T (20 of 35 [57.1%]) in RAD51D. In untreated breast cancer and ovarian cancer, the prevalence of functional and genomic HRD was 55.2% (16 of 29) and 61.1% (11 of 18) for RAD51C, respectively, and 66.7% (6 of 9) and 90.0% (9 of 10) for RAD51D. The concordance between HRD biomarkers was 91%. Tumors with the same PV displayed contrasting HRD status, and age at diagnosis did not correlate with the occurrence of HRD. All breast cancers retaining the wild-type allele were estrogen receptor positive and lacked HRD., Conclusions and Relevance: In this cohort study of germline RAD51C/D breast cancer and ovarian cancer, less than 70% of tumors displayed functional HRD, and half of those that did not display HRD were explained by retention of the wild-type allele, which was more frequent among estrogen receptor-positive breast cancers. Understanding which tumors are associated with RAD51C/D and HRD is key to identify patients who can benefit from targeted therapies, such as PARP (poly [adenosine diphosphate-ribose] polymerase) inhibitors.
Published: 2024
Full Text: View/download PDF

50. MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations.

Author: Lubinski J, Kotsopoulos J, Moller P, Pal T, Eisen A, Peck L, Karlan BY, Aeilts A, Eng C, Bordeleau L, Foulkes WD, Tung N, Couch FJ, Fruscio R, Ramon Y Cajal T, Singer CF, Neuhausen SL, Zakalik D, Cybulski C, Gronwald J, Huzarski T, Stempa K, Dungan J, Cullinane C, Olopade OI, Metcalfe K, Sun P, and Narod SA
Subjects: Female, Humans, Adult, Aged, Middle Aged, BRCA1 Protein genetics, Genes, BRCA2, BRCA2 Protein genetics, Mastectomy, Cohort Studies, Genes, BRCA1, Mutation, Risk Management, Magnetic Resonance Imaging, Breast Neoplasms pathology
Abstract: Importance: Magnetic resonance imaging (MRI) surveillance is offered to women with a pathogenic variant in the BRCA1 or BRCA2 gene who face a high lifetime risk of breast cancer. Surveillance with MRI is effective in downstaging breast cancers, but the association of MRI surveillance with mortality risk has not been well defined., Objective: To compare breast cancer mortality rates in women with a BRCA1 or BRCA2 sequence variation who entered an MRI surveillance program with those who did not., Design, Setting, and Participants: Women with a BRCA1 or BRCA2 sequence variation were identified from 59 participating centers in 11 countries. Participants completed a baseline questionnaire between 1995 and 2015 and a follow-up questionnaire every 2 years to document screening histories, incident cancers, and vital status. Women who had breast cancer, a screening MRI examination, or bilateral mastectomy prior to enrollment were excluded. Participants were followed up from age 30 years (or the date of the baseline questionnaire, whichever was later) until age 75 years, the last follow-up, or death from breast cancer. Data were analyzed from January 1 to July 31, 2023., Exposures: Entrance into an MRI surveillance program., Main Outcomes and Measures: Cox proportional hazards modeling was used to estimate the hazard ratios (HRs) and 95% CIs for breast cancer mortality associated with MRI surveillance compared with no MRI surveillance using a time-dependent analysis., Results: A total of 2488 women (mean [range] age at study entry 41.2 [30-69] years), with a sequence variation in the BRCA1 (n = 2004) or BRCA2 (n = 484) genes were included in the analysis. Of these participants, 1756 (70.6%) had at least 1 screening MRI examination and 732 women (29.4%) did not. After a mean follow-up of 9.2 years, 344 women (13.8%) developed breast cancer and 35 women (1.4%) died of breast cancer. The age-adjusted HRs for breast cancer mortality associated with entering an MRI surveillance program were 0.20 (95% CI, 0.10-0.43; P < .001) for women with BRCA1 sequence variations and 0.87 (95% CI, 0.10-17.25; P = .93) for women with BRCA2 sequence variations., Conclusion and Relevance: Results of this cohort study suggest that among women with a BRCA1 sequence variation, MRI surveillance was associated with a significant reduction in breast cancer mortality compared with no MRI surveillance. Further studies of women with BRCA2 sequence variations are needed to ascertain these women obtain the same benefits associated with MRI surveillance.
Published: 2024
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

94 results on '"Ramon Y Cajal T"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources